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Preamble
This document has been developed as an expert consensus
document by the American College of Cardiology Founda-
tion (ACCF), and the American Heart Association (AHA),
in collaboration with the American Academy of Neurology
(AAN), the American College of Physicians (ACP), theAmerican Geriatrics Society (AGS), the American Society
of Hypertension (ASH), the American Society of Nephrol-
ogy (ASN), the American Society for Preventive Cardiology
(ASPC), the Association of Black Cardiologists (ABC), and
the European Society of Hypertension (ESH). Expert
consensus documents are intended to inform practitioners,
payers, and other interested parties of the opinion of ACCF
and document cosponsors concerning evolving areas of
clinical practice and/or technologies that are widely available
or new to the practice community. Topics chosen for
coverage by expert consensus documents are so designed
because the evidence base, the experience with technology,
and/or clinical practice are not considered sufficiently well
developed to be evaluated by the formal ACCF/AHA
practice guidelines process. Often the topic is the subject of
considerable ongoing investigation. Thus, the reader should
view the expert consensus document as the best attempt of
the ACCF and document cosponsors to inform and guide
clinical practice in areas where rigorous evidence may not
yet be available or evidence to date is not widely applied to
clinical practice. When feasible, expert consensus docu-
ments include indications or contraindications. Typically,
formal recommendations are not provided in expert consen-
sus documents as these documents do not formally grade the
quality of evidence, and the provision of “Recommenda-
tions” is felt to be more appropriately within the purview of
the ACCF/AHA practice guidelines. However, recommen-
dations from ACCF/AHA practice guidelines and ACCF
appropriate use criteria are presented where pertinent to the
discussion. The writing committee is in agreement with
these recommendations. Finally, some topics covered by
expert consensus documents will be addressed subsequently
by the ACCF/AHA Task Force on Practice Guidelines.
The ACCF Task Force on Clinical Expert Consensus
Documents makes every effort to avoid any actual or
potential conflicts of interest that might arise as a result of
an outside relationship or personal interest of a member of
the writing panel. Specifically, all members of the writing
committee are asked to provide disclosure statements of all
such relationships that might be perceived as relevant to the
writing effort. This information is documented in a table,
reviewed by the parent task force before final writing
committee selections are made, reviewed by the writing
committee in conjunction with each conference call and/or
meeting of the group, updated as changes occur throughout
the document development process, and ultimately pub-
lished as an appendix to the document. External peer
reviewers of the document are asked to provide this infor-
mation as well. The disclosure information for writing
committee members and peer reviewers is listed in Appen-
dixes 1 and 2, respectively, of this document. Disclosure
information for members of the ACCF Task Force on Clinical
Expert Consensus Documents—as the oversight group for this
document development process—is available online at
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Guidelines-and-Documents-Task-Forces.aspx.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on
Clinical Expert Consensus Documents
Executive Summary
This document was written with the intent to be a complete
reference at the time of publication on the topic of managing
hypertension in the elderly. Given the length of the document,
the writing committee included this executive summary to
provide a quick reference for the busy clinician. Because
additional detail is needed, please refer to the sections of
interest in the main text. The tables and figures in the
document also delineate important considerations on this
topic, including the treatment algorithm in Section 4.2.2.1.
General Considerations
Our population is aging, and as hypertension affects most
elderly people (65 years of age), these individuals are more
likely to have organ damage or clinical cardiovascular disease
(CVD). They represent management dilemmas because
most hypertension trials had upper age limits or did not
present age-specific results. However, because the Hyper-
tension in the Very Elderly Trial (HYVET) documented
antihypertensive therapy benefits in persons 80 years of
age, it is timely to place into perspective issues relevant to
hypertension management in elderly patients.
Pathophysiology of Hypertension in the Elderly
Age-associated increases in hypertension prevalence derive
from changes in arterial structure and function accompany-
ing aging. Large vessels become less distensible, which
increases pulse wave velocity, causing late systolic blood
pressure (SBP) augmentation and increasing myocardial
oxygen demand. Reduction of forward flow also occurs,
limiting organ perfusion. These undesirable alterations are
enhanced with coronary stenosis or excessive drug-induced
diastolic blood pressure (DBP) reduction. Autonomic dys-
regulation contributes to orthostatic hypotension (a risk
factor for falls, syncope, and cardiovascular [CV] events)
and orthostatic hypertension (a risk factor for left ventricular
hypertrophy [LVH], coronary artery disease [CAD], and
cerebrovascular disease). Progressive renal dysfunction, be-
cause of glomerulosclerosis and interstitial fibrosis with a
reduction in glomerular filtration rate (GFR) and other
renal homeostatic mechanisms such as membrane sodium/
potassium–adenosine triphosphatase, fosters hypertension
through increased intracellular sodium, reduced sodium–
calcium exchange, and volume expansion. Microvascular
damage contributes to chronic kidney disease (CKD) as
reduced renal tubular mass provides fewer transport path-
ways for potassium excretion; thus elderly hypertensivepatients are prone to hyperkalemia. Secondary causes of
hypertension should be considered, such as renal artery stenosis
(RAS), obstructive sleep apnea, primary aldosteronism, and
thyroid disorders. Lifestyle, substances, and medications (to-
bacco, alcohol, caffeine, nonsteroidal anti-inflammatory drugs
[NSAIDs], glucocorticoids, sex hormones, calcium, and vita-
mins D and C) can also be important contributors.
End-Organ Effects
The following are highly prevalent among the elderly and
associated with poor blood pressure (BP) control: cerebro-
vascular disease (ischemic stroke, cerebral hemorrhage, vas-
cular dementia, Alzheimer’s disease, and accelerated cogni-
tive decline); CAD (including myocardial infarction [MI]
and angina pectoris); disorders of left ventricular (LV)
structure and function (including LVH and heart failure
[HF]); cardiac rhythm disorders (atrial fibrillation [AF] and
sudden death); aortic and peripheral arterial disease [PAD])
(including abdominal aortic aneurysm [AAA], thoracic
aortic aneurysm, acute aortic dissection and occlusive PAD);
CKD (estimated glomerular filtration rate [eGFR] 60
mL/min/1.73 m2; ophthalmologic disorders (including hy-
pertensive retinopathy, retinal artery occlusion, nonarteritic
anterior ischemic optic neuropathy, age-related macular
degeneration, and neovascular age-related macular degen-
eration); and quality of life (QoL) issues.
Interactions Between Aging and CV Risk Conditions
Associated With Hypertension
Because dyslipidemia and hypertension are common among
the elderly, it is reasonable to be aggressive with lipid
lowering in elderly hypertensive patients. Elderly patients
with hypertension and diabetes mellitus have a higher
mortality risk than similarly aged nondiabetic controls.
Hypertension is an insulin-resistant state because SBP,
fasting glucose, and thiazide diuretic and/or beta-blocker
use are independent risk factors for incident diabetes mel-
litus. Albuminuria is a predictor of higher mortality risk
among those with diabetes mellitus. Obesity is associated
with increases in LV wall thickness, volume, and mass,
independent of BP. Adipose tissue produces all components
of the renin-angiotensin-aldosterone system (RAAS) lo-
cally, leading to development of obesity-related hyperten-
sion. Increased angiotensin II (AII) may contribute to
insulin resistance. Activation of tissue RAAS contributes to
vascular inflammation and fibrosis. Renin and aldosterone
may also promote atherosclerosis and organ failure. Mi-
croalbuminuria is associated with CAD, HF, and mortality.
Screening for albuminuria is recommended for all elderly
hypertensive patients with concomitant diabetes mellitus
and for those with mild and moderate CKD. Gout inci-
dence rates are 3 times higher in hypertensive patients
versus normotensive patients; thiazide diuretics increase
serum uric acid levels and may provoke gout. Serum uric
acid independently predicts CV events in older hypertensive
persons; therefore, monitoring serum uric acid during di-
uretic treatment is reasonable. Arthritis is a common prob-
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May 17, 2011:2037–114 Hypertension in the Elderlylem in the elderly, with implications for hypertension and
adverse outcomes related to medications. NSAIDs are
implicated in BP elevation, and a chronic inflammatory
burden may lead to increased arterial stiffness. Other drugs
such as cyclo-oxygenase-2 inhibitors, glucocorticoids, and
some disease-modifying antirheumatic drugs (e.g., cyclo-
sporine, leflunomide) may increase BP.
Clinical Assessment and Diagnosis
Diagnosis of hypertension should be based on at least 3
different BP measurements, taken on 2 separate office
visits. At least 2 measurements should be obtained once the
patient is seated comfortably for at least 5 minutes with the
back supported, feet on the floor, arm supported in the
horizontal position, and the BP cuff at heart level. Pseudo-
hypertension is a falsely increased SBP that results from
markedly sclerotic arteries that do not collapse during cuff
inflation (e.g., “noncompressible”). Although this occurs
more commonly in the elderly, the actual prevalence is
unclear. Identification of pseudohypertension is necessary to
avoid overtreating high BP and should be suspected in
elders with refractory hypertension, no organ damage,
and/or symptoms of overmedication. White-coat hyperten-
sion is more common in the elderly and frequent among
centenarians. Ambulatory BP monitoring is recommended
to confirm a diagnosis of white-coat hypertension in pa-
tients with persistent office hypertension but no organ
damage. Ambulatory BP monitoring (ABPM) is indicated
when hypertension diagnosis or response to therapy is
unclear from office visits, when syncope or hypotensive
disorders are suspected, and for evaluation of vertigo and
dizziness. The case for using out-of-office BP readings in
the elderly, particularly home BP measurements, is strong
due to potential hazards of excessive BP reduction in older
people and better prognostic accuracy versus office BP.
Recommendations for Management
General Considerations. Because there is limited information
for evidence-based guidelines to manage older hypertension
patients, the following recommendations are based on
expert opinion that we believe provide a reasonable clinical
approach. Evaluation of the elderly patient with known or
suspected hypertension must accurately determine BP, and
if elevated: 1) identify reversible and/or treatable causes; 2)
evaluate for organ damage; 3) assess for other CVD risk
factors/comorbid conditions affecting prognosis; and 4)
identify barriers to treatment adherence. Evaluation in-
cludes a history, physical exam, and laboratory testing. It is
most important to focus on aspects that relate to hyperten-
sion, including details concerning the duration, severity,
causes, or exacerbations of high BP, current and previous
treatments including adverse effects, assessment of target
organ damage, and other CVD risk factors and comorbidi-
ties, as noted in the preceding text. There is limited
evidence to support routine laboratory testing. Instead, a
more deliberative, reasoned approach to testing is recom-
mended: 1) urinalysis for evidence of renal damage, espe- dcially albuminuria/microalbuminuria; 2) blood chemistries
(especially potassium and creatinine with eGFR); 3) total
cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and triglycerides; 4) fasting
blood sugar (including hemoglobin A1c if there are con-
cerns about diabetes mellitus); and 5) electrocardiogram
(ECG). In selected elderly persons, 2-dimensional echocar-
diography is useful to evaluate for LVH and LV dysfunction
that would warrant additional therapy (i.e., angiotensin-
converting enzyme inhibitors [ACEIs], beta blockers).
BP Measurement and Goals. Reliable, calibrated BP mea-
surement equipment is essential for hypertension manage-
ment. The BP should also be measured with the patient
standing for 1 to 3 minutes to evaluate for postural hypo-
tension or hypertension. The general recommended BP goal
in uncomplicated hypertension is 140/90 mm Hg. How-
ver, this target for elderly hypertensive patients is based on
xpert opinion rather than on data from randomized con-
rolled trials (RCTs). It is unclear whether target SBP
hould be the same in patients 65 to 79 years of age as in
atients 80 years of age.
oL and Cognitive Function. Because symptomatic well-
eing, cognitive function, physical activity, and sexual func-
ion are diminished by aging and disease, it is important to
ive particular attention to QoL areas when making thera-
eutic decisions.
onpharmacological Treatment. Lifestyle modification may
e the only treatment necessary for milder forms of hyper-
ension in the elderly. Smoking cessation, reduction in
xcess body weight and mental stress, modification of
xcessive sodium and alcohol intake, and increased physical
ctivity may also reduce antihypertensive drug doses.
eight reduction lowers BP in overweight individuals, and
ombined with sodium restriction, results in greater benefit.
P declines from dietary sodium restriction are generally
arger in older than in young adults. Increased potassium
ntake, either by fruits and vegetables or pills, also reduces
P, especially in individuals with higher dietary sodium
ntake. Alcohol consumption of2 alcoholic drinks per day
s strongly associated with BP elevations, and BP generally
eclines after reduced alcohol intake, though evidence is
imited among older adults. Exercise at moderate intensity
licits BP reductions similar to those of more intensive
egimens.
anagement of Associated Risk Factors and Team Approach.
any risk stratification tools calculate risk estimates using
n overall or “global” instrument like the Framingham Risk
core for predicting MI, stroke, or CVD. These instru-
ents emphasize age and classify all persons 70 or 75
ears of age as high risk (i.e., 10% risk of CAD in next 10
ears), or very high risk (e.g., those with diabetes mellitus or
AD), thus deserving antihypertensive therapy. Further-
ore, analyses have not suggested that elderly subgroupsiffered from younger subgroups in response to multiple risk
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Hypertension in the Elderly May 17, 2011:2037–114interventions. Patient management is often best accom-
plished by employing a health care team that may include
clinical pharmacists, nurses, physician assistants, clinical
psychologists, and others (as necessary). Technology en-
hancements to assist in achieving and maintaining goals
range from simple printed prompts and reminders to tele-
medicine and text messaging.
Considerations for Drug Therapy
Drug treatment for elderly hypertensive patients has been
generally recommended but with a greater degree of caution
due to alterations in drug distribution and disposal and
changes in homeostatic CV control, as well as QoL factors.
However, patients in most hypertension trials were 80
years of age. Pooling the limited number of octogenarians from
several trials mainly composed of younger patients, treated
patients showed a reduction in both stroke and CV morbidity,
but a trend toward increased all-cause mortality compared to
controls. Thus, the overall benefits of treating octogenarians
remain unclear despite epidemiological evidence that hyper-
tension remains a potent CV risk factor in this age group.
Results of HYVET, documenting reduced adverse outcomes
with antihypertensive drugs in persons 80 years of age,
equires updating previous recommendations.
nitiation of Drug Therapy
he initial antihypertensive drug should be started at the
owest dose and gradually increased, depending on BP
esponse, to the maximum tolerated dose. An achieved SBP
140 mm Hg, if tolerated, is recommended except for
ctogenarians (see special populations in the following text).
f the BP response is inadequate after reaching “full dose”
not necessarily maximum recommended dose), a second drug
rom another class should be added provided the initial drug is
olerated. If there are adverse effects or no therapeutic response,
drug from another class should be substituted. If a diuretic is
ot the initial drug, it is usually indicated as the second drug.
f the antihypertensive response is inadequate after reaching
ull doses of 2 classes of drugs, a third drug from another class
hould be added. When BP is 20/10 mm Hg above goal,
herapy should be initiated with 2 antihypertensive drugs.
owever, treatment must be individualized in the elderly.
efore adding new antihypertensive drugs, possible reasons for
nadequate BP response should be examined. On average,
lderly patients are taking6 prescription drugs, so polyphar-
acy, nonadherence, and potential drug interactions are im-
ortant concerns.
pecific Drug Classes
hiazide diuretics (hydrochlorothiazide [HCTZ], chlortha-
idone, and bendrofluazide [bendrofluomethiazide]) are rec-
mmended for initiating therapy. They cause an initial
eduction in intravascular volume, peripheral vascular resis-
ance, and BP, and are generally well tolerated. Several trials
emonstrate reduced CV, cerebrovascular, and renal adverse
utcomes in the elderly. Aging-related physiological
hanges can be exacerbated with diuretics. The elderly Benerally have contracted intravascular volumes and im-
aired baroreflexes. Diuretics cause sodium and water de-
letion and may promote orthostatic hypotension. Older
eople have a high prevalence of LVH, which predisposes
hem to ventricular arrhythmias and sudden death. Thiazide
iuretics can cause hypokalemia, hypomagnesemia, and
yponatremia, which increase arrhythmias. The elderly have
tendency toward hyperuricemia, glucose intolerance, and
yslipidemia, all of which are exacerbated by thiazides.
evertheless, thiazides reduce CV events in the elderly to a
imilar extent as other drug classes.
on-Thiazide Diuretics. Indapamide is a sulfonamide di-
retic used for hypertension. This drug increases blood
lucose, but not uric acid, and can cause potassium-
ndependent prolongation of the QT interval. Caution is
dvised when used with lithium. Furosemide and analogs
bumetanide or torsemide) are loop diuretics sometimes
sed for hypertension complicated by HF or CKD. They
ncrease glucose and may cause headaches, fever, anemia, or
lectrolyte disturbances. Mineralocorticoid antagonists (spi-
onolactone and eplerenone) and epithelial sodium trans-
ort channel antagonists (amiloride and triamterene) are
seful in hypertension when combined with other agents. In
ontrast to thiazides and loop diuretics, these drugs cause
otassium retention and are not associated with adverse
etabolic effects.
Beta blockers have been used for hypertension, but
vidence for a benefit in the elderly has not been convincing.
hey may have a role in combination therapy, especially
ith diuretics. Beta blockers are indicated in the treatment
f elderly patients who have hypertension with CAD, HF,
ertain arrhythmias, migraine headaches, and senile tremor.
lthough earlier beta blockers have been associated with
epression, sexual dysfunction, dyslipidemia, and glucose
ntolerance, these side effects are less prominent or absent
ith newer agents. Although the efficacy of alpha blockers is
ocumented, their usefulness is very limited because dox-
zosin showed excess CV events compared with chlorthali-
one in ALLHAT (Antihypertensive and Lipid-Lowering
reatment to Prevent Heart Attack Trial) (greater than a
-fold increase in HF and 20% increase in stroke). Based
n these findings, alpha blockers should not be considered
s first-line therapy for hypertension in older adults.
Calcium antagonists (CAs) have widely variable effects on
eart muscle, sinus node function, atrioventricular conduc-
ion, peripheral arteries, and coronary circulation. They
nclude phenylalkylamines (verapamil); benzothiazepines
diltiazem); and dihydropyridines (nifedipine, nicardipine,
imodipine, amlodipine, felodipine, isradipine, nitrendip-
ne). Results of controlled trials have demonstrated the
afety and efficacy of CAs in elderly patients with hyper-
ension. They appear well suited for elderly patients, whose
ypertensive profile is based on increasing arterial stiffness,
ecreased vascular compliance, and diastolic dysfunction.
ecause they have multiple applications, including treat-
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May 17, 2011:2037–114 Hypertension in the Elderlyment of angina and supraventricular arrhythmias, CAs are
useful for elderly hypertensive patients with these comorbid
CV conditions. Most adverse effects of dihydropyridines
relate to vasodilation (e.g., ankle edema, headache, postural
hypotension). Postural hypotension is associated with an in-
creased risk of dizziness and falls and a serious concern for
elderly patients. Short-acting rapid-release dihydropyridines
must be avoided. Verapamil and diltiazem can precipitate heart
block in elderly patients with underlying conduction defects.
First-generation CA (nifedipine, verapamil, and diltiazem)
should be avoided in patients with LV systolic dysfunction.
ACEIs block conversion of AI to AII, both in tissue and
plasma to lower peripheral vascular resistance and BP without
reflex stimulation of heart rate and contractility. They reduce
morbidity and mortality in patients with HF, reduce systolic
function post-MI, and retard progression of diabetic renal
disease and hypertensive nephrosclerosis. Main adverse effects
include hypotension, chronic dry cough, and, rarely, angio-
edema or rash. Renal failure can develop in those with RAS.
Hyperkalemia can occur in patients taking potassium supple-
ments, as well those with renal insufficiency. Rarely, neutro-
penia or agranulocytosis can occur; close monitoring is sug-
gested during the first months of therapy. Angiotensin receptor
blockers (ARBs) selectively block AT1-receptor subtype and,
overall, are similar to other agents in reducing BP, are well
tolerated, protect the kidney, and reduce mortality and mor-
bidity in HF patients. In elderly hypertensive patients with
diabetes mellitus, ARBs are considered first line and as an
alternative to ACEI in patients with hypertension and HF
who cannot tolerate ACEIs.
Direct Renin Inhibitors. Aliskiren is as effective as ARBs or
ACEIs for BP lowering without dose-related increases in
adverse events in elderly patients. Combined with HCTZ,
ramipril, or amlodipine, aliskiren causes greater BP lowering
than with either agent alone. Evidence is lacking combining
aliskiren with beta blockers or maximal dose ACEIs, and
only limited data are available in black hypertensive patients.
In patients 75 years of age, including those with renal
disease, aliskiren appears well tolerated. The major side
effect is a low incidence of mild diarrhea, which usually does
not lead to discontinuation. There are no data on treating
patients with an eGFR below 30 mL/min/1.73 m2.
Nonspecific Vasodilators. Because of their unfavorable side
effects, hydralazine and minoxidil are fourth-line antihyper-
tensive agents and only used as part of combination regi-
mens. As a monotherapy, both drugs cause tachycardia, and
minoxidil causes fluid accumulation and atrial arrhythmias.
Centrally acting agents (e.g., clonidine) are not first-line
treatments in the elderly because of sedation and/or brady-
cardia. Abrupt discontinuation leads to increased BP and
heart rate, which may aggravate ischemia and/or HF. These
agents should not be considered in noncompliant patients
but may be used as part of a combination regimen if needed
after several other agents are deployed. tCombination therapy provides more opportunity for
enhanced efficacy, avoidance of adverse effects, enhanced
convenience, and compliance. It is important to consider the
attributes of ACEIs, ARBs, and CAs, in addition to BP
lowering. Some combinations of these agents may provide
even more protective effects on the CV system. One trial of
high-risk hypertensive elders, ACCOMPLISH (Avoiding
Cardiovascular Events in Combination Therapy in Patients
Living with Systolic Hypertension), found an ACEI–long-
acting CA combination superior to an ACEI–HCTZ
combination in reduction of morbidity and mortality.
Uncomplicated Hypertension
The 2009 updated European Society of Hypertension
guidelines recommend initiating therapy in the elderly with
thiazide diuretics, CAs, ACEIs, ARBs, or beta blockers
based on a meta-analysis of major hypertension trials (23).
Most elderly persons with hypertension will need 2 drugs.
hen BP is 20/10 mm Hg above goal, consideration
hould be given to starting with 2 drugs.
omplicated Hypertension
n elderly patients who have CAD with hypertension and
table angina or prior MI, the initial choice is a beta blocker.
long-acting dihydropyridine CA should be administered
n addition to the beta blocker when the BP remains
levated or if angina persists. An ACEI should also be
iven, particularly if LV ejection fraction is reduced and/or
f HF is present. A verapamil SR–trandolapril-based strat-
gy is as clinically effective, in terms of BP control and
dverse outcomes, as an atenolol–HCTZ-based strategy in
ypertensive elderly CAD patients including those with
rior MI. Angina was better controlled with the verapamil
R–trandolapril strategy. With acute coronary syndromes,
ypertension should be treated with beta blockers and
CEI, with additional drugs added as needed for BP
ontrol. Verapamil and diltiazem should not be used with
ignificant LV systolic dysfunction or conduction system
isease. Although some guidelines recommend reducing BP
o 130/80 mm Hg in CAD patients, there is limited
vidence to support this lower target in elderly patients with
AD. Observational data show the nadir BP for risk was
35/75 mm Hg among CAD patients 70 to 80 years of age
nd 140/70 mm Hg for patients 80 years of age. Beta
lockers with intrinsic sympathomimetic activity must not
e used after MI.
Hypertension associated with LVH is an independent
isk factor for CAD, stroke, PAD, and HF. A large
eta-analysis found ACEIs more effective than other anti-
ypertensive drugs in decreasing LV mass. However, all
gents except for direct-acting vasodilators reduce LV mass
f BP is controlled.
Elderly patients with hypertension and systolic HF
hould receive a diuretic, beta blocker, ACEI, and an
ldosterone antagonist, in the absence of hyperkalemia or
ignificant renal dysfunction, if necessary. If a patient cannot
olerate an ACEI, an ARB should be used. Elderly black
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Hypertension in the Elderly May 17, 2011:2037–114hypertensive patients with HF may benefit from isosorbide
dinitrate plus hydralazine. Based on expert opinion, the BP
should be reduced to 130/80 mm Hg in HF patients with
AD. Elderly patients with hypertension and asymptom-
tic LV systolic dysfunction should be treated with ACEIs
nd beta blockers. Because HF may improve in hypertensive
lderly patients with RAS after renal revascularization, a
earch for RAS should be considered when HF is refractory
o conventional management. Diastolic HF is very common
n the elderly. Fluid retention should be treated with loop
iuretics, hypertension should be adequately controlled, and
hen possible, comorbidities should be treated.
Although “The Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and Treat-
ent of High Blood Pressure” recommends that elderly
ypertensive patients with cerebrovascular disease (prior stroke
r transient ischemic attack) should be treated with a diuretic
lus an ACEI (22), reduction of stroke risk among elderly
ersons with hypertension is related more to reduction in BP
han to type of antihypertensive drug.
Presence of aortic aneurysm requires very intense BP control
o the lowest tolerated level. Therapy should include an ACEI
r ARB plus a beta blocker because, in addition to lowering
P, beta blockers decrease peak LV ejection rate. In acute
ortic dissection (acute aortic syndrome), control of BP with
ultiple drugs, including beta blockers, is needed for both type
and B (not involving the ascending aorta) dissections. For
AD, lifestyle interventions include smoking cessation, weight
oss, and a structured walking program. Management of
ypertension as well as coexistent CAD and HF are essential,
s is control of blood glucose and lipids. ACEIs or ARBs, and
ntiplatelet therapy are required.
In the absence of RCT data, guidelines recommend that
atients with diabetes mellitus should have a BP 130/80
m Hg. If tolerated, multiple drugs are often required.
owever, RCT data among those 65 years of age from
he ACCORD BP (Action to Control Cardiovascular Risk
n Diabetes Blood Pressure) trial found no additional
enefit from a target SBP 120 mm Hg versus a target of
40 mm Hg. Observational data from extended follow-up
f the predominantly elderly INVEST (INternational
Erapamil SR/Trandolapril Study) diabetes cohort suggest
n increase in mortality when on-treatment SBP is 115
m Hg or DBP 65 mm Hg. Reduction of macrovascular
nd microvascular complications in elderly hypertensive
iabetic patients depends more on reducing BP than on type
f drugs used. Drug choice depends on associated comor-
idities. However, thiazide diuretics will increase hypergly-
emia. Elderly persons with diabetes mellitus, hypertension,
nd nephropathy should be treated initially with ACEIs or
RBs. In ACCOMPLISH, over the background of ACEI,
iabetic patients treated with amlodipine had a 21% relative
isk reduction and 2.2% absolute risk reduction in CV events
ompared with HCTZ plus the ACEI. In elderly persons with
rediabetes/metabolic syndrome, attempts should be made to
educe BP using lifestyle modification. If drugs are needed,thiazide diuretics increase risk for incident diabetes mellitus,
which has been associated with increased HF hospitalizations
and other CV events in elderly patients with hypertension.
Based on expert opinion and observational data, elderly
hypertension patients with CKD should have a target BP
130/80 mm Hg, if tolerated. Drug regimens including
ACEIs or ARBs are more effective than regimens without
them in slowing progression of CKD. ACEIs are indicated
in patients with nondiabetic nephropathy. However, there
are no data on outcomes with any class of antihypertensive
agent among elderly patients with hypertension and CKD.
Without proteinuria 300 mg/d, there are no data that
ACEIs or ARBs are better than BP control alone with any
other antihypertensive agent. ACEIs or ARBs should be
administered to elderly hypertensive patients with CKD if
proteinuria is present. Hypertension and HF are both
associated with a more pronounced decline in renal function
in older age. With the recognition of early renal dysfunc-
tion, more patients should benefit from aggressive therapy.
In an observational study of elderly patients who were
hospitalized with acute systolic HF and advanced CKD,
ACEI use was associated with reduced mortality. A retro-
spective cohort of elderly individuals with CKD and acute
MI found benefit from aspirin, beta blockers, and ACEIs.
Aortorenal bypass has been used to treat hypertension,
preserve renal function, and treat HF and unstable angina in
RAS patients with ischemic nephropathy. Advanced age and
HF are independent predictors of mortality. Percutaneous
transluminal renal artery balloon angioplasty with stenting has
replaced angioplasty alone because the stenosis usually involves
narrowing of the ostium. However, there is uncertainty regard-
ing the benefit of stenting on BP control and CKD.
Other Conditions/Special Populations
Among elderly persons with osteoporosis and calcium reg-
ulatory disorders, thiazide diuretics may preserve bone
density and raise blood calcium levels. Loop diuretics can
decrease serum calcium. Epithelial sodium transport chan-
nel antagonists may decrease urinary calcium and may be
considered for people with calcium oxalate kidney stones.
Beta blockers and heart rate–slowing CAs (verapamil or
diltiazem) should be used for ventricular rate control with
supraventricular tachyarrhythmias in elderly persons with
hypertension. Beta blockers should be used for elderly
patients with hypertension, complex ventricular arrhyth-
mias, HF, hyperthyroidism, preoperative hypertension, mi-
graine, or essential tremor.
Blacks: RAAS inhibitors appear less effective than other
drug classes in decreasing BP in elderly blacks, unless
combined with diuretics or CAs. The initial agent in blacks
with uncomplicated hypertension should be a thiazide
diuretic. CAs effectively lower BP in blacks and decrease
CV events, especially stroke. A diuretic or CA plus an
ACEI would be a reasonable combination in blacks. Blacks,
many of whom have severe and complicated hypertension,
usually will not achieve control with monotherapy. Aldo-
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May 17, 2011:2037–114 Hypertension in the Elderlysterone antagonists (spironolactone and eplerenone) are
often beneficial in resistant hypertension, including blacks.
Hispanics: Recommendations for pharmacological man-
agement of elderly Hispanic patients are the same as for
elderly patients in general.
Women: There is no evidence that elderly women respond
differently than elderly men to antihypertensive drugs.
Available data from HYVET (4) and other RCTs suggest
that treatment of hypertension in octogenarians may sub-
stantially reduce CV risk and mortality, but benefits on
cognitive function are less certain. Although a BP 140/90
mm Hg is recommended for all patients in “The Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure,” except for a lower level in special populations (22),
randomized trial evidence to support this BP level in the
very elderly is not robust. Secondary analyses from INVEST
and ACCOMPLISH showed no difference in effects of
antihypertensive drug therapy on outcomes among those
80 years of age versus those 80 years of age. However,
ACCORD BP found no additional benefit, and increased
drug-related adverse experiences, targeting a SBP of 120
versus 140 mm Hg in high-risk patients with diabetes
mellitus who were 55 years of age. Observational data
rom INVEST in hypertensive CAD patients showed a
adir for adverse outcomes at a mean on-treatment SBP of
35 mm Hg for patients 70 to 79 years of age and at 140
m Hg for those 80 years of age.
The following recommendations are offered for persons
80 years of age. Initiate treatment with a single drug
ollowed by a second drug if needed. Achieved SBP 140 to
45 mm Hg, if tolerated, can be acceptable. Low-dose
hiazides, CAs, and RAAS blockers are preferred, but
oncomitant conditions often dictate which drugs are most
ppropriate. Octogenarians should be seen frequently with
he medical history updated at each visit. Standing BP
hould always be checked for excessive orthostatic decline.
lthough BP values below which vital organ perfusion is
mpaired in octogenarians are not known, SBP 130 and
BP 65 mm Hg should be avoided.
Resistant hypertension (e.g., BP that remains above goal
hen patient adheres to lifestyle measures and maximum
olerated doses of complementary antihypertensive agents,
ncluding a diuretic) is associated with increasing age.
easons include higher arterial stiffness, decreased antihy-
ertensive medication efficacy, higher baseline BP, higher
ncidence of organ damage and comorbidities, excess salt
ntake, weight, alcohol, nicotine, poor treatment compli-
nce, volume overload, pseudohypertension, and NSAID
se. Elderly patients with higher baseline SBP typically have
ore severe or longer duration of hypertension that makes
t more difficult to treat because it is often associated with
utonomic dysfunction and organ damage. Volume overload
s commonly due to excessive salt intake, inadequate kidney
unction, or insufficient diuretic therapy. Physicians are less
ggressive treating very elderly patients as many believe thatypertension treatment in an 85 year old has more risks than
enefits. Pseudohypertension represents another reason for
esistant hypertension. Increased arterial stiffness due to
eavily calcified arteries that cannot be fully compressed
akes BP readings falsely higher than the intra-arterial BP.
Although therapy of resistant hypertension must be
ndividualized, a combination of a RAAS blocker, a CA,
nd an appropriately dosed diuretic is frequently effective.
hese agents must be given in adequate dosages at appro-
riate time intervals. Lifestyle modifications (e.g., weight
eduction, sodium restriction, reduction in alcohol intake,
nd the DASH [Dietary Approaches to Stop Hypertension]
iet) may be useful, and secondary causes of hypertension
hould be considered.
dherence to Pharmacological Therapy. Adherence, defined as
xtent to which a patient takes medication as prescribed, is a
ajor issue in antihypertensive therapy in all age groups. A
arge proportion of elderly patients will discontinue or take the
rugs inappropriately. Nonadherence often results in failing to
each recommended BP targets and impacts outcomes. Older
ge, previous nonadherence, low risk for CV events, competing
ealth problems, nonwhite race, low socioeconomic status,
reatment complexity (e.g., multiple dosing, pill burden), side
ffects, and cost of medications predict nonadherence.
reatment Initiation and Goals. Elderly patients who have
ypertension are candidates for nonpharmacological interven-
ions; if they remain hypertensive, drug therapy should be
onsidered. Achieved SBP values140 mm Hg are appropri-
te goals for most patients 79 years of age; for those 80
ears of age, 140 to 145 mm Hg, if tolerated, can be acceptable.
uture Considerations
revention of Hypertension and Its Consequences. Research
hould include both fundamental and clinical investigation
efining pathogenesis of increased vascular and LV stiffness;
CTs to define appropriate treatment thresholds and goals;
omparative effectiveness trials testing various treatment strat-
gies (i.e., different regimens and different intensities of lifestyle
odification); and assessing the relative safety and efficacy of
hese approaches in the prevention of mortality and morbidity.
1. Introduction
1.1. Document Development Process
and Methodology
1.1.1. Writing Committee Organization
The writing committee consisted of acknowledged experts
in hypertension among elderly patients representing the
ACCF, AHA, AAN, ABC, ACP, AGS, ASH, ASN,
ASPC, and ESH. Both the academic and private practice
sectors were represented. Representation by an outside
organization does not necessarily imply endorsement.
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Hypertension in the Elderly May 17, 2011:2037–1141.1.2. Relationships With Industry and Other Entities
Prior to finalizing writing committee membership, all po-
tential authors reported their relevant relationships with
industry and other entities pertinent to this writing effort
that began 24 months prior to receiving their invitation
letter to participate. This information was organized into a
table and reviewed by the ACCF Task Force on Clinical
Expert Consensus Documents for writing committee bal-
ance across a series of elements including relationships with
industry and other entities, regional distribution, sex, race,
and specialty area. The ACCF Task Force on Clinical
Expert Consensus Documents approved the constitution of
this group. On each full-committee conference call, authors
were asked to review the disclosure table and verbally
disclose any additions to their information. As noted in the
Preamble, relevant relationships with industry and other
entities of writing committee members are published in
Appendix 1 of this document. In addition, in the spirit of
full transparency, author comprehensive disclosure informa-
ion (relationships the author deemed not applicable to this
ocument) is made available online as a supplement to this
ocument. For detailed information regarding ACCF’s
isclosure policy, including the definitions of relevant rela-
ionships with industry, visit www.cardiosource.org/
cience-And-Quality/Practice-Guidelines-and-Quality-
tandards/Relationships-With-Industry-Policy.aspx.
1.1.3. Consensus Development
Prior to the first writing committee conference call, an
outline of the document was drafted, and preliminary
writing assignments were made. During the committee’s
first call, the timeline, draft outline and writing assign-
ments, definition of hypertension, and relationships with
industry were discussed and finalized. A thorough liter-
ature review was undertaken on hypertension and the
elderly, results were distributed to authors, and primary
authors drafted their sections for review by secondary
authors prior to submitting their sections for incorpora-
tion into the master draft. The co-chairs edited the
manuscript and sent it back to committee members for
further editing. Several additional conference calls with
the entire committee were held to discuss document
issues in order to achieve consensus. Smaller subgroup
meetings were held when necessary to focus on a partic-
ular area (e.g., management of the patient). Each indi-
vidual contributor of the document had his or her initial
full written presentation critiqued by all other members
of this writing committee. Considerable discussion
among the group focused on the best and most proper
way to manage the elderly patient with hypertension as
the clinical data are limited for this population. The
writing committee arrived at consensus on the document
and signed off on the draft for external peer review.1.1.4. External Peer Review
The document was reviewed by 2 official reviewers nomi-
nated by each of the participating societies in this document,
as well as 5 content reviewers, totaling 25 reviewers in all. A
task force lead reviewer was assigned to the review process to
ensure that the writing committee reviewed and responded
to all reviewer comments in a reasonable and balanced
manner. A complete listing of peer reviewers and their
relevant relationships with industry are listed in Appendix 2.
1.1.5. Final Writing Committee and Task Force
Approval of the Document
The writing committee formally approved the final document.
Subsequently, the task force lead reviewer signed off on the
completeness of the external review process, and the ACCF
Task Force on Clinical Expert Consensus Documents re-
viewed the document for completeness and approved the
document to be sent for final organizational review.
1.1.6. Document Approval
The document was approved for publication by each of the
following participating societies: ACCF, AHA, AAN,
AGS, ASPC, ASH, ASN, and ESH. This document will
be considered current until the task force revises or with-
draws it from distribution.
1.1.7. Document Methodology
An extensive literature search was conducted using the U.S.
National Library of Medicine’s PubMed database that led
to the incorporation of 742 references. Searches were
limited to studies, reviews, and other evidence conducted in
human subjects and published in English. Key search words
included but were not limited to hypertension, aged, elderly,
pharmaceutical preparations, cost, compliance, diagnosis, phys-
ical examination, tobacco, smoking, drug therapy, family his-
tory, premature CVD, risk factors, complications, dyslipidemia,
obesity, cerebrovascular disease, HF, MI, angina, PAD, diabe-
tes mellitus, lifestyle, J-curve, adverse drug event, renal revas-
cularization, osteoarthritis, hypokalemia, prognosis, microalbu-
minuria, and retinopathy. Additional relevant references
have also been identified by personal contacts of the writing
committee members, and substantial efforts were made to
identify all relevant manuscripts that were currently in press.
References selected and published in this document are
representative and not all-inclusive.
The writing committee agreed uniformly that the defini-
tion of elderly would include those 65 years of age.
Recommendations for management of hypertension in the
elderly are largely based on randomized controlled trials and
meta-analyses. However, specific data as they pertain di-
rectly to the elderly population remain limited in some
areas, including specific BP recommendations for patients
with comorbid conditions such as diabetes mellitus, CKD,
and PAD. Recommendations made in these and other areas
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May 17, 2011:2037–114 Hypertension in the Elderlymay be based on expert consensus opinion or on the limited
data available from observational studies.
The recommendations listed in this document are, when-
ever possible, evidence-based. Unlike ACCF/AHA guide-
lines, there is not a large body of peer-reviewed published
evidence to support most recommendations, which will be
clearly indicated in the text. To ensure concordance across
ACCF clinical documents, the writing committee reviewed
documents related to the subject matter previously pub-
lished by the ACCF. Prior ACCF/AHA guidelines contain
recommendations for BP management, but none of these
recommendations are directed to the elderly.
1.2. Purpose of This Expert Consensus Document
Our population is aging, and hypertension in elderly patients is
increasing in prevalence. Approximately 34 million Americans
are currently65 years of age; this number is expected to reach
75 million by 2040, representing more than20% of the U.S.
population. Individuals 85 years of age are the largest
rowing subset in the United States (1), and there have been
ramatic improvements in life expectancy in older adults (2).
lso, the clinical importance of treating this subgroup is
mphasized from the National Hospital Discharge Survey
2000) where the far majority of patients admitted to CV
ervices are 65 years of age, and nearly 80% to 90% of those
ho die on our services are65 years of age. Hypertension in
lderly patients is a complex CV disorder that affects women
ore than men and occurs in essentially all races, ethnic
roups, and countries. Although it appears to be underdiag-
osed in general and particularly among women, minorities,
nd underserved populations, clearly it is also undertreated.
lderly persons are more likely to have hypertension and
solated systolic hypertension (ISH), organ damage, clinical
VD, develop new CV events, and are less likely to have
ypertension controlled.
Hypertension is a very prevalent disorder (about 1 billion
eople worldwide) (3), and as such, it is the most common
odifiable risk factor for conditions such as atherosclerosis,
troke, HF, AF, diabetes mellitus, sudden cardiac death,
cute aortic syndromes, CKD, and may cause death and
isability in patients of all ages. Because it increases with
ging and is also compatible with longevity, there is often
ncertainty about its management in older patients. Indeed,
ypertension in elderly patients represents a management
ilemma to CV specialists and other practitioners. Further-
ore, with the wide adoption of multiple drug treatment
trategies targeting subgroups of hypertension patients with
pecific risk conditions to lower BP beyond traditional
oals, difficult questions arise about how vigorously elderly
atients should be treated. Until very recently, this was a
articular dilemma for the very elderly because most hyper-
ension management trials had upper age thresholds for
nrollment and/or did not present age-specific results. How-
ver, HYVET documented major benefit in those 80 years
f age (4), and consequently, it seems particularly timely to
larify and place into perspective clinical issues relevant to the Sanagement of hypertension in elderly patients. Prior to
YVET, although some clinicians favored treating hyperten-
ion in the very elderly (5), others did not (6,7).
1.3. General Considerations
This clinical scientific statement represents the consensus of
a panel of experts appointed by the ACCF, AHA, AAN,
ABC, ACP, AGS, ASH, ASN, ASPC, and ESH. The
writing group is composed of CV specialists with extensive
experience in hypertension among elderly patients. The
panel focused largely on management of this complex
disease and derived practical and contemporary treatment
strategies for the many subgroups of patients comprising the
broad disease spectrum. Because of limited published clin-
ical trial data in elderly patients, the level of evidence
governing management decisions for drugs or other strate-
gies has often been derived from nonrandomized and
observational-type investigations. Many studies, such as
those that have provided important answers regarding
management of CAD and/or HF, had often limited enroll-
ment of elderly patients. Therefore, treatment strategies
have necessarily evolved based on available data from
younger populations or from observational data, sometimes
obtained in relatively small patient groups, or from the
accumulated clinical experience of individual investigators.
Consequently, construction of strict clinical algorithms
designed to assess prognosis and dictate treatment decisions
for elderly patients with hypertension has been challenging
and with their multiple comorbidities, management deci-
sions must be individualized to the particular patient. This
data gap seems to be closing as many recent trials have
included older patients. The age details of these trials are
summarized in Table 1.
Understanding of the clinical course and optimal manage-
ment of hypertension and associated CVD is increasing. There
is growing awareness of the heterogeneity of patients with
hypertension and the many patient subgroups that inevitably
influence considerations for treatment. Some management
strategies are evolving, and this document cannot, in all
instances, convey definitive assessments of their role in treat-
ment. For some uncommon subsets, there are limited data
currently available to definitively guide therapy. With these
considerations in mind, the panel has aspired to create a
document that is not only current and pertinent, but also has
the potential to remain relevant for years.
1.4. Nomenclature, Definitions, and
Clinical Diagnosis
The usual definitions of hypertension and target BP levels
might not be applicable to the elderly hypertensive popula-
tion. Criteria for categorizing BP vary (22–25) and have not
been further characterized for the elderly. In the United
States, a clinical diagnosis of hypertension is established by
demonstrating a SBP 140 mm Hg and/or a DBP 90
m Hg on at least 2 occasions as summarized in “The
eventh Report of the Joint National Committee on Pre-
Table 1. Trials of Antihypertensive Treatment in the Elderly
Trial Name
(Reference) N
Age
Range (y)
Mean
Age (y) Drug(s)
% Risk Reduction
CVA MI
Hospitalization
for CHF
Total CVD
(or All CV
Events)
All-Cause
Mortality
CV
Mortality
Response to
Therapy Same
Above Mean Age
ACCOMPLISH (8) 11,506 55 68 (Benazepril amlodipine)
versus (benazepril  HCTZ)
16 NR 1 4 17* 10 20* Yes†
ALLHAT (9) 33,357 55 67 Amlodipine versus
chlorthalidone
7 No
difference
1 38* 1 4 4 NR Yes
Lisinopril versus
chlorthalidone
1 15* 1 5 1 19* 1 10* No
difference
NR Yes
ANBP 2 (10) 6,083 65–84 72 ACE inhibitors versus
diuretics
1 2 14 15 11* 10 NR Yes
Coope and
Warrender (11)
884 60–79 68 Atenolol  bendrofluazide 42* 3 32 24 3 22 Stroke only
EWPHE (12) 840 60 72 HCTZ  triamterence 
methyldopa
36 20 22 29 9 27* NR
HYVET (4) 3,845 80–105 84 Indapamide  perindopril 30 NR 64* 34* 21* 23 Yes‡
INVEST (13) 22,576 50 66 Verapamil versus atenolol No
difference
No
difference
No
difference
No
difference
No
difference
No
difference
Yes§
LIFE (14) 9,193 55–80 67 Losartan versus atenolol 25* NR 3 13* 10 11 NR
MRC (15) 4,396 65–74 70 Atenolol  HCTZ or amiloride 25* 19 NR 17* 3 9 Yes‡
SHEP (16) 4,736 60 72 Chlorthalidone 36* 25 55 32 13 20 NR
STONE (17) 1,632 60–79 67 Nifedipine 57* 6 68 60* 45 26 Yes‡
STOP-HTN (18) 1,627 70–84 76 Atenolol  HCTZ or amiloride
or metroprolol or pinodolol
47 13 51 40 43 50 Yes‡
Syst-China (19) 2,394 60 67 Nitrendipine captopril HCTZ 38* 33 38 37* 39* 39* All but CV
mortality
Syst-Eur (20) 4,695 60 70 Nitrendipine 42 26 36 31 14 27 NR
VALUE (21) 15,245 50 67 Amlodipine versus valsartan 1 15 NR 11 1 6 1 4 NR NR
*Statistically significant; †65 years of age, HR0.81, 70 years of age, HR0.79; ‡Specific data not reported; §70 years of age, RR1.06, 70 years of age, RR0.93.
ACE indicates angiotensin-converting enzyme; ACCOMPLISH, Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP2, Second
Australian National Blood Pressure study; CHF, congestive heart failure; CV, cardiovascular; CVA, cerebrovascular accident; CVD, cardiovascular disease; EWPHE, European Working Party on High Blood Pressure in the Elderly; HCTZ, hydrochlorothiazide; HYVET,
Hypertension in the Very Elderly; INVEST, International Verapamil SR/Trandolapril Study; LIFE, Losartan Intervention For Endpoint; MI, myocardial infarction; MRC, Medical Research Council; N, number of randomized patients; NR, not reported; SHEP, Systolic Hypertension
in the Elderly Program; STONE, Shanghai Trial of Nifedipine in the Elderly; STOP-HTN, Swedish Trial in Old Patients with Hypertension; Syst-China, Systolic Hypertension in China; Syst-Eur, Systolic Hypertension in Europe; VALUE, Valsartan Long-term Use Evaluation;
and 1, increase.
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May 17, 2011:2037–114 Hypertension in the Elderlyvention, Detection, Evaluation, and Treatment of High
Blood Pressure” (22). In addition, considerable evidence has
evolved to classify SBP 130 mm Hg but 140 mm Hg as
ess than optimal for individuals with certain conditions.
pecific BP goals based on coexisting conditions (Table 2)
ave been recommended for prevention and management of
AD (26). These conditions include HF or asymptomatic
V dysfunction (27) with a BP goal of 120/80 mm Hg.
or patients with diabetes mellitus (and impaired glucose
olerance without clinical diabetes mellitus or “prediabetes”
nd metabolic syndrome) and/or CKD, “The Seventh
eport of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pres-
ure” (22), the American Diabetes Association (28), and the
ational Kidney Foundation (29) recommend a BP goal
130/80 mm Hg. Many also consider patients with CAD,
s well as those with coronary risk equivalents (i.e., CAD,
AD, aortic or intracerebral artery aneurysm) in this cate-
ory. Evidence is evolving to support the suggestion that
argeting a BP lower than traditional goals may prevent or
elay progression or promote stabilization of atherosclerosis
30,31). Thus, although the traditional BP 140/90 mm
g will be used herein to define hypertension, for special
opulations (Table 2), a lower BP target may be considered
ptimal. However, BP targets are based primarily on obser-
ational data in middle-aged patients, and optimal targets
or elderly patients, especially those with systolic hyperten-
ion and normal or low DBP (e.g., ISH) remain to be
efined from randomized trial data. Importantly, AC-
ORD BP found among patients with type 2 diabetes
ellitus at high risk for CV events targeting SBP120 mm
g, as compared with 140 mm Hg, did not reduce the
ate of fatal and nonfatal major CV events at the expense of
n increase in adverse experiences attributed to BP medica-
ions. Furthermore, results were the same among the sub-
roup of 1,617 patients 65 years of age (32).
It is also important to note that, although a specific BP
Table 2. American Heart Association Recommendations for
Prevention and Management of Ischemic Heart Disease:
Blood Pressure Targets
Patient Type
Goal BP
(mm Hg)
eft ventricular dysfunction 120/80
iabetes mellitus 130/80
hronic renal disease 130/80
AD or CAD risk equivalents* 130/80
arotid artery disease 130/80
eripheral arterial disease 130/80
bdominal aortic aneurysm 130/80
igh-risk (10-y FRS 10%) 130/80
Uncomplicated hypertension (none of above) 140/90
*CAD risk equivalents include diabetes mellitus, peripheral arterial disease, carotid arterial
disease, and abdominal aortic aneurysm.
BP indicates blood pressure; CAD, coronary artery disease; and FRS, Framingham Risk Score.
Modified from Rosendorff et al. (26).evel may be used to classify a person as hypertensive, a finiteBP level, per se, is only a biomarker that is somewhat
removed from the complex CV disorder termed hyperten-
sion. In the future, improved descriptors more closely linked
to the disorder itself may evolve to better define who has the
disorder, to better predict those at risk for adverse outcomes,
and also to better target treatment.
Criteria to define elderly also vary, because it is not
possible to develop a specific age-based definition derived
from physiological or pathological data because aging is a
continuous and progressive process for both sexes in all
cultures. In addition, vascular aging rates vary considerably
among individuals as a result of genetic, cultural, environ-
mental, behavioral, and disease-related factors. It is there-
fore not possible to define elderly on a purely physiological
basis, and any definition is inherently arbitrary and subjec-
tive. For this document, writing committee members agreed
to use the traditional demographic definition of 65 years
of age to define the elderly population. However, recogniz-
ing that there are clinically relevant physiological differences
between the “young old” (65 to 74 years of age), the “older
old” (75 to 84 years of age), and the “oldest old” (85 years
of age), age-specific subgroup data are presented when
available, and limitations of existing data are noted. It may
also be important to determine whether the elderly individ-
ual requires “assisted living” or is “ambulant and free-living”
because these qualifiers begin to describe physiological
impairments and comorbidities associated with the aging
process.
1.5. Magnitude and Scope of the Problem
1.5.1. Epidemiology of Hypertension Related
to Aging
Between 1999 and 2004, the prevalence of hypertension in
the U.S. population (18 years of age) was 27% for both
men and women, (33) and prevalence increases progressively
with age, so the majority of elderly are hypertensive (Figure 1)
(34). In the Framingham Heart Study (FHS), 90% of
participants with a normal BP at age 55 years eventually
developed hypertension (35). Hypertension prevalence is
Figure 1. Prevalence of High Blood Pressure
in Adults by Age and Sex (NHANES 2005–2006)NHANES indicates The National Health and Nutrition Examination Survey. Modified
from Lloyd-Jones et al. (34).
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Hypertension in the Elderly May 17, 2011:2037–114greater in older African Americans, especially women, than
in older non-Hispanic whites, and somewhat higher in
non-Hispanic whites than in Hispanic Americans (34).
In older Americans, hypertension is the most important
risk factor for CVD, with estimates that 69% of patients
with an incident MI, 77% with incident stroke, and 74%
with incident HF have antecedent hypertension (34). In
addition, hypertension is a major risk factor for incident
diabetes mellitus (36), as well as for AF (37) and CKD (34).
In 2005, hypertension was the primary cause of death for
57,356 Americans, and a primary or contributory cause for
300,000 of the 2.4 million total deaths that year (34).
Moreover, hypertension death rates increased 25.2% from
1995 to 2005, and the actual number of deaths rose by
56.4%, in part reflecting increasing numbers of older Amer-
icans and high prevalence of hypertension at older age (34).
In 2009, total direct and indirect costs attributable to
hypertension were estimated to be $73.4 billion (34).
People 65 years of age currently comprise 13.0% of the
U.S. population (38). With aging of the “baby boomer”
generation, it is anticipated that by 2030, the number of
people in this age group will increase by almost 80%, and
that approximately 1 in 5 Americans will be 65 years of
age (Table 3) (34). Although older patients with hyperten-
ion are more likely to be aware of their condition and
eceiving treatment than middle-aged patients (Figure 2),
P control rates are lower in the elderly, especially after age
0 years (34). The marked growth in size of the older
opulation anticipated over the next decades means the
ocietal burden of hypertension will rise progressively if we
o not develop more effective strategies for enhancing BP
ontrol rates.
1.5.1.1. ISOLATED SYSTOLIC HYPERTENSION
Aging is associated with a progressive increase in aortic
stiffness, in part, related to increased collagen with cross-
linking and degradation of elastin fibers. Consequently,
SBP rises gradually throughout adult life, although DBP
peaks and plateaus in late middle-age, declining slightly
thereafter (Figure 3) (39). So, the proportion of hyperten-
ive patients with ISH increases with age—65% of patients
ith hypertension 60 years of age (39) and over 90% 70
ears of age (Figure 4) (40). The prevalence of ISH is higher
n women than in men, whereas the proportion of hyper-
ension attributable to ISH in older adults is similar across
acial and ethnic groups (34).
In decades past, the apparently inexorable rise in SBP
ith increasing age fostered the view that this was an
daptive response essential to support organ perfusion, and
n empiric formula “100  age” was often used to estimate
he “appropriate” SBP. However, data from the FHS and
ther epidemiologic investigations provide compelling evi-
ence that SBP is a strong independent risk factor for
ncident CV events in all decades of life (41,42). Further-
ore, as discussed in Section 4.2, randomized trials docu-
ent that treatment of elevated SBP substantially reducesV risk in cohorts of elderly patients. As a result, beginning
ith “The Fifth Report of the Joint National Committee on
etection, Evaluation, and Treatment of High Blood Pres-
ure” (43), the focus of management shifted from a primary
mphasis on controlling DBP to progressively greater em-
hasis on controlling SBP, particularly in older patients
22).
1.5.1.2. SYSTOLIC AND DIASTOLIC HYPERTENSION AND PULSE PRESSURE
After age 70 years, diastolic hypertension accounts for
10% of all patients with hypertension (Figure 4) (40). In
addition, the relationship between DBP and CV risk is
bimodal in older individuals, with DBPs of 90 mm Hg
associated with similar increased risk as that associated with
DBPs lower than about 70 mm Hg (40,45). As a result, at
any given level of SBP, CAD risk increases as DBP
decreases (Figure 5) (46,47).
An important implication of this observation is that pulse
pressure (i.e., difference between SBP and DBP), which
increases with age (Figure 5) and is a measure of the degree
of age-related vascular stiffness, emerges as a potent risk
factor for CAD events in older individuals. Pulse pressure
has been identified as a stronger risk factor than SBP, DBP,
or mean pressure in older adults in some studies (48–50). In
the FHS, with increasing age, there was a gradual shift from
DBP to SBP and then to pulse pressure as the strongest
predictor of CAD risk. In patients 50 years of age, DBP
was the strongest predictor. Age 50 to 59 years was a
transition period when all 3 BP indexes were comparable
predictors, and from 60 to 79 years of age, DBP was
negatively related to CAD risk so that pulse pressure
became superior to SBP (49).
1.5.1.3. SPECIAL POPULATIONS
From the standpoint of epidemiology, pathophysiology, and
treatment, there are important subgroups with distinctive
characteristics, including elderly women, blacks, Hispanics,
Table 3. Population Projections by Selected Age Groups and
Sex for the United States: 2010 to 2050 (in 1,000s)
Population Year 2010 Year 2030 Year 2050
Both sexes
65 y of age 40,229 (13.0%) 72,092 (19.3%) 88,547 (20.2%)
85 y of age 5,751 (1.9%) 8,745 (2.3%) 19,041 (4.3%)
Total 310,233 373,504 439,010
Men
65 y of age 17,292 (11.3%) 32,294 (17.6%) 39,917 (18.5%)
85 y of age 1,893 (1.2%) 3,284 (1.8%) 7,458 (3.5%)
Total 152,753 183,870 215,825
Women
65 y of age 22,937 (14.6%) 39,798 (21.0%) 48,630 (21.8%)
85 y of age 3,859 (2.5%) 5,461 (2.9%) 11,583 (5.2%)
Total 157,479 189,634 223,185
Modified from U.S. Census Bureau (38).and Asians that require additional focus. These populations
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May 17, 2011:2037–114 Hypertension in the Elderlyare discussed in more detail in Section 1.5.2 on pathophys-
iology and Section 4 on management.
1.5.1.3.1. ELDERLY WOMEN. Among elderly women, hyper-
tension is a major risk factor for CAD and stroke and a major
contributor to CV and renal morbidity and mortality (51).
Hypertension prevalence is less in women than in men until 45
years of age, is similar in both sexes from 45 to 64 years of age,
and is much higher in women than men65 years of age (52).
Age-adjusted hypertension prevalence, both diagnosed and
undiagnosed, from 1999 to 2002, was 78% for older women
and only 64% for older men (53). Both the prevalence and
severity of hypertension increase markedly with advancing age
in women, such that after age 60 years, a majority of women
have stage 2 hypertension (BP 160/100 mm Hg) or receive
ntihypertensive treatment (54–57). A substantial proportion
f elderly women also have prehypertension or stage 1 hyper-
ension, so the prevalence of normal BP in this group is very
ow (15% of those 60 to 79 years and 6% of those80 years of
ge in the FHS cohort) (55).
Figure 2. Extent of Awareness, Treatment, and Control of High
NHANES indicates The National Health and Nutrition Examination Survey.
Modified from Lloyd-Jones et al. (34).
Figure 3. Mean Blood Pressure According to Age and Ethnic GReprinted from Chobanian et al. (44).Further, BP control is difficult to achieve in elderly
omen. Data from the FHS showed an age-related decrease
n BP control rates that was more pronounced in women
han men (55). Among the oldest participants (80 years of
ge) with hypertension, only 23% of women (versus 38% of
en) had BP 140/90 mm Hg. Gender differences in the
attern of antihypertensive medications prescribed were
oted in this cohort: 38% of women but only 23% of men
ere taking thiazide diuretics. Whether the age-related
ecline in BP control among women is related to inadequate
ntensity of treatment, inappropriate drug choices, lack of
ompliance, true treatment resistance because of biological
actors, or to other factors is unclear.
Data from the NHANES (U.S. National Health and
utrition Examination Survey) highlight a likely contribu-
ory factor to poor BP control in elderly women: an
ncreased prevalence of other CV risk factors, including
entral obesity, elevated total cholesterol, and low high-
ensity lipoprotein cholesterol levels (57). Among adults
d Pressure by Age (NHANES 2005–2006)
in U.S. AdultsBlooroup
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Hypertension in the Elderly May 17, 2011:2037–114with hypertension in NHANES 1999 to 2004, women were
at higher CV risk compared with men: 53% of women, but
only 41% of men had 3 of the 6 risk factors studied
(p0.001).
Contributions of postmenopausal hormonal changes to
BP elevation in elderly women are controversial, in large
part because determining the role of sex hormones (or their
withdrawal) on BP is complex and confounded by effects of
aging and related alterations in CV risk factors such as body
weight and lipid levels (58–64). Conversely, there is strong
evidence from prospective longitudinal studies that
menopause-related BP elevation is dependent on increased
body mass index (BMI) and aging, rather than ovarian
failure, per se (51,62). The pathophysiology of the
menopause-related increase in BP has been inferred from
studies in animals (65,66) and human subjects (58). Endo-
thelial dysfunction, increased arterial stiffness, activation of
RAAS, increased salt sensitivity, oxidative stress, obesity,
and genetic factors have been implicated (58).
1.5.1.3.2. ELDERLY BLACKS. Blacks have the highest age-
djusted hypertension prevalence in the United States:
bout 40% of African-American men and women, versus
bout 27% of white men and women (33). Hypertension
mong blacks is earlier in onset, more severe and uncon-
rolled, and contributes to the highest CAD mortality rates
n the United States, in addition to highest morbidity and
ortality attributable to stroke, LVH, HF, and CKD (22).
ypertension is a significant factor in the disproportionate
ecreased life expectancy for blacks: African-American
en, 70.0 years versus 75.9 years for white men, and
frican-American women, 76.8 years versus 80.8 years for
hite women (67).
Approximately 9 million, or 13.7%, of the total U.S.
ypertensive population is black, 21.2% higher than ex-
ected, based on the percentage of U.S. population (11.3%)
68). From the NHANES III (1988 to 1994) versus
HANES 1999 to 2004, there was a significant increase in
ypertension among non-Hispanic black men aged 60 to 69
Figure 4. Frequency of Untreated Hypertension
According to Subtype and Age
Reprinted from Chobanian et al. (44).ears and 70 years old, from 65.0% and 69.6% to 74.2%nd 83.4%, respectively odds ratio ([OR]: 1.14; 1.20;
0.05) (33). For non-Hispanic black women, aged 60 to
9 years and 70 years, hypertension prevalence increased
rom 73.7% and 71.7% to 84.1% and 83.1%, respectively
OR: 1.14, 1.16; p0.01 and p0.05) (33). Overall, age-
tandardized hypertension rates are increasing, not com-
letely explained by obesity. Interestingly, non-Hispanic
lack men and women showed 14% and 7% significant
mprovement in hypertension treatment rates, possibly as a
esult of focused efforts in that community (33). Although
wareness and treatment have increased, control rates for
hose 70 years of age did not significantly improve from
HANES III to NHANES 1999 to 2004 (21.5% and
8.6%, respectively; pNS).
Compared with whites, blacks are more likely to have
ypertension, more likely to be aware of it, and more likely
o be pharmacologically treated, but less likely to achieve BP
ontrol, especially in middle age (Table 4) (69). Hyperten-
ion awareness was higher among blacks than whites 60
ears of age in NHANES III and NHANES 1999 to 2002
76.9% versus 68.3% in 1998 to 1994 and 81.7% versus
2.3% in 1999 to 2002). Hypertension treatment rates were
lso higher in older blacks versus whites (74.0% versus
4.8%, respectively) (69). Despite improved control rates,
here remains a racial disparity in BP control, especially in
ounger blacks (69). In the group 70 years of age, control
roups were 20.7% in blacks but 30.0% in whites.
Education is associated with improved BP control; less
han high school graduate status is an independent risk
actor and a possible proxy for decreased health literacy (69).
ontrol rates among non-Hispanic blacks 60 years of age
ere 36.8% in NHANES III (1988 to 1994) and 47.4% in
HANES 1999 to 2002, a 28.7% change in BP control
Figure 5. Joint Influences of Systolic Blood Pressure
and Pulse Pressure on Coronary Heart Disease
Joint influences of SBP and pulse pressure on CHD risk, from the Framingham
Heart Study. CHD hazard ratio was determined from level of pulse pressure within
SBP groups. Hazard ratios were set to a reference value of 1.0 for SBP values of
110, 130, 150, and 170 mm Hg, respectively. All estimates were adjusted for age,
sex, body mass index, cigarettes smoked per day, glucose intolerance, and total
cholesterol/high-density lipoprotein. The p values refer to the CHD hazard ratios
determined from the level of pulse pressure within the SBP groups. CHD indicates
coronary heart disease; SBP, systolic blood pressure.
Reprinted from Franklin et al. (46).
2053JACC Vol. 57, No. 20, 2011 Aronow et al.
May 17, 2011:2037–114 Hypertension in the Elderlyover time (p0.01). This was not significantly different
from whites over the same period (38.4% and 50.4%), a
30.3% increase in the same age group (p0.001).
Blacks have increased rates of overweight and obesity,
physical inactivity, and inadequate potassium intake, espe-
cially in a high sodium dietary environment. Environmental
factors affect differences in rates of elevated BP in popula-
tions of African descent, related to increased BMI and ratio
of sodium-to-potassium intake (70). Sodium restriction,
weight maintenance or loss, increased aerobic activity,
decreased alcohol intake, and high potassium/low sodium
diets, such as the DASH diet, rich in fruits, vegetables, and
low-fat dairy products have all been shown to be beneficial
in reducing BP, as in other populations (22). The beneficial
effect of sodium restriction increased with age in blacks;
however, the mean age of DASH participants was 4410
Figure 6. Age-Specific Prevalence of Hypertension in U.S. Adul
Table 4. Hypertension Awareness, Treatment, and Control in
the U.S. Adult Hypertensive Population (NHANES 1999–2004)
NHANES Population
(by Age, y)
Awareness
1999–2004, %
Treatment
1999–2004, %
Control
1999–2004, %
MA men, 50–69 67.3 56.1 28.4
NHW men, 50–69 76.5 68.1* 48.1*
NHB men, 50–69 80.7 72.9* 39.6*
MA men, 70 71.2 62.7 25.1
NHW men, 70 73* 65.7* 34.8*
NHB men, 70 75.1 70.2 28.6
MA women, 50–69 72.2 60.0 28.0
NHW women, 50–69 79.6 68.9 39.6
NHB women, 50–69 87.7* 80.3 43.0*
MA women, 70 66.4 58.5* 19.0*
NHW women, 70 70.7 63.9* 25.8
NHB women, 70 81.6 77.7* 26.0
*Statistically significant.
MA indicates Mexican American; NHANES, The National Health and Nutrition Examination
Survey; NHB, non-Hispanic black; and NHW, non-Hispanic white.
Modified from Cutler et al. (33).MA indicates Mexican American; NHANES, The National Health and Nutrition Examination S
Modified from Cutler et al. (33).years (71). Reduced sodium intake and DASH diet should
be advocated for prevention and treatment of hypertension,
especially in blacks, and response to reduced sodium
strengthens with increasing age.
1.5.1.3.3. ELDERLY HISPANICS. Hispanics constitute the larg-
est growing ethnic group in the United States, comprising
approximately 15% of the population with a growth rate
almost 4 times that of the total population (72). Strategies
to reduce morbidity and mortality from hypertension among
elderly Hispanics are therefore essential.
Hypertension prevalence, treatment, and control rates are
often thought to be worse in Hispanics than in non-
Hispanic whites and blacks; however, data are conflicting
(73). This difference, in part, is because Hispanics are not a
homogeneous group in terms of genetics, sociodemograph-
ics, and health-related lifestyles. Accordingly, certain His-
panic subpopulations are characterized by low levels of
hypertension awareness, treatment, and control. In addition,
different Hispanic subgroups may have different levels and
frequencies of other CVD risks and health outcomes. For
example, Puerto Ricans have a worse health status than
Mexican Americans and Cuban Americans (74), including
consistently higher hypertension-related mortality rates
than other Hispanic subpopulations and non-Hispanic
whites (73). Much of this disparity appears driven by
sociodemographic and health-related lifestyle factors. Pov-
erty, language issues, lack of education, diet, increased social
stress, and high prevalence of diabetes mellitus and obesity
all contribute.
Mexican-American men age 60 to 69 years had a lower
hypertension prevalence than non-Hispanic white men and
non-Hispanic black men (33) (Figure 6), and those 70
years of age had a greater prevalence than non-Hispanic
white men but less than non-Hispanic black men. For
Mexican-American women 60 to 69 years of age, the
HANES 1999–2004)ts (Nurvey; NHB, Non-Hispanic Black; and NHW, Non-Hispanic White.
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less than non-Hispanic black women. For Mexican-
American women 70 years of age, the prevalence was the
same as non-Hispanic white women but less than non-
Hispanic black women. In NHANES 1999 to 2004, hy-
pertension awareness, treatment, and control rates in
Mexican-American men 50 to 69 years of age were 67.3%,
56.1%, and 28.4%, respectively, and consistently less than in
non-Hispanic whites and non-Hispanic blacks (Table 4).
Older (age 70 years) Mexican and Mexican-American
women have a greater prevalence of hypertension than male
counterparts (75). Also, older Mexican women who mi-
grated to the United States have greater risk for hyperten-
sion than female counterparts in Mexico (75). Conversely,
older Mexican-American men that immigrated have a lower
risk than male counterparts in Mexico.
Although population-based studies often reveal BP prev-
alence, treatment, and control rates that are worse in
Hispanics than in non-Hispanic whites, these disparities
often disappear when Hispanics are provided with afford-
able and easy access to appropriate medical care. Older
Hispanics have achieved similar BP control as non-
Hispanic whites and blacks (76–82), and no differences
were seen in BP responses or outcomes in those above the
mean age (65.9 years for Hispanics and 68.5 for non-
Hispanics). For example, the INVEST compared 8,045
Hispanic with 14,531 non-Hispanic hypertensive CAD
patients randomized to a CA-based or beta-blocker–based
strategy (76) with an ACEI or HCTZ as needed for BP
control or organ protection. After 61,835 patient-years
follow-up and adjusting for baseline BP values, Hispanic
patients had better BP control (defined as the proportion
with 140/90 mm Hg) than non-Hispanic patients at 24
months (p0.001). They also experienced significantly
fewer deaths, nonfatal MIs, or nonfatal strokes. Recom-
mendations for pharmacological management of elderly
Hispanic patients are the same as for elderly patients in
general, as described in Section 4.
1.5.1.3.4. ELDERLY ASIANS. Asian Americans (familial origin
Far East, Southeast Asia, or Indian subcontinent) are
rapidly growing in percentage in the United States, and
CVD is their leading cause of death, with perhaps higher
stroke mortality than whites (83). Asians constitute approx-
imately 5% of the U.S. population; 23.8% are Chinese,
18.3% Filipino, 16.2% Asian Indian, 10.9% Vietnamese,
10.5% Korean, and 7.8% Japanese, with the remaining in
other groups (84). In the 2004 to 2006 National Health
Interview Survey, Filipino adults (27%) and Japanese adults
(25%) were more likely than Chinese (17%) or Korean
adults (17%) to have ever been told they have hypertension,
with overall rates similar to whites (85). The 1999 to 2004
NHANES indicated the prevalence of hypertension in
Asian Americans was 16.1% and that of white Americans
was 28.5% (83). Among community-dwelling Asian Amer-
icans, mean age 74 years, hypertension rate, awareness rate,
and treatment rate were 51.9%, 37.9%, and 24.9%, respec-tively. Hypertension control was worst among the oldest
persons (86).
There may be some differences in responses and side
effects to antihypertensive treatments in AsianAmericans
versus whites. Japanese appear to have a higher frequency of
salt sensitivity than whites (87), possibly influenced by more
prevalent polymorphisms of the angiotensinogen, alpha-
adducing, and aldosterone synthase genes. Beta blockers
and CAs may give more robust BP response at lower
dosages, and ACEI-associated cough may be more common
than in whites. Chinese may have greater sensitivity to
BP-lowering and bradycardic effects of propranolol than
whites. Genetic variants in the beta1-adrenergic receptor
gene might contribute (88). Eplerenone is very effective at
lowering SBP in Japanese patients with hypertension, in-
cluding those with low-renin hypertension (89). A study in
Hong Kong found that patients with hypertension had a
larger decrease in BP in response to isradipine than seen in
whites in the United States (90).
The Systolic Hypertension in China trial (19) assigned
2,394 patients 60 years of age (mean 66 years of age) with
SBP 160 to 219 mm Hg and DBP 95 mm Hg to either
nitrendipine (10 to 40 mg/d) or placebo, with addition of
captopril (12.5 to 50.0 mg/d), and/or HCTZ (12.5 to 50
mg/d) as needed for BP control. Stepwise treatment, start-
ing with nitrendipine, improved prognosis, particularly in
patients with diabetes mellitus. At 2 years, the between-
group differences were 9.1 mm Hg SBP (95% CI: 7.6 to
10.7 mm Hg) and 3.2 mm Hg DBP (95% CI: 2.4 to 4.0
mm Hg). Active treatment reduced total stroke 38%
(p0.01), all-cause mortality 39% (p0.003), CV mortality
39% (p 0.03), stroke mortality 58% (p0.02), and all fatal
and nonfatal CV events 37% (p0.004). The adjusted
relative risk for fatal and nonfatal CV events continued to
decline as age increased. They concluded that treatment of
1,000 Chinese patients for 5 years could prevent 55 deaths,
39 strokes, or 59 major CV events. After 5 years of
treatment, the number needed to treat to prevent 1 major
CV event was 16.9 in the Systolic Hypertension in China
trial (19), and 18.9 in the Systolic Hypertension in Europe
trial, which involved white Europeans (20).
1.5.2. Pathophysiology of Hypertension in the Elderly
1.5.2.1. AORTA AND LARGE ARTERIES
The marked age-associated increase in hypertension preva-
lence is largely attributable to changes in arterial structure
and function that accompany aging. Large vessels such as
the aorta become less distensible (91), and although the
precise mechanisms are incompletely understood, they pri-
marily involve structural changes within the media, such as
fatigue fracture of elastin, collagen deposition (92), and
calcification (93), resulting in increases in vessel diameter
and intima-medial thickness. Calcification may occur in the
intima (in conjunction with atherosclerosis), as opposed to
the media (arteriosclerosis); although there is an association
between these processes, they are pathologically distinct
n; LA,
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aging, is associated with diabetes mellitus, LVH (Section
1.6.3.2), and CKD (Section 1.6.6). (96–99). Arterial stiff-
ness is not only a product of structural changes in the arterial
wall but is also induced by circulating and endothelium-
derived vasoactive mediators such as norepinephrine and
endothelin 1 (100). In a group of elderly patients (686
years of age) compared with young patients (379 years of
age), endothelial dysfunction and decreased nitric oxide
availability was associated with increased arterial stiffness
and development of ISH (101).
In addition to structural changes, a number of functional
alterations impact the aging CV system. The increased
stiffening increases pulse wave velocity, which has functional
consequences (Figure 7). One is a change in arterial pulse
contour caused by earlier return of reflected waves from the
periphery to the proximal aorta. These returning waves
summate with anterograde waves to produce late SBP
augmentation quantified as the augmentation index
(102,103). The late SBP peak creates an additional load
against which the older heart must eject blood thereby
increasing LV wall tension. Another functional alteration
with aging is a decline in flow-mediated arterial dilation,
primarily caused by a decrease in endothelium-derived nitric
oxide (104). Reduction in flow-mediated vasodilator capac-
ity further compromises the ability of aged arteries to buffer
flow-related increases in SBP such as during vigorous
exercise (105).
As a result of these and other less well-understood
structural and functional arterial aging changes, there is a
gradual rise in SBP across the adult age span (40,106),
Figure 7. Conceptual Framework for Cardiovascular Adaptation
CBF indicates coronary blood flow; DBP, diastolic blood pressure; EF, ejection fractio
decreased. Modified from Fleg (146).which persists even when overtly hypertensive individualsare excluded (106). The decline in DBP in older adults
(Section 1.5.1.1) is related to blunted ability of the stiffer
aorta and other capacitance arteries to expand in systole and
contract during diastole, to augment DBP. Thus aging,
even in normotensive individuals, is characterized by an
increased pulse pressure, creating greater pulsatile stress on
the arterial system (107–109). In contrast to younger pa-
tients with hypertension, in whom elevated BP is deter-
mined primarily by increased peripheral arterial resistance,
the isolated or predominant elevation of SBP seen in older
adults is mediated by increased conduit artery stiffness.
Because the heart is coupled to the vasculature, the
age-associated increase in arterial stiffness has critically
important effects on cardiac structure and function in the
elderly (Figure 7). A consistent finding (110–112) is a
modest age-associated increase in LV diastolic wall thick-
ness, even among normotensive individuals. Consequent
normalization of systolic wall stress by the thickened LV
wall, in combination with prolonged contractile activation
in the older heart, helps preserve resting LV systolic
function (113). However, prolonged contractile activation
results in less complete myocardial relaxation at the time of
mitral valve opening, reducing the early diastolic LV filling
rate (114,115). Conversely, late LV filling caused by atrial
contraction increases with age (114–116). This augmented
atrial contribution to LV filling, accomplished by a modest
increase in left atrial size (111), preserves LV end-diastolic
volume across the age span (110,117). Notably, these aging
changes in cardiac structure and function, including increased
LV wall thickness, preserved systolic LV function, and reduced
early diastolic filling with increased late filling from a larger left
Arterial Stiffening That Occur With Aging
left atrial; LV, left ventricular; SBP, systolic blood pressure; 1, increased; and 2,s toatrium, mimic changes observed in mild hypertension among
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increase in AF prevalence (Section 1.6.4).
Cardiac output is lower and peripheral vascular resistance
is higher in older patients with hypertension than in
younger ones, but postural decreases in cardiac output,
stroke volume, and LV filling pressure in the upright
posture are less pronounced in elderly patients. Elderly
patients may also have reduced venous capacitance, which
leads to reduced blood volume in the lower body during
upright posture (118).
Stiffening of the aorta also negatively influences myocar-
dial perfusion (119). Because oxygen extraction from blood
perfusing myocardium is very high, an increase in myocar-
dial oxygen supply can only be met by an increase in
coronary flow. Because most (80%) myocardial blood flow
occurs in diastole, central aortic DBP amplitude and dura-
tion of diastole are the principal noncoronary determinants
of myocardial perfusion. Minor changes in diastolic dura-
tion may have as much effect on coronary flow as a severe
coronary stenosis (120). As central arterial stiffness and wave
reflection amplitude increase, SBP rises, pulse pressure
widens, and myocardial systolic wall stress and oxygen
demand increase while diastolic (e.g., coronary perfusion)
pressure decreases (121). Such changes in ventricular/
vascular coupling unbalance the supply/demand ratio and
promote myocardial ischemia. With normal coronary ves-
sels, however, flow is maintained over a wide range of
perfusion pressures by autoregulation (e.g., as perfusion
pressure declines, vasodilation maintains flow) (122). In the
presence of LVH and other conditions associated with
increased myocardial oxygen demand (e.g., increased SBP,
tachycardia), coronary flow increases to meet demands.
When the LV ejects into a stiff aorta, SBP, and hence
myocardial oxygen demand, increases while DBP decreases,
but coronary flow increases to maintain contractile function
(123–125). However, increased aortic stiffness decreases
coronary flow reserve, and during increases in myocardial
contractility, endocardial flow becomes impaired, resulting
in subendocardial ischemia (124). These undesirable alter-
ations are enhanced with coronary stenosis or during reduc-
tions in DBP (123,125,126). In patients with stable angina,
there is an inverse relationship between central aortic stiffness
and coronary flow (127).
Although age-associated increases in arterial stiffness and
SBP are often considered an immutable aging change in
industrialized societies, there is accumulating evidence that
these “normative” aging changes are markedly attenuated in
populations not exposed to a lifestyle of high sodium,
high-calorie diets, low physical activity levels, and increasing
obesity rates. For example, populations with habitually low
sodium intake demonstrate less arterial stiffening with age
than those with high sodium consumption (128). Improve-
ment in arterial distensibility has been observed after a low
sodium diet (129). In addition, arterial distensibility (102)
and flow-mediated vasodilator capacity are enhanced (130)
in older endurance athletes compared with their sedentarypeers of similar age. A less atherogenic lipid profile, thinner
carotid artery wall, markedly lower BP, and better preserved
early diastolic LV filling have been observed in lean middle-
aged and older adults practicing voluntary caloric restriction
of approximately 30% for several years compared with
persons with more typical dietary patterns (131,132). It is
therefore likely that the striking age-associated rise in SBP
and incident hypertension in developed countries, and
certain individuals in the United States, could be substan-
tially reduced by adoption of a healthier lifestyle.
1.5.2.2. AUTONOMIC DYSREGULATION
Age-associated reduction in baroreflex function and increase
in venous insufficiency contribute to a high prevalence of
orthostatic hypotension in the elderly, which is a risk for CV
events as well as falls and syncope (133–137). In contrast,
orthostatic hypertension, where BP increases with postural
change, is also prevalent among the elderly (138–142). This
is part of the orthostatic BP dysregulation associated with
aging. The orthostatic SBP increase can exceed 20 mm Hg.
These patients are generally older, have a greater frequency
of LVH, CAD, and silent cerebrovascular disease by mag-
netic resonance imaging (MRI) than elderly patients with
hypertension with or without orthostatic hypotension. The
orthostatic BP increase is blocked by alpha-adrenergic
blockade, indicating that alpha-adrenergic activity may be a
predominant pathophysiological mechanism (143).
Yet the neurohormonal plasma profile of older patients
with hypertension is similar to that observed in normoten-
sive older individuals. Plasma norepinephrine increases with
age, though to a greater degree in normotensive patients
(144,145). The age-associated rise in plasma norepinephrine
is thought to be a compensatory mechanism for reduction in
beta-adrenergic responsiveness with aging (145,146). In con-
trast, plasma renin activity declines with age and is lower in
older than younger patients with hypertension (144,146); this
has been attributed to the effect of age-associated nephroscle-
rosis on the juxtaglomerular apparatus. Thus, hypertension in
the elderly is usually associated with low plasma renin levels.
Plasma aldosterone levels also decline with age, resulting in
greater risk for hyperkalemia, especially when coupled with an
age-associated decline in GFR (146).
1.5.2.3. RENAL FUNCTION AND CATION BALANCE
Between 30 and 85 years of age, renal mass, particularly the
cortex, declines 20% to 25% (147). The aging kidney is
characterized by progressive development of glomeruloscle-
rosis and interstitial fibrosis, which is associated with a
decline in GFR and reduction of other renal homeostatic
mechanisms (147,148). Age-associated declines in mem-
brane sodium/potassium–adenosine triphosphatase may also
contribute to geriatric hypertension because this results in
increased intracellular sodium that may reduce sodium–
calcium exchange and thereby increase intracellular calcium
and vascular resistance. Reductions in cellular calcium efflux
caused by reduced calcium–adenosine triphosphatase activ-
ity may similarly increase intracellular calcium and vascular
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contributes to suppression of plasma renin activity and low
aldosterone levels (148).
Renal hemodynamics are impaired in elderly patients
with untreated ISH. Lower GFR and effective renal plasma
flow characterize the older hypertension patient with a BMI
26.5 kg/m2 (150). In the elderly, pulse pressure is in-
ersely related to GFR, suggesting that increased vascular
tiffness may accelerate age-related decline of GFR and
enal plasma flow, which is a probable reflection of preglo-
erular resistance. In elderly patients with untreated ISH
151), increasing SBP was associated with the greatest risk
f decline in renal function; whereas DBP, pulse, and mean
rterial pressure had no significant association with decline
n kidney function. Thus, elevated SBP and pulse pressure
re strong risk factors for declining kidney function among
lder persons with ISH. Because renal arterial resistance is
ery low, high flow and low resistance to flow expose the
mall vessels to large pressure fluctuations that may increase
p to 4-fold with aging (152). This exposure to high flow
nd pulsatile pressure causes microvascular damage, contrib-
ting to CKD.
1.5.2.3.1. SODIUM. Mechanisms underlying hypertensive re-
ponses to high salt intake and salt sensitivity are contro-
ersial. Earlier studies have shown the central role that
idneys play in BP control, as well as the relationship
etween alterations in BP and the ability of kidneys to
odulate fluid volume through rapid increase in natriuresis
r “pressure natriuresis” (153). Salt sensitivity, characterized
y an increase in BP in response to positive salt balance,
ccurs in obese and elderly populations (154). Low natri-
retic activity in salt-sensitive individuals may stimulate the
AAS; thus, together with vasoconstrictor effects of endo-
helin, inhibition of nitric oxide regulation of renal flow,
atriuresis, and increase in SNS activity may explain the
elationship between sodium sensitivity, obesity, and aging
nd hypertension (155). The capacity of the kidney to
xcrete a sodium load is impaired with age, contributing to
P elevation (148,156). Increased fractional reabsorption of
odium in the proximal tubule in the elderly may contribute
o their tendency to exhibit an expanded sodium space
esulting in salt-sensitive BP, and eventually fluid overload
148,156). There is a significant positive association be-
ween 24-hour sodium excretion as well as urinary sodium/
otassium ratio and SBP (157). The relation between
odium excretion and SBP is stronger for older than
ounger adults, perhaps reflecting longer exposure with
ging or diminished capacity to handle sodium.
A chronic high-sodium diet in elderly individuals with
ypertension is associated with an increase in BP that is
ore marked for SBP than DBP (158). Moderate sodium
estriction in elderly patients with hypertension significantly
ecreases SBP (159,160).
Age-related increases in salt sensitivity result, in part,
rom reduced ability to excrete a salt load due to reduction
n both kidney function and generation of natriureticubstances such as prostaglandin E2 and dopamine (149).
ailure of a sodium pump inhibitor, marinobufagenin, in
lder persons may be involved in the increased salt sensi-
ivity with aging (161). An increase in BP with increasing
alt load appears most pronounced in ISH and could be
odulated by angiotensin genotype (162). Additionally, the
ytoskeleton protein alpha-adducin polymorphism has been
ssociated with excess risk among elderly patients with
ypertension and CAD (163). This polymorphism is im-
licated in renal sodium handling and BP regulation (164),
lastic properties of conduit arteries (165), and hypertension
166), as well as ischemic stroke in elderly women (167).
1.5.2.3.2. POTASSIUM. Potassium excretion is limited in the
ged normal individual (147). The decrease in kidney mass
hat occurs with aging includes reduction in tubular mass,
roviding fewer transport pathways for potassium excretion
147). Plasma aldosterone levels also decline with age,
onsequently, elderly patients with hypertension are more
rone to drug-induced hyperkalemia (147).
.5.3. Secondary Causes of Hypertension Important in
he Elderly
1.5.3.1. RENAL ARTERY STENOSIS
The demographics of patients with RAS are shifting toward
older ages and more severe comorbid disease. The incidence
of RAS increases with age, and RAS is a risk factor for poor
kidney function, but there is very limited evidence-based
information about effective screening or treatment
strategies.
RAS occurs in ostial segments extending from adjacent
aortic plaque (168). Hemodynamically significant RAS is
defined as70% diameter narrowing of the renal artery that
results in significant reduction of renal blood flow (70%),
decreased intraglomerular pressure, activation of the RAAS
to increase BP, and decreased kidney size. Increases in
plasma AII levels result in vasoconstriction and increase BP.
A key role for AII is to maintain perfusion pressure within
the intraglomerula through constriction of efferent arterioles
and increases in systemic BP (168). Increases in intrarenal
AII also cause transient sodium retention, through AII
effects on proximal tubules, which culminates in pressure
natriuresis secondary to increases in BP over time and
reestablishes sodium balance. When RAS is bilateral, the
mechanism of hypertension is through volume expansion.
In autopsy studies, RAS prevalence ranges from 4% to
50% and increases with increasing age. A population-based
study of subjects 65 years of age (mean 77.2 years of age)
without recognized kidney disease, found RAS (60%
lumen narrowing by ultrasound) in 6.8% (169,170). Elderly
patients with widespread PAD have RAS rates ranging
from 35% to 50% (171). Evaluation of the entire renal
arterial tree of both kidneys (172) showed a RAS prevalence
of 87% for those 75 years of age with PAD. Aortic
angiography identified RAS in 38% of patients with aortic
aneurysm, 33% of those with PAD, and 39% of those with
lower limb occlusive disease (173).
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unclear. When elderly patients (mean age 73.28.1 years,
median eGFR 51.2 mL/min/1.73 m2) undergoing non-
emergent coronary angiography were angiographically
screened for RAS, and those with 50% RAS referred for
nuclear renography, about half had evidence of reduced
perfusion to 1 kidney (174,175). Of these, 13% were
discordant with the angiographic lesion, and only 9% had
positive captopril renograms. A positive captopril renogram
was associated with severe (70%) unilateral RAS. Thus,
presence of known anatomic lesions does not correlate with
captopril renogram positivity. It is unclear whether nuclear
renography is a poor functional test in this population or the
stenotic lesions are not functionally significant (174).
The importance of “incidental” RAS identified at non-
emergent cardiac angiography has been examined (175).
Patients with 50% stenosis underwent nuclear renography
and were managed with or without stenting as recom-
mended by their nephrologist and/or cardiologist. Of the
140 patients, 67 (48%) were stented, mostly for “preserva-
tion of kidney function” (70.1%) and/or resistant hyperten-
sion (53.7%). Patients who received stents were younger and
had higher SBP and more severe RAS. After follow-up
(median 943 days), there was no difference between groups
in rate of GFR decline; presence of cerebrovascular disease
was the only factor associated with a poor outcome. Al-
though there was no evidence of either harm or benefit of
stenting, the significance of these lesions and how they are
best managed remains unclear (175). The ASTRAL (An-
gioplasty and Stenting for Renal Artery Lesions) trial of 806
patients found substantial risks, but no evidence of mean-
ingful clinical benefit from revascularization in patients with
atherosclerotic RAS (669). Additional information should
come from the ongoing CORAL (Cardiovascular Out-
comes in Renal Atherosclerotic Lesions) trial to determine
whether stenting atherosclerotic RAS in patients reduces
cardiovascular and/or renal events (www.coralclinicaltrial.org).
Knowledge about natural history of atherosclerotic RAS in
the elderly is limited because of variation of study cohorts
and potential selection and/or follow-up (survivor) bias.
Data on progression of RAS were provided from the
Cardiovascular Health Study using follow-up renal ultra-
sound for an elderly cohort (mean age 82.83.4 years
[277]). The overall estimated change in renovascular disease
among all 235 kidneys studied was 14.0%, with progression
to significant RAS in only 4.0%. Longitudinal increase in
DBP and decrease in kidney size were significantly associ-
ated with progression to new (i.e., incident) significant
renovascular disease but not prevalent disease. This was the
first prospective, population-based estimate of incident
renovascular disease and progression of prevalent disease
among elderly Americans living in the community. In
contrast to previous reports among selected patients with
hypertension, these participants had a low frequency of
hypertension and an annualized rate of only 1.3% per year
for significant RAS and 0.5% per year for progression tosignificant RAS as no prevalent RAS progressed to occlu-
sion over 8 years (176).
The risks of RAS are related both to declining kidney
function and to accelerated CVD, with increased morbidity
and mortality (177). Recent studies reemphasize the predic-
tive value of clinical variables, including age, symptomatic
vascular disease, elevated serum cholesterol, and presence of
abdominal bruit, as the most powerful predictors of detect-
ing lesions of at least 50% stenosis (178,179). Additional
clues include hypertension requiring 3 agents that is
controlled only to have significant increases in BP over the
next 4 to 6 months requiring higher doses or additional
medications. Another clue is “flash pulmonary edema,”
when BP spikes occur. Bilateral RAS may be signaled by a
serum creatinine increase50% within the first month after
starting RAAS blockers. This serum creatinine increase can
be associated with hyperkalemia. If testing fails to reveal
RAS, intrarenal ischemia must be considered. Antihyper-
tensive therapy, especially with RAAS blockers, may result
in underperfusion of the kidneys and loss of function (177).
This is particularly true when bilateral stenosis is present or
in those with a solitary kidney.
1.5.3.2. OBSTRUCTIVE SLEEP APNEA
Approximately 30% of adults with hypertension have ob-
structive sleep apnea (180), and its prevalence more than
doubles for each 10-year increase in age in both sexes (181).
bstructive sleep apnea is associated with a high prevalence
f isolated diastolic hypertension (182), and there is a
ignificant association between the incidence of combined
ystolic and diastolic hypertension and obstructive sleep
pnea in patients 60 years of age but not in older patients
183,184). Thus, elderly obstructive sleep apnea patients
ay be less susceptible to consequent hypertension than
ounger patients. Alternatively, these findings may repre-
ent survivor bias for a life-threatening disorder. Interest-
ngly, a population-based study, investigating stroke risk in
eople 70 to 100 years of age, found severe obstructive sleep
pnea independently associated with increased stroke risk
adjusted HR: 2.52) over 6 years (185).
1.5.3.3. PRIMARY ALDOSTERONISM
Although most cases are in younger patients, rare cases with
primary aldosteronism in elderly patients have been reported
(186,187). Primary aldosteronism prevalence varies from 1%
to 11%, increases according to hypertension severity (188),
and cross-sectional and prospective studies report primary
aldosteronism in10% of patients with hypertension (189),
with approximately 70% caused by adrenal adenomas (190).
The adenoma is usually unilateral and comprised of glo-
merulosa cells in the adrenal cortex. Rarely, primary aldo-
steronism is caused by adrenal carcinoma or hyperplasia.
Adrenal hyperplasia is more prevalent among older men,
and both adrenals are overactive without adenoma. Diag-
nosis is suspected in patients with hypertension with per-
sistent hypokalemia confirmed by elevated plasma aldoste-
rone levels and low plasma renin activity (PRA) without
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blockers, even thiazide diuretics).
Laparoscopic adrenalectomy is recommended for tumors
shown to be aldosterone-secreting by adrenal vein sampling.
After adenoma removal, BP decreases in all patients, with
complete hypertension remission in 50% to 70%. With
adrenal hyperplasia, however, approximately 70% will re-
main hypertensive after bilateral adrenalectomy, so surgery
is not recommended. Medical recommendations include a
mineralocorticoid receptor antagonist (Section 4.2.2.1.1.2).
1.5.3.4. THYROID STATUS AND HYPERTENSION
With aging, changes in thyroid homeostasis interact with
age-related CV factors to complicate the usual interactions
between thyroid homeostasis and BP regulation. In a study
of 688 consecutive patients (ages 15 to 70 years) referred for
hypertension management, 3.8% were found to have unrec-
ognized hyperthyroidism, whereas 3.6% had serum levels
indicative of hypothyroidism (191).
1.5.3.4.1. HYPERTHYROIDISM AND BLOOD PRESSURE. Rela-
ively few studies have investigated BP alterations in hyper-
hyroidism in older patients. Although the prevalence of
ypertension itself increases with age, no studies indicate an
ge-related alteration in prevalence of hypertension with
yperthyroidism. Subclinical hyperthyroidism, defined as
educed thyroid stimulating hormone (TSH) in the pres-
nce of normal serum thyroid hormone levels, has a preva-
ence in patients older than 60 estimated between 1% and
% (192). The link between risk of hypertension in patients
ith subclinical hyperthyroidism remains controversial. One
tudy (4,087 German subjects, mean age 49 years, range 35
o 63) found no association between suppressed TSH levels
nd hypertension (193), but there was a trend toward higher
ulse pressures in older ages, independent of TSH levels.
nother study (2,033 patients ages 17 to 89 years) found a
igher prevalence of hypertension in patients with subclin-
cal hyperthyroidism than in euthyroid subjects (194). It is
ikely that inclusion of elderly patients in the latter study
ncreased the power to detect an association.
1.5.3.4.2. HYPOTHYROIDISM AND BLOOD PRESSURE. The
revalence of subclinical hypothyroidism clearly increases
ith age: a study of 3,607 community-living Japanese (ages
7 to 89 years) found 14.6% of subjects age 70 to 80 years
nd 20.1% of subjects 80 years of age with elevated TSH
nd normal free T3 and free T4 (195). In this study, no
ssociation was found between subclinical hypothyroidism
nd BP.
In other studies, hypothyroidism was associated with
iastolic hypertension (196), which may return to normal
ith thyroxine treatment (191). Hypertension incidence
ncreased with age in both euthyroid and hypothyroid
omen with thyroiditis, but hypothyroid patients had sig-
ificantly higher DBP in the fifth and sixth decades of life
han did euthyroid controls. Patients who achieved thera-
eutic levels of L-thyroxine replacement (13 of 14) exhibited
eductions in BP (1575/99  6 mm Hg versus 1433/ i903 mm Hg) (197). A study of subjects not being treated
for hypertension or thyroid disease (mean age 5614 years,
range 29 to 89 years) showed an association between SBP
and DBP with increasing TSH within the normal range of
TSH levels (198). Another study of community-dwelling
subjects (4,140 of whom were 70 years of age) found a
small but consistent rise in SBP (approximately 2 mm Hg)
and DBP (approximately 1.5 mm Hg) with increases in
TSH levels which remained within the reference range.
Interestingly, men 70 years of age with increased TSH
levels failed to show an increase in SBP, while still mani-
festing the increase in DBP.
Studies in primary care settings have yielded differing
results. In a study of postmenopausal women 50 years of
age, 45.4% had hypertension, and 10.9% had hypothyroid-
ism. Although hypertension was correlated with diabetes
mellitus and use of NSAIDs, no association was observed
between hypertension and either untreated or treated hypo-
thyroidism (199). A study of patients referred to an aca-
demic geriatrics clinic identified elevated TSH levels in 122
patients; compared with age-matched controls, the hypo-
thyroid patients showed no significant difference in SBP or
DBP, and linear regression analysis of TSH and DBP
showed no association (200).
Although lower levels of T4/T3 or higher TSH levels
seem to be associated with a rise in DBP, this effect may be
blunted in the oldest old (201). Treatment of overt hypo-
thyroidism can reduce DBP levels to normal. However, the
literature describing asymptomatic, subclinical hypothyroid-
ism does not show a consistent, clinically significant asso-
ciation with hypertension, especially in older patients.
1.5.3.5. LIFESTYLE, SUBSTANCES, AND MEDICATIONS THAT AFFECT
BLOOD PRESSURE
1.5.3.5.1. TOBACCO. Tobacco use is the most common avoid-
ble cause of death and illness in our society, and 4.5 million
dults 65 years of age smoke cigarettes (202). There are
omplex interactions between hypertension and smoking
hat increase the risk of CVD, PAD, cerebrovascular dis-
ase, and kidney disease at all BP levels. Smoking increases
ascular damage by increasing sympathetic tone, platelet
ggregability and reactivity, free radical production, damage
o endothelium, and surges in arterial pressure (203).
moking increases SBP, especially in those60 years of age
204), and smoking cessation reduces SBP (205). These
emodynamic changes are caused, in part, by changes in
ympathetic nervous system activity. Elderly patients have a
onger duration of exposure to these risk factors, as well as
diminished capacity to adjust to them, resulting in an
ncreased incidence of CV events at any level of CVD risk
actors compared with younger candidates (206).
CAD, the most common cause of death in individuals
ith hypertension, occurs at a rate 2 to 3 times higher in
ypertensive versus normotensive individuals, and smoking
ncreases this risk by an additional 2- to 3-fold. For every
ncrement of 10 cigarettes smoked per day, CV mortality
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Chinese study involving patients 60 years of age (mean
age 67 years) followed for 3 years (median), both smoking
and SBP were associated with a higher risk of stroke (208).
Smoking 10 to 20 or20 cigarettes per day increased stroke
risk about 2-fold (risk ratios [RR]: 1.78 and 2.23, respec-
tively). When moderate (10 to 20 cigarettes per day) and
heavy (20 cigarettes per day) smokers were combined and
compared with those that had never smoked, the risk ratio
for fatal stroke was 2.66. Smoking 20 cigarettes per day
also increased the risk of all-cause mortality, non-CV
mortality, and cancer mortality (RR: 2.04, 4.66, and 4.74,
respectively).
1.5.3.5.2. ALCOHOL. Several mechanisms have been sug-
gested for the relationship between alcohol and elevated BP,
but these are not known to differ among the elderly.
Proposed mediators include: neurohormonal (sympathetic
nervous system, endothelin, RAAS, insulin/insulin resis-
tance, corticotrophin, or cortisol); inhibition of vascular
relaxing substances (nitric oxide); calcium depletion; mag-
nesium depletion; increased intracellular calcium or other
electrolytes in vascular smooth muscle cells; and increased
plasma acetaldehyde (209). Drinking, especially outside
meals, is significantly associated with hypertension. There is
no difference in risk between beer, wine, and liquor.
1.5.3.5.3. CAFFEINE/COFFEE. Because of the greater propor-
ion of adipose tissue to lean body mass in older subjects,
nd because caffeine is distributed through lean body mass,
dose of caffeine expressed as milligrams per kilogram of
otal bodyweight may result in a higher plasma and tissue
oncentration in elderly compared with younger individuals
210). Metabolism of, and physiological responses to, caf-
eine are similar in elderly and younger individuals, but there
s limited evidence that responses to caffeine in some
ystems may be greater in the elderly at doses in the 200- to
00-mg range (210). One small study found a 4.8 mm Hg
p0.03) higher mean 24-hour SBP and a 3.0 mm Hg
p0.010) mean 24-hour DBP in elderly coffee drinkers
ompared with abstainers. Findings suggest restriction of
offee intake may be beneficial in some older individuals
ith hypertension (211).
1.5.3.5.4. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS.
NSAIDs, including cyclo-oxygenase-2 inhibitors, are fre-
quently used to provide analgesia and anti-inflammatory
benefits (212), but are not without adverse effects in elderly
hypertensive patients (213). In fact, NSAIDs may nega-
tively impact hypertension control in elderly individuals as
NSAID users have higher SBP versus nonusers that are not
explained by age, weight, and type or dose of antihyperten-
sive regimen (214). In persons 65 years of age, NSAID
use increased the risk for initiation of antihypertensive
therapy. Compared with nonusers, low daily NSAID doses
significantly increased the risk 1.55 times, medium daily
doses increased risk 1.64 times, and high daily doses
increased risk 1.82 times (213). A meta-analysis found thatNSAIDs elevated mean supine BP by 5.0 mm Hg (95% CI:
1.2 to 8.7 mm Hg) (215). Not all NSAIDs affect BP in the
same way. Rofecoxib significantly increases SBP compared
with celecoxib (216). Piroxicam seems to produce more
marked elevation in BP (6.2 mm Hg) compared with
sulindac or aspirin (215).
There are several mechanisms by which NSAIDs may
influence BP elevation. Use of NSAIDs or cyclo-
oxygenase-2 inhibitors influences production of prostaglan-
dins: This decreases inflammation but also results in renal
side effects (217). In the setting of physiological stress, renal
function becomes dependent upon prostaglandins, and
NSAID use may be associated with acute deterioration of
kidney function, including sodium retention, decreased
GFR, edema, hyperkalemia, and/or papillary necrosis, as
well as hypertension (218–221).
NSAIDs may also contribute to increased vascular resis-
tance due to increased ET-1 synthesis and/or altered ara-
chidonic metabolism (222–226). They also interfere with
BP control in the elderly through partial reversal of antihy-
pertensive effects of diuretics (218,227–230), beta-receptor
antagonists, and ACEIs (231–233) and ARBs, but not
CAs. NSAIDs antagonize antihypertensive effects of beta
blockers more than vasodilators or diuretics (234). Effects of
NSAIDs on antihypertensive drug effects vary with the
specific NSAID and dose (235).
Caution must be taken when prescribing NSAIDs to
elderly patients with hypertension. Close monitoring for BP
changes, weight gain, fluid retention, and kidney dysfunc-
tion are required. Changing class of antihypertensive drug,
keeping NSAID doses as low as possible, or up-titrating
antihypertensive drugs may be necessary.
1.5.3.5.5. GLUCOCORTICOIDS. Glucocorticoid-induced hy-
pertension occurs more often in the elderly (236) compared
with younger patients. Oral glucocorticoids can increase
SBP as much as 15 mm Hg within 24 hours (236).
Mineralocorticoids and other compounds, such as licorice
and carbenoxolone, that inhibit 11-beta hydroxysteroid
dehydrogenase enzyme increase exchangeable sodium and
blood volume, induce hyp kalemia and metabolic alkalosis,
and suppress plasma renin and AII (236).
Potential complications of corticosteroid use among el-
ders (mean age 67 years) with Crohn’s disease (237) include
an increased risk for developing BP 160/90 (RR: 1.46,
95% CI: 1.09 to 1.95). Analyses stratified by patient age
showed a similar risk of complications for patients 65
years of age and patients 65 years of age.
1.5.3.5.6. SEX HORMONES. Estradiol treatment effects on
SBP in healthy postmenopausal women (238) differ signif-
icantly by age, suggesting an increase in SBP in younger
postmenopausal women, while having the opposite effect in
older postmenopausal women (Section 1.5.1.3.2).
In a cohort of men 60 to 80 years of age who did not have
diabetes mellitus, did not smoke, were not obese, and were
ountreated for hypertension, testosterone levels decreased
which
rval. R
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elevated SBP and DBP hypertensive treatments, and those
with elevated SBP only (ISH) (239). Testosterone levels
were significantly lower in hypertensive treatments (15%)
and ISH men (21%) than in normotensive men (p0.05).
Adjusting for BMI confirmed a significant difference in
plasma testosterone levels between ISH and normotensive
men, but not between hypertensive treatments and normo-
tensive men. Multiple regression analysis confirmed a strong
relationship between testosterone levels and SBP in all 3
groups, whereas a significant relationship between testos-
terone levels and DBP was found only in normotensive
men. Although further studies are needed, findings suggest
that in elderly men with ISH, reduced plasma testosterone
levels may contribute to increased arterial stiffness typical of
these subjects. However, available data do not suggest a
significant effect of testosterone supplementation on BP
(240). The relationship between serum testosterone levels,
testosterone replacement, and arterial BP and other clinical
outcomes among elderly men is under investigation in a
large randomized by trial by the National Institutes of
Health’s National Institute on Aging.
1.5.3.5.7. CALCIUM AND VITAMINS D AND C. Investigators
examined the effect of calcium plus vitamin D supplemen-
tation on BP and the incidence of hypertension in post-
menopausal women (241); calcium plus vitamin D3 supple-
mentation did not reduce either BP or risk of developing
hypertension over 7 years of follow-up. Others have found
high intakes of ascorbic acid in older adults may have
modest effects on lowering high SBP (242). With increasing
baseline BP, the magnitude of the decline in BP with
Figure 8. Absolute Risk of Stroke Mortality in Relation to Bloo
(A) Systolic blood pressure. (B) Diastolic blood pressure. Stroke mortality rate in eac
ted on a floating absolute scale, and each square has area inversely proportional to
specific regression line ignores the left-hand point (i.e., at slightly 75 mm Hg), for
broken line below 75 mm Hg). The y-axis is logarithmic. CI indicates confidence intevitamin C supplementation increased.1.6. End-Organ Effects of Hypertension in
the Elderly
1.6.1. Cerebrovascular Disease and
Cognitive Impairment
Hypertension in the elderly is a risk factor for both ischemic
stroke and cerebral hemorrhage. ISH is as an important
component of BP-related stroke risk (243). The strength of
the association between BP level and stroke decreases with
increasing age (244). But because of the increased risk of
stroke-related mortality and morbidity with increasing age
(Figure 8) (42), and evidence of benefit from antihyperten-
sive treatment, hypertension remains critically important
relative to stroke risk in the elderly.
The benefit of BP reduction for stroke risk was demon-
strated in SHEP (Systolic Hypertension in the Elderly
Program) evaluating active treatment of ISH with chlortha-
lidone with or without atenolol or reserpine (with nifedipine
as third-line therapy) compared with placebo (RR: 0.64;
95% CI: 0.50 to 0.82; p0.003) on nonfatal and fatal stroke
with active treatment for over 5 years (16). Patients in the
active treatment arm had reduced incidence of both isch-
emic (37%) and hemorrhagic stroke (54%) (245). In the
PROGRESS (Perindopril Protection Against Recurrent
Stroke Study), over 4 years of perindopril plus indapamide
significantly reduced ischemic stroke 24% (10% to 35%) and
hemorrhagic stroke 50% (26% to 87%) compared with
placebo (246). The Syst-Eur trial of patients (mean age was
70.2 years) with ISH confirmed stroke prevention with BP
control using nitrendipine with possible addition of enal-
april, HCTZ, or both. This study was stopped after 2 years
instead of the planned 5 years because of a 42% reduction in
ssure
ade of age versus usual blood pressure at the start of that decade. Rates are plot-
fective variance of the log mortality rate. For diastolic blood pressure, each age-
the risk lies significantly above the fitted regression line (as indicated by the
eprinted from Lewington et al. (42).d Pre
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follow-up study with open-label treatment that assessed the
benefits of early or delayed treatment on stroke risk. The
placebo arm from the earlier study received active treatment
as the delayed treatment arm. The initial treatment group
continued active treatment as the early treatment arm. Early
treatment remained more protective against stroke than
delayed treatment, with a 28% reduction in stroke (p0.01)
(247). These findings support the suggestion that earlier
antihypertensive treatment is associated with better out-
come. The LIFE (Losartan Intervention For Endpoint
Reduction) study showed a 25% reduced overall risk of
stroke in the losartan arm versus atenolol, despite similar
reduction in BP in both groups (14).
Patients in the aforementioned studies consisted predom-
inantly of the “early elderly.” In HYVET, patients in the
“late elderly” group (80 years of age with elevated SBP)
were randomized to indapamide, with addition of perindo-
pril if needed, or placebo and followed over 2 years. Patients
in the indapamide arm had a 30% risk reduction in fatal or
nonfatal stroke (p0.06). Although there have been con-
sistent benefits in reduction of stroke with antihypertensive
therapy in elderly patients, some reports have suggested that
these benefits may be offset by an increase in death in
treated patients (248,249). The HYVET, however, found
benefits consistent with a 21% risk reduction (95% CI: 4%
to 35%; p0.02) of all-cause death in the indapamide arm (4).
In the majority of studies to date, benefits in stroke
reduction appear related to BP reduction, as a 10 mm Hg
reduction in SBP was associated with a 20% to 30% lower
risk of stroke in individuals 70 years of age. Furthermore,
there is greater benefit with greater reduction in BP (9,250).
t is unclear whether the benefits are related solely to BP
eduction or whether there are additional benefits conferred
y class of BP medication. Although there is consistent
enefit in stroke reduction when drugs were compared with
lacebo, there is little difference between drug classes (250).
n addition, there are no differences in benefits conferred by
ifferent classes of antihypertensive agents comparing
ounger and older adults. A meta-analysis of 31 randomized
rials showed no difference between younger (65 years of
ge) and older patients (65 years of age) in protection
gainst major vascular events provided by major drug classes
251).
The prevalence of both hypertension and dementia in-
reases with advancing age. Hypertension is considered a
isk factor for vascular dementia and Alzheimer’s disease.
oor BP control is associated with an even greater cognitive
ecline (252,253). Observational studies report a long-term
ncreased SBP with paradoxical BP reduction in years
mmediately preceding dementia onset (254,255). In older
atients with hypertension, nocturnal nondipping of BP
ccurred in 35% and was associated with mild cognitive
mpairment in about half of the cases compared to dippers
256), where this impairment occurred in only 13%.Three randomized studies evaluated dementia as an
outcome with treatment of hypertension in elderly patients.
In Syst-Eur and PROGRESS, active treatment was asso-
ciated with 50% and 19% reduction in dementia incidence,
respectively (246,257). The SCOPE (Study on Cognition
and Prognosis in the Elderly) assessed candesartan com-
pared with placebo in 70 to 89 year olds with hypertension,
and over 44 months (mean); there were no differences in
cognitive outcome between the 2 groups (258). However, a
SCOPE post hoc analysis reported less cognitive decline
among those with only mild cognitive impairment (Mini-
Mental State Exam score 24 to 28) at baseline in the
candesartan-treated group (p0.04) (259). The SHEP
showed no significant difference in dementia incidence
between active and placebo; however, the SBP target was
160 mm Hg, and results indicated that in those with mild
cognitive impairment, better BP control may reduce cogni-
tive decline. The HYVET-COG, a HYVET substudy,
found a nonsignificant 14% decrease in dementia with active
treatment versus placebo (260). Although no specific class of
antihypertensive drugs have been definitively linked with
cognitive decline in the elderly, inadequate BP reduction is
associated with cognitive decline.
There is a theoretical risk that BP control may impair
cerebral perfusion and negatively impact cognitive function.
Although benefits in HYVET-COG were limited to CV
outcomes, hypertension treatment was not associated with
negative effects on cognition. Although there is clear evi-
dence of the benefits of hypertension treatment in reduction
of both ischemic and hemorrhagic stroke, the benefits in
reducing cognitive impairment and dementia have only
been demonstrated in the early elderly. In patients, mean
age 6410 years, in PROGRESS, a perindopril-based
BP-lowering regimen among patients with previous isch-
emic stroke or transient ischemic attack significantly re-
duced stroke-related dementia (34%) and severe cognitive
decline (19%) (261).
1.6.2. Coronary Artery Disease
CAD is highly prevalent among the elderly. Elderly patients
with hypertension have a higher prevalence of MI than
elderly patients without hypertension. According to 2004
AHA statistics, 83% of CAD deaths occurred in persons
65 years of age (34). The median age of occurrence of a
first MI is approximately 65 years for men and 74 for
women. In the very old, the male predominance in MI
observed among younger elderly is attenuated as the rate in
women approximates that of men. Among autopsies in
persons with average age 80 years, the age-related increase
in atherosclerosis was evident even after age 80 (262).
Atherosclerosis was more severe in men than in women 60
to 70 years of age, but this gender difference diminished
with increasing age and disappeared in the nineties. Cen-
tenarians have lower prevalence of CVD and are less likely
to have the usual CV risk factors. This has been attributed
2063JACC Vol. 57, No. 20, 2011 Aronow et al.
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therapy (263) and survivor bias.
Hypertension precedes MI and angina in a large majority
of the elderly with these conditions. In the case of angina,
hypertension may play a causal role (as a risk factor for
underlying CAD and as a precipitating factor by increasing
myocardial oxygen demand). For persons 60 to 69 years of
age, a 20 mm Hg SBP increase doubles CAD risk, and the
absolute risk difference for a given BP difference increases
with age (42). However, the positive relationship between
absolute risk increase and SBP increase becomes less steep
with each decade increase in age (42), so the absolute benefit
for a given SBP reduction would be expected to decrease
among the very elderly. Benefits of BP lowering on inci-
dence of angina and MI are generally similar with different
antihypertensive drug classes, and overall, better BP control
is associated with better outcomes; effects were not different
among older individuals (251,264). A more detailed analysis
of the influence of age from INVEST (265) compared
patients 60 years of age (n6,668), 60 to 69 years of age
(n7,602), 70 to 79 years of age (n6,126), and 80 years
of age (n2,180), and showed that for 70 to 79 and 80
years of age, higher SBP (135 and 140 mm Hg, respectively)
was associated with less risk for death, MI, or stroke than
SBP130 mm Hg (Figure 9). The oldest patients appeared
to tolerate a higher SBP better and a lower SBP worse
compared with younger patients, and patients 70 years of
Figure 9. Risk of Adverse Outcomes by Age and Blood Pressur
BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood
Reprinted from Denardo et al. (13).age had a relatively narrow range of optimal DBP.Another study in 12,000 patients (mean age 66 years)
suggested that hypertension recorded during admission for
acute MI is not independently associated with higher
mortality (266). Although crude hospital mortality in this
study was higher in patients with hypertension (14.4%
versus 12.4%, p0.001), hypertension was not an indepen-
dent predictor of mortality on multivariate analysis. Of note,
patients with hypertension had a 17% lower risk of ventric-
ular fibrillation but a 26% greater risk of AF in this analysis.
Hypertension is an established risk factor for sudden
cardiac death among the elderly, and both ECG and echo
evidence for LVH are also predictors (267). Treatment for
hypertension reduces the risk of sudden cardiac death in the
elderly (14).
The optimal BP level in hypertension patients with prior
MI is not definitely established. In INVEST, a J-curve
between BP and all-cause mortality, MI, or stroke, as well as
total MI, was observed with a nadir of 119/84 mm Hg
(268). Results were particularly strong for DBP and were
the same for those above and below the mean age of 65
years. Interestingly, this relationship was not observed for
total stroke (fatal and nonfatal) and was not present among
patients who had undergone coronary revascularization.
Because there were no differences in BP control (70%
with 140/90 mm Hg) comparing the randomized CA
versus beta-blocker treatment strategies, the entire cohort
was analyzed. After 61,835 patient-years, 2,269 patients
suffered an adverse outcome (as death, or stroke). The
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each age group (Figure 9). But the optimal BP level for
these very elderly post-MI individuals is unknown and may
be 140/90 mm Hg.
Our understanding of the growing population of elderly
atients with hypertension with prior coronary revascular-
zation is limited. An analysis of patients with prior revas-
ularization from INVEST found that they were older
mean age 67 years) and had higher frequencies of prior MI,
F, stroke/transient ischemic attack, PAD, and diabetes
ellitus compared with those who were not revascularized
269). They also had worse outcomes: death, MI, or stroke,
4.2% versus 8.5% among those without prior revascular-
zation. Interestingly, both SBP and DBP were more
ifficult to control among those with prior revascularization,
uggesting more severe vascular disease, and again the
-curve between BP and mortality, MI, or stroke was
bserved even with propensity score adjustment.
.6.3. Disorders of Left Ventricular Function
1.6.3.1. HEART FAILURE
Aging and hypertension are both strongly associated with
development of HF (270). In 1 study, approximately 82% of
incident HF occurred among individuals 65 years of age
and 55% among those 75 years of age. Hypertension may
lead to HF through different but frequently overlapping
pathways. These include development of LVH, impaired
LV filling, and increased wall thickness as discussed in the
preceding text, especially when coexistent with diabetes
mellitus (see Section 2.3), obesity, AF, and/or CAD with
MI. After MI, neurohormonal activation results in LV
remodeling, systolic dysfunction, and elevated filling pres-
sures. In addition to hypertension and CAD, HF with
depressed ejection fraction may occur in dilated cardiomy-
opathies of alcoholic and other etiologies.
Aging and hypertension result in decreased arterial com-
pliance, initially with impaired systolic and diastolic CV
reserve and impaired responsiveness to catecholamines. At a
later stage, LV dilation occurs. Thus, development of HF
among patients with hypertension occurs in the presence of
decreased LV systolic function (e.g., LV ejection fraction
45% or 50%), as well as with preserved LV systolic
function, where it is attributed to impairment of diastolic
function (e.g., from LVH) as described previously. HF with
preserved systolic function is important in the elderly and
probably related to progressive fibrosis and myocardial
stiffening associated with CAD, diabetes mellitus, and age
per se plus LVH attributable to hypertension.
In a cross-sectional study of patients with hypertension
65 years of age with LV ejection fraction 45%, HF was
observed in 22.6% and diastolic dysfunction in 25.8% (271).
In ALLHAT, persons 55 years of age developing HF
ith preserved systolic function were more likely to be
omen and to have higher BMI, SBP, and high-density
ipoprotein cholesterol than those who developed HF with
mpaired LV systolic function (272). In this study, HFsymptoms and signs were similar among those with and
without impaired LV systolic function. Ankle edema was
present in a higher percentage of patients with preserved
ejection fraction, whereas S3 gallop, hepatomegaly, and
paroxysmal nocturnal dyspnea were present in a smaller
percentage in this group compared with those with impaired
LV systolic function (272). Patients with HF and preserved
ejection fraction are in general less likely to have CAD and
more likely to have diabetes mellitus than patients with HF
and depressed ejection fraction (273).
Although hospital mortality of elderly patients (65
ears of age) with first MI has declined in the last decade,
F developed in over three fourths of them over 5 years of
ollow-up (274). In addition, new-onset HF significantly
ncreased the mortality of MI survivors (274). In a popula-
ion study from Scotland, mean age at first discharge
ncreased from 70.7 years in 1986 to 72.4 years in 2003 for
en and from 76 to 77.3 years for women, whereas the
ge-standardized rate decreased after 1994 in both sexes
275). Also, case fatality rates decreased in parallel with an
ncrease in HF therapies. In another study of patients with
ypertension or at high CV risk, the rate of HF was 8.5
vents per 1,000 and the rate for stroke was 9.1 events per
,000 patients, because HF was more likely to occur in
atients 65 years of age and those with diabetes mellitus
OR: 4.91; 95% CI: 4.40 to 5.43) (276).
1.6.3.2. LEFT VENTRICULAR HYPERTROPHY
As discussed previously, aging and hypertension-related
aortic and conduit artery stiffening (Figure 7) increase LV
loading and promote LVH. Among the older population
included in the Cardiovascular Health Study, LV mass
index was an independent predictor of incident HF not
related to prevalent or incident MI (277). LVH is associated
with adverse outcomes, including CAD, stroke, and espe-
cially HF (277). The association of LVH with CV events is
especially strong in the elderly (278,279). After a 36-year
follow-up in FHS, the relative risk related to LVH in those
65 to 94 years of age for CVD in general was 2.82 for men
and 4.13 for women. The risk imposed by LVH is not
totally explained by development of CAD, but regression of
LVH with BP control is associated with reduced risk of
CVD, especially development of HF (280). ECG LVH was
present in 23.4% of 782 patients (mean age 66 years, BMI
28.2 kg/m2, baseline BP 155.717.7/90.810.6 mm Hg),
and predictors of LVH were age, male sex, and grade II
hypertension (281).
Myocardial fibrosis and diastolic dysfunction precede
LVH development in hypertension (282). In the LIFE
study, regression of LVH was associated with a 36%
reduction in the rate of new HF (283), and BP lowering
improved diastolic function (284). In the same study,
regression of LVH during therapy was related to reduced
risk for sudden cardiac death after adjustment for BP
reduction, CAD, antihypertensive treatment modality, and
other cardiovascular risk factors (285).
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AF is primarily a disorder of older age, with a prevalence as
high as 10% in octogenarians (286–288); hypertension is a
major risk factor for AF. Aging of the population, more
sensitive diagnostic modalities such as ambulatory electro-
cardiography, and increased prevalence of hypertension,
obesity, and HF have contributed to a growing number of
elderly persons diagnosed with AF. In those 65 years of
age, the risk for new onset of AF is approximately 2% per
year (289). In the Cardiovascular Health Study, among
patients 65 years of age, incidence of a first episode of AF
during average follow-up of 3.28 years, was 19.2 per
thousand person-years (277). This was associated with age,
male sex, and the presence of CVD. For men 75 to 84 years
of age, the incidence of AF was 42.7 per thousand patient
years. Use of diuretics, older age, higher SBP, glucose, left
atrial size, height, and history of valvular or CAD increased
the risk (290). In the elderly, the pathophysiology of AF is
related to increased arterial stiffness and reduced LV com-
pliance, findings often predicted by elevated pulse pressure,
a surrogate for increased proximal aortic stiffness, higher
BMI, and prevalent diabetes mellitus (291). Occurrence of
AF is associated with increased mortality, cardiac sudden
death, HF, embolic stroke, and reduced QoL.
Control of BP is associated with reduced occurrence or
recurrence of AF in patients with hypertension. In SHEP
(average age 72 years), AF increased CV mortality risk at
4.7 and 14.3 years (292). In the STOP-Hypertension-2 trial
(Swedish Trial in Old Patients with Hypertension) (mean
age 76 years, range was 72 to 84 years with ISH), AF was
present in approximately 5% at baseline. During follow up,
“newer” antihypertensive therapy (ACEI, CA) was signifi-
cantly better than “conventional” (diuretic/beta blockers) in
preventing stroke. However, there were more new cases of
AF in patients randomized to newer agents, especially CAs
(RR: 1.53; 95% CI: 1.05 to 2.21) (293). The conventional
agents were associated with less new AF. Others, however,
have reported lower AF recurrence rates with agents affect-
ing the RAAS. A meta-analysis of 22 studies including
56,309 patients showed that ACEI and ARBs significantly
reduced the risk of AF by 28%, with a 44% significant
reduction in AF in patients with congestive HF (294). This
benefit was limited to patients with reduced LV ejection
fraction or LVH. In patients with diabetes mellitus, hyper-
tension, and paroxysmal AF, combination valsartan and
amlodipine was associated with a lower rate of recurrence
than combination amlodipine and atenolol with similar BP
reductions (295). However, in the GISSI-AF (Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico-Atrial Fibrillation) trial, symptomatic AF pa-
tients (average age 68 years) with diabetes mellitus, CVD, or
enlarged left atrium, valsartan did not prevent AF recur-
rence compared with placebo. This secondary prevention
trial addresses a different population than the earlier pre-
vention studies (296). Regardless of treatment, survival is sworse for those 65 years of age as well as for patients with
history of CAD, HF, or abnormal ejection fraction (297).
1.6.5. Abdominal Aortic Aneurysm and
Peripheral Arterial Disease
1.6.5.1. ABDOMINAL AORTIC ANEURYSM
AAAs, defined as dilation of the aorta with a minimum
anteroposterior diameter of 30 mm, occur with increasing
frequency with increasing age. The prevalence of AAAs is
12.5% among men 75 to 84 years of age (298). Usually
AAAs are due to aortic medial degeneration associated with
abnormalities in tissue metalloproteinases, metalloprotei-
nase inhibitors, elastase, and other proteinases. Risk factors
for asymptomatic AAAs resemble those for obstructive
PAD and include older age, male sex, smoking, hyperten-
sion, diabetes mellitus, family history of AAA, history of
MI, and PAD.
1.6.5.2. THORACIC AORTIC DISEASE
Thoracic aortic aneurysm is increasingly prevalent in the
elderly and, although the pathology is denegation of the
aortic wall, hypertension is a major risk factor for develop-
ment along with smoking, chronic obstructive pulmonary
disease, and several genetic syndromes (299). Acute aortic
dissection (acute aortic syndrome) is a catastrophic compli-
cation in the elderly patient. Chest and or back pain are the
classic symptoms, although older patients can present with-
out chest or back pain. The incidence varies from 5 to 30
cases per million persons per year, but hypertension and age
are major risk factors (300). Surgery is indicated for type A
dissections (those involving the ascending aorta). Control of
BP, including beta blockade, is needed for both type A and
B (not involving the ascending aorta) dissection. Endovas-
cular techniques may be used in patients with high operative
risk (301).
1.6.5.3. PERIPHERAL ARTERIAL DISEASE
PAD, or occlusive arterial disease distal to the aortic arch
and including arterial narrowing usually caused by athero-
sclerotic disease as well as aneurysmal dilation with or
without dissection, may lead to intermittent claudication,
rest pain, critical limb ischemia, and amputation. PAD is
usually not limited to the peripheral arterial system, but
often associated with CAD as well as cerebrovascular
disease. It is estimated that 10 million persons have PAD
in the United States, the prevalence among persons 75
ears of age is approximately 20% and is 50% in persons
85 years of age (302,303).
PAD is associated with a 4-fold increase in MI risk and
3-fold increase in stroke or transient ischemic attack risk
304,305). Among persons with PAD, average age 66 years,
he 5-year mortality risk approaches 25% and the 10-year
isk approaches 48% (305). Mortality adjusted for age, sex,
nd CVD risk factors is 2 to 3 times higher than that of
ersons without PAD. Although about 1 of 3 persons with
ymptomatic PAD has typical claudication, 50% have leg
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ischemia (306).
Age and hypertension, along with risk factors for athero-
sclerosis, are also associated with PAD. In addition, hyper-
homocysteinemia (307–309), high plasma lipoprotein (a),
and AAAs are associated with increased risk of PAD
(310,311). In persons screened for AAAs, increasing age,
male sex, and PAD were independent predictors. The
prevalence in persons 60 years of age was 4% for men and
1.2% in women (311). Patients with combined CAD and
PAD in the REACH (REduction of Atherothrombosis for
Continued Health) registry (German cohort, mean age 67.3
years) were older and more likely to be treated with
antithrombotic agents, statins, and ACEIs (312).
Hypertension is associated with more rapid progression
of PAD (313). Therefore, elderly patients with hypertension
and exertional limitation involving lower extremity muscles,
non- or poorly healing lower extremity wounds should be
screened for PAD (298) by comprehensive examination of
the pulses, measurement of the ankle-brachial index, and
careful examination of the feet. A clinical prediction model
(PREVALENT) giving 1 point per 5 years of age starting
at age 55 years, 2 points for smoking history, 7 for current
smoking, and 3 for hypertension identifies a subset of
individuals in whom PAD is highly prevalent and who may
benefit from ankle-brachial index measurement (314). The
risk of PAD increased from 7% in patients with a score of
0 to 3 to 41% in those with a score of 13. A strategy to
screen for cerebrovascular disease and CAD, as well as limb
preservation and claudication relief, needs to be included in
the evaluation.
1.6.6. Chronic Kidney Disease
Hypertension and aging both impact renal function. Elderly
patients are more likely to have CKD, usually defined by a
measured eGFR 60 mL/min/1.73 m2. Multiple studies
over the past 2 decades have shown that CKD is a powerful
CVD risk factor. Unless GFR is eGFR, CKD is often
unrecognized in elderly patients. Patients 75 years of age
have more than a 2-fold risk of CKD versus younger
patients, and a 60% risk for further loss of kidney function
independent of baseline function (315). Prevalence of CKD
ranges from 11% to 14% in the United States, and 75% of
the CKD population is 65 years of age (316). However, it
should be noted that the equation for eGFR has not been
validated in this age group (317). Thus, although this group
is more vulnerable to renal injury as a result of surgical or
diagnostic procedures, the actual estimation of CKD in the
population may be inaccurate.
In the elderly, CKD is an independent risk factor for
congestive HF (318). CV outcomes increase in patients with
hypertension as GFR decreases (319). Moreover, SBP is a
strong independent predictor of decline in kidney function
among older persons with ISH (151). Reduced kidney
function in elderly people is a marker for adverse outcomes
(318,320–322). Substantial proteinuria is associated with arapid decline in kidney function. A progressive decline in
kidney function is more prevalent in elderly patients with
diabetic nephropathy (323). Hypertension and HF are
associated with a more pronounced decline in renal function
in older age (324).
1.6.7. Ophthalmologic Impairment
1.6.7.1. AGE-ASSOCIATED RETINAL CHANGES
The major cause of vision limitation in patients with
hypertension of all ages is retinopathy, defined as arteriolar
narrowing (generalized and focal), arteriovenous nicking,
flame and blot hemorrhages, cotton-wool spots, and optic
disk edema (325,326). Based on population studies, markers
of hypertensive retinopathy (e.g., arteriovenous nicking,
focal arteriolar narrowing) were found in 3% to 14% of those
40 years of age (327). Retinal lesion prevalence increased
with higher SBP, but not necessarily with DBP. The
specificity of retinal changes, however, decreases with age:
Arteriolar narrowing is common in normotensive elders,
and focal arteriolar sclerosis has been reported in 2% to 15%
of normotensive patients 40 years of age (326,328).
In a study of people with nonmalignant hypertension of
at least 10 years duration, 33% had no fundoscopic changes,
37% had slight arteriolar narrowing (especially in older
patients), and 6% had hemorrhages or lipid deposits (329).
n older patients, retinal vessel changes are less reliable
ndicators of the presence or duration of hypertension. For
ndividual patients with hypertension, retinal findings may
e reasonable indicators of organ damage. Significant retinal
amage (e.g., hemorrhages, exudates, or disc edema) is more
ignificantly associated with stroke and warrants prompt
valuation and treatment of elevated BP.
1.6.7.2. PATHOPHYSIOLOGY
A series of retinal changes in response to increased BP
includes generalized arteriolar narrowing due to alterations
in local auto-regulatory vasoconstrictive responses (some
mediated by nitric oxide). Persistent BP elevation produces
intimal thickening, medial hyperplasia, and hyaline degen-
eration (sclerosis). These later changes are associated with
focal narrowing, disturbed arteriovenous nicking, and wid-
ening of the arteriolar light reflex (“copper wiring”). Aging
itself is also associated with most of these “early” changes,
which makes grading of retinal pathology in older patients
less reliable versus younger patients. The final stages of
retinal disease are caused by disruption of the retinal/blood
barrier and lead to hemorrhages and lipid exudates. Optic
disk swelling usually indicates severely elevated BP (330)
and can be associated with visual impairment, and this is
extremely serious in a patient of any age. Papillidema
associated with hypertension is an extremely serious
condition.
Hypertension is also associated with retinal artery occlu-
sion and nonarteritic anterior ischemic optic neuropathy
(331). Other than a general increase in prevalence with age,
information is limited about age-related changes in these 2
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prevalence of glaucoma is reported (332). Older population-
based studies failed to show consistent association of hyper-
tension and age-related macular degeneration (333), but
more recent studies have linked neovascular age-related
macular degeneration with moderate to severe hypertension,
particularly among elderly patients (median age 72 years)
receiving antihypertensive treatment (334,335). In addition
to SBP, pulse pressure is also a strong predictor of neovas-
cular age-related macular degeneration (334). These find-
ings support the hypotheses that neovascular and non-
neovascular age-related macular degeneration have a
different pathogenesis, and that neovascular age-related
macular degeneration and hypertensive vascular disease have
a similar underlying systemic process. Age-related macular
degeneration is the most common cause of blindness in the
Western world.
1.6.8. Quality of Life Issues
Hypertension is often portrayed as a “silent killer” because
patients with mild or moderate hypertension are often
asymptomatic. When symptoms appear as a result of organ
damage, therapeutic options are limited. Although the
symptoms produced by these organ complications (MI, HF,
stroke, or chronic renal failure) are associated with decreased
QoL, possible alterations in QoL in patients with mild to
moderate hypertension who do not have such complications
remain controversial. Declines in QoL seen in aging popu-
lations complicate the analysis of a potential relationship
between “asymptomatic” hypertension and QoL in older
patients.
The INVEST study examined a measure of subjective
well-being, which was validated in a substudy (336,337), in
22,576 CAD patients 50 years of age (mean age 6610
years) with hypertension (338). Patients were asked a single
question rating their overall feeling of well-being in the
prior 4 weeks. Data were collected at baseline and at each
follow-up visit before BP was measured. Measures of
subjective well-being were highly negatively correlated with
SBP measured during treatment. Age had minimal effect on
measured subjective well-being, but the presence of angina
was also a predictor.
QoL alterations were examined in hypertensive patients
from hospital-based clinics in China using a standard QoL
instrument focusing on self-report of symptoms across
several domains (339); 2,331 were 65 years of age.
Whereas hypertension prevalence was highest in those 65
years of age (65%), as expected, decreases in QoL with age
were seen in almost all domains, with older hypertensive
subjects reporting more stress, worries about health, and
difficulties with coping. Although contributions to QoL
changes by other comorbid conditions were not assessed,
treatment of hypertension resulted in modest improvement
in these scales. Two additional studies reported decreases in
QoL scores with hypertension. In another study, although
older hypertensive patients had more comorbid conditions,subanalysis showed small decreases in selected physical
health QoL measures (340). Yet another study found
increasing prevalence of hypertension and comorbid condi-
tions in older patients but the presence of any illness was
correlated with decreased QoL. Conversely, a study of
community-based Finns found no correlation between QoL
symptoms and hypertension (341), and 2 additional studies
found QoL changes correlated with age, more so than with
hypertension (342,343).
Some question the effects of labeling a patient with the
diagnosis of hypertension, and the effects of that diagnostic
label on QoL (340,342). Although small changes in QoL
scales in younger patients with the solitary diagnosis of
hypertension might be measurable, the additional effect of a
diagnosis of hypertension on the lower QoL scores seen in
older patients is likely minimal. In “younger old” patients in
the seventh decade, control of systolic hypertension has
been associated with modest improvement in QoL scores, a
conclusion also supported by previously discussed findings
from INVEST (344).
Finally, excessive reduction in BP is an important cause of
symptoms that impair QoL and is linked to adverse out-
comes among the elderly. In older persons, orthostatic
hypotension (decrease of SBP 20 mm Hg after 3 minutes
of standing) is common and is associated with increased CV
risk. In the Honolulu Heart Program, orthostatic hypoten-
sion was present in 6.9% of 3,522 Japanese-American men
71 to 93 years of age and was a significant independent
predictor of 4-year all-cause mortality (137). Postprandial
hypotension, defined as a fall in SBP of20 mm Hg 1 hour
after a meal while sitting, was associated with advanced age,
higher baseline BP, and use of vasodilating antihypertensive
drugs (345), as well as with increased overall total mortality
(RR: 1.79; 95% CI: 1.19 to 2.68) among elderly individuals
(346).
2. Interactions Between Aging and
Other CV Risk Conditions Associated
With Hypertension
2.1. Family History of Premature
Coronary Artery Disease
Premature coronary disease is defined as a first-degree male
relative with established CAD at 55 years of age or a
first-degree female relative with established CAD at age
65 years (347). Although several studies have shown that
the presence of a family history of premature coronary
events increases an individual’s risk for CV events anywhere
from 2- to 12-fold (348,349), data on this relationship in
older adults are sparse. In the FHS, history of parental
premature CAD in persons 60 years of age was associated
with a doubling of CAD risk compared with a 3-fold risk
increase in persons 30 to 59 years of age (350). Of note, this
increased risk in older persons was seen only in women.
Thus, the limited data available suggest an attenuated risk
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2.2. Dyslipidemia
Concordance of dyslipidemia and hypertension is common;
both increase with aging and hence are management targets
(351–354). The specific approach to management of dys-
lipidemia in the elderly, however, has rarely been consoli-
dated with that for hypertension (355). In the PROSPER
(Prospective Study of Pravastatin in the Elderly at Risk)
trial, 60% of subjects (mean age 75 years) had elevated
low-density lipoprotein cholesterol. In HYVET, the mean
total cholesterol was 205 mg/dL (4). Given the independent
CVD risk associated with both conditions and proven
benefits of treatment across age (356), it is reasonable to be
aggressive with lipid lowering in elderly patients with
hypertension.
Elderly persons with hypertension are often treated with
statins because of concomitant hypercholesterolemia. The
CAFÉ-LLA (Conduit Artery Function Evaluation-Lipid-
Lowering Arm) substudy of the ASCOT (Anglo-
Scandinavian Cardiac Outcomes Trial) included 891 pa-
tients, mean age 63 years, randomized to atorvastatin or
placebo, with central aortic pressures and hemodynamic
indices (radial artery applanation tonometry) repeated over
3.5 years (357). Statin therapy, sufficient to significantly
decrease CV events in treated patients with hypertension in
ASCOT, did not influence central aortic BP or hemody-
namics (357).
However, in the UCSD (University of California, San
Diego) Statin Study, simvastatin and pravastatin signifi-
cantly lowered SBP by 2.2 mm Hg and DBP by 2.4 mm Hg
in 973 adults without known CVD (358). A meta-analysis
of 12 trials including 69,984 patients, mean ages 55 to 75
years, treated for at least 2 years, found that statin therapy
significantly reduced CV morbidity and mortality to the
same extent in patients with hypertension (by 22%) and
nonhypertensive patients (by 24%) (359). Meta-regression
also showed that the efficacy of statins on reducing adverse
outcomes was not moderated by presence of hypertension at
baseline (359).
2.3. Diabetes Mellitus
Cumulative life-time risk for diabetes mellitus in the United
States increases exponentially between about 35 and 70
years of age but then plateaus (360). Overall risk of diabetes
mellitus ranges from approximately 25% to 45% in men and
approximately 30% to 55% in women and is frequently
associated with hypertension. Risk of diabetes mellitus is
higher in Hispanics and non-Hispanic blacks versus non-
Hispanic whites. Elderly patients with hypertension and
diabetes mellitus have a higher mortality risk than similarly
aged controls without diabetes mellitus (361,362).
Hypertension is well recognized as an insulin-resistant
state. Among patients with hypertension, SBP level, fasting
glucose level, and thiazide diuretic and/or beta-blocker useare independent risk factors for incident diabetes mellitus
(363–365). Although several of the previously referenced
hypertension trials were comprised mostly of elderly pa-
tients, increasing age was associated with less incident
diabetes mellitus (365,366).
Diabetes mellitus is a risk factor for development of HF
among those 65 years of age (367). The ONTARGET/
TRANSEND (Ongoing Telmisartan Alone and in combi-
nation with Ramipril Global Endpoint/Telmisartan Ran-
domized Assessment Study in ACE Intolerant Subjects
With Cardiovascular Disease) trials of 31,546 high-risk
subjects (mean age 67 years, about 70% with hypertension,
coronary, peripheral, or cerebrovascular disease or diabetes
mellitus with organ damage) found fasting plasma glucose
level was an independent predictor of HF hospitalization
(598). These data provide theoretical support for potential
direct beneficial effects of lowering blood glucose in reduc-
ing HF risk and suggest need for specific studies targeted at
this issue (368).
Elderly patients with diabetes mellitus have a higher
prevalence and incidence of microvascular and macrovascu-
lar complications (369), as well as excess mortality risk
compared to age-matched controls without diabetes melli-
tus (370). Albuminuria is a predictor of higher mortality risk
among those with diabetes mellitus (371). In older patients
with type 2 diabetes mellitus, both high-office SBP and
high-awake ambulatory SBP independently predict albu-
minuria (372).
2.4. Obesity and Weight Issues
Obesity and its clinical consequences have been described
for centuries (373), and obesity has reached epidemic
proportions worldwide (374). In the United States, the
prevalence of obesity, defined as a BMI 30 kg/m2 in
adults, has doubled from 15% to 32.9% in the last 24 years,
and 66.6% of adults are now overweight (BMI 25 to 30
kg/m2) or obese (375). When ORs were calculated to
determine the prevalence of hypertension in the period from
1999 to 2004 before and after adjustments for BMI, the
increases in BMI adjusted for age accounted for nearly all
the increases in hypertension in men and much of the
increase in women (33). Thus, in overweight or obese
elderly, including those with metabolic syndrome, obesity-
related health risks add to the pathophysiologic changes of
aging. These changes ultimately affect the structure of the
heart, blood vessels, and the kidneys and may adversely
affect CV and renal morbidity and mortality (376).
2.4.1. Structural and Hemodynamic Changes
Obesity may be associated with increases in LV wall
thickness, volume, and mass independent of a patient’s BP
(377). Pressure overload leads to thickening of the LV wall
without increasing cavity size. Myocyte thickening then
leads to concentric hypertrophy, and volume overload causes
cavity dilation, fiber elongation, and eccentric hypertrophy.
Each of these factors leads to elevated stroke work (377).
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cular volume, high cardiac output, and a normal total periph-
eral resistance when compared with lean patients with hyper-
tension. The high stroke volume in obese subjects is caused by
increased intravascular volume in the context of normal heart
rate (378). Obese patients with hypertension are also charac-
terized by a circadian rhythm that does not show the expected
BP drop during sleep time (nondipping), and they respond to
mental stress with a higher increase in total peripheral resis-
tance and smaller increase in heart rate, stroke volume, and
cardiac output than lean patients with hypertension (379).
In the LIFE study, the association of Cornell ECG
voltage criteria with greater body mass supported the known
association of anatomic LVH with obesity (380) and
showed obese, elderly patients with hypertension had sim-
ilar cardiac changes previously described in younger pa-
tients: LVH with a high prevalence of geometric abnormal-
ities, especially eccentric hypertrophy (381).
2.4.2. Vascular Changes
Several metabolic and hormonal changes that occur in
obesity–hypertension are associated with impaired endothelial
function and premature atherosclerosis (382). Metabolic syn-
drome and obesity have been linked to altered vasodilation.
Other markers such as arterial stiffness or intima-media thick-
ness increase in overweight or obese subjects and in aging
individuals. However, the contribution of obesity to adverse
outcome among elderly hypertensive patients is unclear.
An analysis from INVEST showed that in a well-treated
cohort with hypertension with CAD, increased BMI in the
elderly population was associated with decreased morbidity
and mortality compared with normal BMI (383).
2.4.3. Role of the Sympathetic Nervous System
Increased sympathetic activity in obese subjects is associated
with an increased incidence of hypertension, arrhythmias,
and angina pectoris (384). This mechanism may also be
important in overweight or obese elderly subjects, as studies
have shown an age-dependent increase in plasma norepine-
phine levels in individuals 50 years old (385) and an
ncrease in renal norepinephine spillover in obese individu-
ls (386). Plasma epinephrine levels, by the contrary, tended
o decrease with age (385). Furthermore, the reduction in
aroreflex sensitivity in aging may further stimulate norepi-
ephrine production (387).
This increased sympathetic nervous system activity in
bese subjects may be explained by dysregulation of the
ypothalamic-pituitary-adrenal axis and inappropriate re-
ponse to cortisol (388). Another mechanism that may
ncrease sympathetic nervous system activity in obese and
lderly subjects might be sleep apnea and resultant hypoxia
nd hypercapnia (389). Sympathetic hyperactivity increases
P, heart rate, cardiac output, and renal tubular sodium
eabsorption, changes that occur as a consequence of in-
reased alpha- and beta-adrenergic receptor stimulation
ith a consequent increase in RAAS activity (390)..4.4. Role of the Renin-Angiotensin-Aldosterone
ystem
n obesity, adipose tissue may contribute to RAAS activation
391), and a positive correlation has been found between
lasma angiotensin levels, plasma renin activity, angiotensin-
onverting enzyme activity, and BMI (392). Adipose tissue
roduces all components of the RAAS locally and may play an
utocrine, paracrine, and/or endocrine role in the development
f obesity–hypertension. Angiotensin II may also contribute to
he development of insulin resistance through its effect on
lucose metabolism (393).
The RAAS may also contribute to systolic hypertension
n the elderly (394). Activation of the RAAS system at the
issue levels contributes to the vascular inflammation and
brosis triggered by AII; renin and aldosterone may also
ontribute. These changes eventually induce vascular ath-
rosclerosis and organ failure (395).
Recent studies have explored the genes that encode
omponents of the RAAS. Homozygosity for the D allele of
he ACE gene was found to be associated with abdominal
diposity, obesity, and BP in individuals 54 years of age
396). In TONE (Trial of Nonpharmacological Interven-
ion in the Elderly), obese subjects with DD genotype had
significant decrease in BP after weight loss, suggesting
hat this genotype may be linked with obesity–hypertension
n the elderly through an increase in AII activity and
ldosterone production (397). These findings reinforce the
oncept that obesity within genetically susceptible individ-
als will cause hypertension.
2.5. Microalbuminuria
Microalbuminuria, or urinary albumin excretion expressed
as an albumin-to-creatinine ratio 30 and 300 mg
albumin/g creatinine (398), on 2 separate first–morning-
voided collections, is a marker for heightened CVD risk
(399–402) and may be a marker for abnormal endothelial
function. In people 60 to 74 years of age, an association
between urinary albumin excretion rate and mortality has
been described (403). In elderly subjects who did not have
diabetes mellitus and were followed for 3.5 years, mi-
croalbuminuria was a strong predictor of CAD events
(404,405). A separate prospective study of 70-year-old men
in the community support the observation that microalbu-
minuria is a marker of subclinical CV damage that predis-
poses to future HF (406). Specific prevalence data for
albuminuria focused on the elderly are lacking (407,408).
Screening for albuminuria is recommended for all patients
with hypertension and concomitant diabetes mellitus and
for those with early CKD (23,409).
2.6. Hyperhomocysteinemia
Hyperhomocysteinemia is a risk factor for endothelial dys-
function (410). Investigators have reported a positive asso-
ciation between homocysteine levels and both SBP and
DBP (411,412), including a possible causal relationship to
ISH in older individuals (413). Mechanisms that could
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include homocysteine-induced arteriolar constriction, renal
dysfunction and increased sodium reabsorption, and in-
creased arterial stiffness (414). More research is needed to
confirm these mechanisms and to establish whether lower-
ing homocysteine with folic acid is an effective treatment for
older patients with hypertension.
2.7. Gout
Gout incidence rates are 3 times higher for hypertensive
patients than for normotensive patients (p0.01) (415).
Thiazide diuretics, often the preferred initial agent for
treatment of hypertension, increase serum uric acid levels
and may provoke gout (22,416,417). Both hypertension and
diuretic use are independent risk factors for gout (418).
Serum uric acid independently predicts CV events in older
persons with ISH (419–421); therefore, monitoring serum
uric acid change during diuretic treatment is reasonable.
Diuretics should be used cautiously in elderly patients with
hypertension with gout (22).
2.8. Osteoarthritis and Rheumatoid Arthritis
Arthritis is a common problem in the elderly with important
implications for hypertension. Osteoarthritis affects approx-
imately 10% of men and 20% of women 60 years of age,
and they may need medications to reduce pain and inflam-
mation (422). These medications usually include NSAIDs,
which are implicated in BP elevation that is proportional to
the level of BP prior to starting medication. Individuals with
rheumatoid arthritis have excess risk for morbidity and
mortality from CVD, which in part may be due to hyper-
tension (423), with prevalence ranging between 52% and
73% (424–426). In rheumatoid arthritis, the chronic in-
flammatory burden may lead to increased arterial stiffness, a
physical cause of elevated SBP (427). Drugs commonly
administered to patients with rheumatoid arthritis, such as
NSAIDS, cyclo-oxygenase-2 inhibitors (234), oral steroids
(236), and some disease-modifying antirheumatic drugs
(e.g., cyclosporine, leflunomide) may also raise BP levels
(428,429). Additionally, insulin resistance and dyslipidemia
are common comorbidities in rheumatoid arthritis and are
also associated with hypertension (430,431). Hypertension
may be poorly controlled in older patients with rheumatoid
arthritis compared with younger patients, possibly because
of suboptimal therapy or noncompliance (426). Thus, hy-
pertension cannot be addressed in isolation in the elderly
arthritis patient but must be considered in the context of
other CV risk factors and arthritis treatment.
3. Clinical Assessment and Diagnosis
3.1. Measurement of Blood Pressure
BP should be accurately and reliably measured and docu-
mented. The diagnosis of hypertension should be based on
at least 3 different BP measurements, taken on 2 separate
office visits to account for the natural variability of BP and aother factors that can affect BP. To confirm the validity and
reliability of the measurement, at least 2 measurements
should be obtained once the patient is comfortable and
settled for at least 5 minutes. BP should be measured in the
sitting position with the back supported, feet on the floor,
arm supported in the horizontal position, and the BP cuff at
heart level. The BP should also be measured with the
patient standing for 1 to 3 minutes to evaluate for postural
hypotension or hypertension. This is particularly important
in the elderly because of stiff large arteries, age-related
decreases in baroreflex buffering, and autonomic dysregula-
tion (22) (see Section 1.5.2.2). In the initial evaluation, BP
should be measured in each arm, and the arm with the
highest BP used for future BP monitoring. It is important to
use an appropriately sized cuff with a bladder that encircles
at least 80% of the upper arm circumference. An ausculta-
tory gap, as defined by the period during which sounds
indicating true systolic pressure fade away and reappear at a
lower pressure point, is more common in the elderly and is
associated with vascular disease. This is a common source of
underestimating SBP in the elderly. Elderly patients should
also be evaluated for post-prandial hypotension (345,432),
which is especially common in frail elderly patients on
multiple antihypertensive and psychotropic drugs (433).
Pseudohypertension, discussed in detail in the following
section, is another source of inaccurate BP measurement in
the elderly.
3.1.1. Pseudohypertension
Pseudohypertension refers to a falsely increased SBP that
results from markedly sclerotic arteries that do not collapse
during inflation of the BP cuff. Pseudohypertension occurs
in 1.7% to 70% of the elderly (434–438), and this extreme
range in prevalence is likely due to methodological differ-
ences between studies. Thus, the actual prevalence is un-
clear. In the elderly, the brachial arteries may become very
thickened and stiff due to arterial medial sclerosis and
calcification (434,439). The BP reading measured with
indirect techniques may be falsely high if the artery is
excessively thickened and therefore noncompressible (439).
lthough the Osler maneuver (i.e., the presence of a radial
rtery pulse that is still palpable after the cuff is inflated
bove the systolic pressure) has been recommended as a
eans to screen for pseudohypertension, investigators have
eported it to have questionable accuracy and usefulness
438,439). Correct identification of pseudohypertension is
ecessary to avoid overtreating high BP and should be
uspected in elders with refractory hypertension, no organ
amage, and/or symptoms of overmedication (440). Con-
rmation of pseudohypertension requires direct intra-
rterial measurement of BP (441).
.1.2. White-Coat Effect and
hite-Coat Hypertension
hen assessing BP in the elderly, both the white-coat effect
nd white-coat hypertension need to be considered, with
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individuals tend to exhibit more white-coat effect (i.e.,
transient BP elevations when in a medical environment)
than younger individuals (444,445). White-coat hypertension,
a term reserved for those not on antihypertensive medica-
tion but with persistently elevated office BP (140/90 mm
Hg) together with a normal daytime ambulatory BP
(135/85 mm Hg), is also more common in the elderly and
is more frequent among centenarians (446,447). Ambula-
tory BP monitoring is recommended to confirm a diagnosis
of white-coat hypertension in patients with office hyperten-
sion but no organ damage (22).
3.1.3. Ankle Blood Pressure
Ankle BPs measure subclinical atherosclerosis (448). In
healthy individuals, ankle SBPs are slightly higher than the
arm, but as occlusive disease develops in the lower extrem-
ities, the systolic pressure at the level of the ankle decreases
(448,449). The finding of a reduced ankle-to-brachial artery
BP ratio (ankle-brachial index) indicates atherosclerosis of
the lower extremity arteries. The prevalence of an abnormal
ankle-brachial index (0.9) increases dramatically with age.
In 1 study, this prevalence increased from 5.6% in persons
38 to 59 years of age, to 15.9% in persons 60 to 69 years of
age, and to 33.8% in persons 70 to 82 years of age (303).
The prevalence of PAD, defined by an ankle-brachial index
0.9, was 29% in 6,979 men and women (mean age 69
years) screened because they were 70 years of age or were
50 to 69 years of age with either a history of cigarette
smoking or diabetes mellitus. Among these patients with
PAD, classic claudication was present in only 11% (450).
An ankle-brachial index of 0.9 is associated with a
significantly increased risk of CVDs (in particular MI and
stroke) that is independent of other risk factors (449,451).
At 10-year follow-up of 565 men and women (mean age 66
years), PAD significantly increased the risk of all-cause
mortality (RR: 3.1), CV mortality (RR: 5.9), and mortality
from CAD (RR: 6.6) (305). High values of an ankle-
brachial index also carry risk for mortality in adults, includ-
ing the elderly (451,452). An ankle-brachial index 1.30
suggests a noncompressible, calcified vessel (306). Among
older adults, low and high ankle-brachial index values carry
elevated risk for CV events (coronary heart disease, stroke,
and congestive HF) (451). Noncompressible leg arteries
carry elevated risk for stroke and congestive HF specifically
(451).
3.2. Ambulatory Blood Pressure Monitoring
Application and feasibility of automated ambulatory BP
monitoring in the elderly are comparable to younger age
groups (443). Major side effects are sleep disturbances and
pain during cuff inflation (443). Main indications for
ambulatory BP monitoring are for patients in whom the
diagnosis of hypertension or response to therapy is unclear
from office visits. Further indications include suspected
syncope or hypotensive disorders, evaluation of vertigo, anddizziness (443). Ambulatory BP monitoring is also impor-
tant for avoiding overtreatment in the elderly with white-
coat hypertension and also to ensure diagnosis and treat-
ment of those with masked hypertension (453).
Ambulatory BP is a better predictor of risk than clinic or
office BP measurement in older patients with ISH
(454,455). After adjustment for clinical BP measurements,
ambulatory day time, night time, and 24-hour SBP all
independently predict CV mortality (454). For each 10 mm
Hg increase in daytime SBP and nighttime SBP, CV death
increased 10% and 18% respectively, but the same increase
in clinic SBP was not associated with a significant mortality
increase (455). Elevated SBPs, while awake and/or asleep,
by ambulatory BP monitoring, in subjects (mean age
70.49.9 years) over 5023 months predicted increased
risk of CVD more accurately than clinic BP in those with or
without diabetes mellitus (456), and others have confirmed
these findings (454). Heart rate dipping ratios, and an
ambulatory arterial stiffness index using ambulatory BP
monitoring may add significantly to prediction of mortality
in the elderly population who do not have diabetes mellitus
(457).
3.3. Out-of-Office Blood Pressure Recordings
The case for using out-of-office BP readings with the
elderly, particularly home BP measurements, is strong due
to the potential hazards of excessive BP reduction in older
people (458). Home BP monitoring alone may be as useful
as clinic measurements for treatment decisions in the elderly
(459). Others have suggested that home BP measurement
has a better prognostic accuracy than office BP measurement
(460). The difference between the office and home BP (the
white-coat effect) increases progressively with age, so that
the office BP tends to overestimate the out-of-office BP
more in older than younger people; variability of systolic
home BP also increases with age (461). Monitors that
measure BP with an upper arm cuff are the most reliable
(458). Wrist monitors provide convenience and the poten-
tial advantage of use with elderly patients who are obese in
whom putting on an upper arm cuff is difficult (458), but
these monitors must be held at the level of the heart when
a reading is taken. If this does not occur, there is an
increased possibility of erroneous readings. Additionally,
most wrist monitors that have been tested have failed
validation studies; thus, they are not usually recommended
for routine clinical use (458).
Home BP measurement has disadvantages that need to
be considered before advising elderly patients to purchase
and take their BPs at home. Individuals with cognitive and
physical disabilities are potentially unable to operate a home
BP monitor (462). Although automatic electronic devices
are more convenient and easier to use, aneroid manometers
with a stethoscope require manual dexterity and good
hearing. Additionally, the automated devices available for
self-measurement all use the oscillometric technique where
small oscillations in cuff pressure are used to identify SBP,
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niques cannot measure BP in all patients, especially patients
with arrhythmias, such as rapid ventricular rate in a pa-
tient with AF, an arrhythmia common among the elderly
patients with hypertension (463).
Finally, there can be substantial observer error in report-
ing of self-measured BP values (465). Diaries completed by
patients recording BP over time lack reliability. Erroneous
reporting occurs more often in cases of uncontrolled BP and
heart rate, conditions more common in the elderly (466).
Memory-equipped devices and/or telemonitoring are strat-
egies to overcome unreliable reporting, but both strategies
add to nonreimbursable costs of providing care for elderly
patients.
3.4. Clinical Evaluation
There is limited evidence to provide evidence-based rec-
ommendations on history, physical examination, or test-
ing for evaluating elderly patients with hypertension
(22,23,467,468). As such, the following recommendations
are based on expert opinion, rather than evidence, but we
believe they provide a reasonable clinical approach.
Typical evaluation includes a history and physical exam-
ination and ordering laboratory or other diagnostic or
prognostic tests. A good history and examination are the
starting point for the clinical evaluation (468). However,
given the time constraints of a typical outpatient encounter,
often in the range of 10 to 15 minutes, it is most important
to hone in on aspects of the history and examination that
relate to hypertension. These include historical issues such
as duration and severity of high BP, causes or exacerbations
of high BP, current and previous treatments (including
adverse effects of medications or other interventions), target
organ damage, other CVD risk factors and overall CVD
risk, and comorbidities that can affect hypertension man-
agement and prognosis. Because high BP is a risk factor for
CV, peripheral vascular, cerebrovascular, renal, and oph-
thalmologic disease, the history and examination should
look for evidence of organ damage in these systems. The
examination, in addition to the organ systems noted above,
should include the patient’s weight and waist circumference
at the level just above the anterior superior iliac crests.
Many guidelines advocate “routine laboratory testing” in
evaluation of patients with high BP. Despite such recom-
mendations, there is little evidence to support routine
laboratory testing, and clinicians should take a more delib-
erative and reasoned approach to ordering tests. Routine
testing increases costs and may have adverse effects such as
anxiety, pain/discomfort, additional testing, complications
from such testing, and time and travel burden. In elderly
patients, the burden of getting to appointments is often
greater, and the elderly may suffer more discomfort during
testing. Many elderly patients also will have had laboratory
tests performed recently for other reasons, so obtaining
copies of these tests is more cost-effective than repeating
them. In general, tests should only be ordered if they willhelp the clinician make a diagnosis or establish a prognosis
and if the result is likely to affect decisions regarding
management.
The most important role for testing in an elderly patient
with hypertension is to assess for organ damage and mod-
ifiable CVD risk factors, including tobacco smoking, hyper-
cholesterolemia, diabetes mellitus, and excessive alcohol intake
(469–472). Information on the following laboratory tests
should be available:
1. Urinalysis to look for any evidence of renal damage,
especially albuminuria/microalbuminuria
2. Blood chemistry to assess electrolytes and renal function,
especially potassium and creatinine with eGFR
3. Total cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and triglycerides,
preferably fasting levels
4. Fasting blood sugar and, if there are concerns about
diabetes mellitus, hemoglobin A1c
5. ECG
At this time, we cannot routinely recommend other
laboratory tests unless there are other indications for such
testing. In selected elderly persons, 2-dimensional echocar-
diography should be considered because it is more sensitive
and more specific in diagnosing LVH than is ECG and has
a greater prognostic value. In addition, echocardiography
may detect abnormalities in LV function that would warrant
additional therapy (i.e., ACEIs, beta blockers). Future
studies could lead to additional tests being recommended if
evidence becomes available that such testing leads to im-
provements in important health outcomes.
A 12-lead ECG is recommended to assess for evidence of
underlying cardiac abnormalities or previous cardiac damage
and to provide a baseline for future comparison. However,
many elderly patients will have had a recent ECG per-
formed for a variety of reasons, so obtaining a copy of a
recent ECG, especially if it is less than a year old, should at
least be attempted before ordering another ECG. Additional
testing to identify specific causes of high BP are generally not
indicated unless the history, physical examination, or testing
reveals an abnormality that arouses suspicion or if BP is not
well controlled despite adequate dosing of multiple medica-
tions and good patient compliance.
4. Recommendations for Management
4.1. General Considerations
4.1.1. Blood Pressure Measurement and Goal
Reliable, calibrated BP measurement equipment is critical
for hypertension management in any age group, and these
considerations are detailed in Section 3.1. As discussed, the
general recommended goal BP in persons with uncompli-
cated hypertension is 140/90 mm Hg. However, this tar-
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opinion rather than on data from RCTs, and it is unclear
whether the target SBP should be the same in 65 to 79 year
olds versus older patients.
4.1.2. Quality of Life and Cognitive Function
The decision to initiate antihypertensive therapy in the
elderly should include consideration of potential impact on
QoL. Although the high rate of comorbid conditions and
need for polypharmacy influence compliance, these factors
also have QoL and economical impacts for patients and
their families. Because symptomatic well-being, cognitive
function, activity, and sexual function have already been
diminished by aging and disease, it is important to give
particular attention to these QoL areas when making
therapy decisions (473). In general, trials confirm long-term
antihypertensive treatment does not necessarily negatively
impact QoL; however, some specific drug classes may do so.
The TONE study (474) found benefits were similar among
hypertension patients treated with diuretics, beta blockers,
CAs, and ACEIs, but beta blockers increased depressive
symptoms. Conversely, other antihypertensive medications
may be associated with beneficial effects on QoL. For
example, among elderly patients with hypertension with
mild cognitive impairment (Mini-Mental State Exam score
24 to 28), SCOPE (475) found no difference in cognitive
outcomes between treatment groups overall, with evidence
suggesting that candesartan may prevent cognitive decline.
However, BP reduction was greater (2.5/1.9 mm Hg) with
candesartan, also suggesting that better BP control may
delay cognitive decline (259). A SCOPE substudy reported
that “good” health-related QoL was preserved in the pres-
ence of substantial BP reduction with an advantage among
candesartan-treated patients in 4 health-related QoL vari-
ables (476). Existing data do not associate hypertension
treatment in the elderly with significant impairment in
QoL, but there is potential for differences in adverse and
beneficial effects among drug classes (336).
Table 5. Lifestyle Modifications to Manage Hypertension
Lifestyle Modifications
Modification Recommenda
Weight reduction Maintain normal body weight (BMI, 18
dopt DASH eating plan Consume a diet rich in fruits, vegetabl
with a reduced content of saturated
ietary sodium reduction Reduce dietary sodium intake to no m
(2.4 g sodium or 6 g sodium chlorid
hysical activity Engage in regular aerobic physical act
(at least 30 min/d, most days of the
oderation of alcohol consumption Limit consumption to no more than 2
ethanol [e.g., 24-oz beer, 10-oz wine
in most men and no more than 1 dr
lighter-weight persons
*For overall cardiovascular risk reduction, stop smoking. The effects of implementing these mo
BMI indicates body mass index calculated as weight in kilograms divided by the square of height in
Modified from Chobanian et al. (22).4.1.3. Nonpharmacological Treatment:
Lifestyle Modification
Lifestyle modifications may be the only treatment necessary
for preventing or even treating milder forms of hypertension
in the elderly (Table 5) (469). Smoking cessation, reduction
in excess body weight and mental stress, modification of
sodium and alcohol intake, and increased physical activity
may also reduce antihypertensive drug doses needed for BP
control (470,471,477–479). Unfortunately, national surveys
indicate that nutrition and exercise counseling are provided
at only 35% and 26% of visits, respectively, in hypertension
patients, and patients 75 years of age are least likely to
receive such counseling (480).
Smokers65 years of age benefit greatly from abstinence
(202,481–484). Older smokers who quit reduce their risk of
death from CAD, chronic obstructive pulmonary disease,
lung cancer, and osteoporosis (485–487). Age does not
appear to diminish the desire to quit (488) or the benefits of
uitting (489,490). Treatments shown effective in the U.S.
epartment of Health and Human Service’s Guideline have
lso been shown to be effective in older smokers (481).
edicare has expanded benefits for tobacco cessation coun-
eling and prescription medications for treating tobacco
ependence (491). However, smokers 65 years of age are
ess likely to be prescribed smoking cessation medications
492). Because of issues common in the elderly, such as
ifficulty with mobility and travel, use of interventions such
s telephone counseling may be particularly applicable.
Weight reduction lowers BP in overweight individuals: A
eta-analysis of 18 trials concluded that loss of 3% to 9% of
ody weight reduces systolic and DBP about 3 mm Hg each
493). In the TONE study, a diet that reduced weight by a 3.5
g lowered BP by 4.0/1.1 mm Hg among 60- to 80-year-old
atients with hypertension (494). Combining weight reduction
ith sodium restriction in TONE resulted in greater benefit.
Dietary sodium restriction is perhaps the best-studied
ifestyle intervention for BP reduction. A meta-analysis of
6 RCTs found mean BP reduction of 3.7/0.9 mm Hg for
anage Hypertension*
Approximate Systolic BP Reduction, Range
.9 kg/m2) 5–20 mm Hg/10-kg weight loss (160,514,515)
d low-fat dairy products
otal fat
8–14 mm Hg (516,517)
an 100 mEq/L 2–8 mm Hg (160,516–518)
ch as brisk walking
)
4–9 mm Hg (477,511,519)
/d (1 oz or 30 mL
-oz 80-proof whiskey])
in women and
2–4 mm Hg (478)
ns are dose and time dependent and could be higher for some individuals.to M
tion
.5–24
es, an
and t
ore th
e
ivity su
week
drinks
, or 3
ink/d
dificatio
meters; BP, blood pressure; and DASH, Dietary Approaches to Stop Hypertension.
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were generally larger in older adults (495). Strongest evi-
dence for sodium restriction in older persons comes from
TONE (160). In patients 60 to 80 years of age with BP
145/85 mm Hg while taking 1 antihypertensive drug,
mean BP reduction of 4.3/2.0 mm Hg occurred after 3
months of sodium restriction to 80 mmol/d coupled with
medication withdrawal and 30 to 45 minutes brisk walking
most days (494). However, BP and adverse outcome reduc-
tions did not achieve statistical significance in 70 to 80 year
olds. Other studies have confirmed benefits of lifestyle
modification in older subjects for BP control (496–501).
Increased potassium intake, either by fruits and vegeta-
bles or pills, reduces BP. In a meta-analysis of 33 RCTs,
potassium supplements significantly lowered BP by 3.1/2.0
mm Hg, and this effect was enhanced in persons with higher
sodium intake (502). Two trials in this meta-analysis
confirmed significant BP reductions (4.3/1.7 mm Hg and
10.0/6.0 mm Hg, respectively [503,504]) among elderly
patients with hypertension. The DASH diet showed a mean
BP decrease of 11.4/5.5 mm Hg in patients with hyperten-
sion (mean age 47 years) with a diet enriched with fruits and
vegetables and low in saturated and total fat (505). Similar
BP reductions were seen in those 45 years of age (506).
The DASH combination diet lowered SBP more in African
Americans (6.8 mm Hg) than in whites (3.0 mm Hg)
(p0.05) and in persons with hypertension (11.4 mm Hg)
than in persons without hypertension (3.4 mm Hg)
(p0.05). Potassium supplementation (90 mmol [3,500
mg] daily) reduces BP in individuals with and without
hypertension (502,507), and effects are greater in individuals
with higher dietary sodium levels (469). In elderly patients
with substantially impaired renal function, serum potassium
should be monitored when supplementation is given.
Calcium and magnesium supplementation results in min-
imal to no change in BP. However, it is prudent to include
adequate calcium in the diet (469,508). There is no evidence
that vitamin, fiber, or herbal supplements influence BP in
the elderly (469,470,509).
Consumption of 2 alcohol drinks per day is strongly
associated with BP elevations in epidemiologic studies. Al-
though several small RCTs demonstrate significant BP de-
clines after reduced alcohol intake, few older patients are
included. In the multicenter PATHS (Prevention and Treat-
ment of Hypertension Study), reduction of alcohol intake by a
mean of 1.3 drinks/d in patients (mean age 57 years) resulted
in a nonsignificant BP decrease of 1.2/0.7 mm Hg; similar BP
reductions of 1.9/0.6 mm Hg occurred in hypertension pa-
tients (510). Thus, evidence for meaningful BP reduction from
lowering alcohol intake is limited in older adults.
Among the benefits of aerobic exercise training is BP
reduction. A meta-analysis of 54 RCTs found aerobic exercise
programs reduced BP about 3.8/2.6 mm Hg among 21 to 79
year olds, but an analysis by age was not provided (477).
xercise modality, frequency, intensity, and presence or ab-
ence of hypertension did not significantly affect the magnitudeof BP decline. Trials in older patients with hypertension show
BP reductions from aerobic training. In 33 such individuals 60
to 69 years of age, 9 months of training 3 times weekly at either
53% or 73% peak aerobic capacity elicited BP reductions
averaging 7/3 mm Hg and 6/9 mm Hg, respectively (511). In
70 to 79 year old patients with hypertension, BP reductions of
8/9 mm Hg occurred after 6 months training at 75% to 85%
peak aerobic capacity (512). In sedentary men (mean age 59
years) with prehypertension, 9 months of aerobic training 3
days per week elicited a BP reduction of 9/7 mm Hg; men who
combined exercise and a weight loss diet had a 11/9 mm Hg
decline (513). Thus, aerobic exercise alone or combined with a
weight reduction diet reduces BP in older adults with hyper-
tension. The finding that exercise at moderate intensities elicits
BP reductions similar to those of more intensive regimens is
especially meaningful for the elderly.
4.1.4. Management of Associated Risk Factors and
Team Approach
Most guidelines for treatment of hypertension or dyslipide-
mia emphasize risk estimates obtained from an overall or
global instrument such as the Framingham Risk Score for
predicting MI, stroke, or CVD in general (520) or its
modifications such as the Reynolds score (521) or scores
developed in other countries, including Q-risk derived from
practices in the United Kingdom (522). These algorithms
emphasize age and classify all persons 70 or 75 years of
age as high risk (i.e., 10% risk of CAD in next 10 years),
hus deserving therapy. Therefore, older patients with hy-
ertension may be classified at high or very high risk (e.g.,
hose with diabetes mellitus). Patient preferences and values
re also important in deciding on the advisability and mode
f therapy, especially in older individuals where QoL
ometimes becomes more important than duration.
Several trials including some subjects with hypertension
351,353,355,523–525) have evaluated multiple risk interven-
ions. Subgroup post hoc analyses have not suggested that
lderly subgroups differed from younger subgroups in response
o risk factor management. This management is fostered by
ehavioral interventions that focus on re-enforcement tech-
iques to enhance engagement of elderly individuals in their
wn care employing a team. The team should ideally be
omposed of clinical pharmacists, nurses, physician assistants,
linical psychologists, and others (as necessary). Communica-
ion with and compliance by elderly patients might be facili-
ated by interactions at group visits with caregivers or counsel-
rs. Technology enhancements to achieve these goals span the
pectrum from simple printed prompts and reminders through
omplex systems of telemedicine and text messaging.
4.2. Pharmacological Management
4.2.1. Considerations for Drug Therapy
4.2.1.1. EVIDENCE BEFORE HYVET
In the mid-1980s, the EWPHE (European Working Party
on High Blood Pressure in the Elderly) (526) demonstrated
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Hg systolic and/or 90 mm Hg diastolic, drug treatment
reduced CV events. Other studies extended beneficial effects
of antihypertensive drugs to patients 70 years of age
(11,15,18,527) and elderly patients with ISH (i.e., SBP
160 mm Hg but DBP 95 or 90 mm Hg) (20,528,529).
Meta-analyses (45,249) are the basis on which to recom-
mend drug treatment for elderly patients with hypertension
(22,23,530,531). A greater degree of caution is required in
older patients because of alterations in mechanisms respon-
sible for drug disposal as well as changes that occur in
homeostatic CV control (532) as well as QoL factors dis-
cussed in the preceding text.
Most patients recruited in antihypertensive trials in the
elderly were 80 years old, thus limiting informa-
tion about octogenarians. Pooling the limited number
(n1,670) of patients 80 years of age from trials mainly
omposed of younger patients (249) provided data difficult to
nterpret. Compared with controls, treated patients showed a
eduction in the incidence of both stroke and CV morbidity
ut a trend toward increased all-cause mortality. So the overall
enefits of treating a cohort 80 years old seemed question-
ble. Thus, despite epidemiologic evidence that hypertension
emains a risk factor in 80 to 89 year olds (533,534), guidelines
voided firm recommendations on drug treatment in octoge-
arians with statements like “in subjects aged 80 years or over,
vidence for benefits of antihypertensive treatment is as yet
nconclusive.” However, they added that “there is no reason for
nterrupting successful and well-tolerated therapy when a
atient reaches 80 years” (534a, p. 1497).
4.2.1.2. EVIDENCE AFTER HYVET
Results of HYVET (4) modify previous recommendations
for patients 80 years of age. In HYVET, 3,845 patients
80 years of age with SBP 160 mm Hg were randomly
assigned to placebo or drug therapy. The latter included a
non-thiazide sulphonamide diuretic (indapamide) supple-
mented by an ACEI (perindopril) when needed for target
SBP of 150 mm Hg. After 2 years, with about one fourth of
the patients using monotherapy and three fourths combi-
nation therapy, the trial was stopped because drug treat-
ment, although decreasing BP compared with the placebo
group (144/78 mm Hg versus 161/84 mm Hg), reduced
adverse outcomes. This consisted of reductions in the
incidence of stroke (30%), congestive HF (64%), and
CV morbid and fatal events (23%). Most impressively,
there was a significant reduction (21%) in the incidence of
all-cause death. Of importance, drug treatment was well
tolerated. The reduction in BP in the standing position was
similar to that in the sitting position. Furthermore, serum
electrolyte and biochemical values were similar in drug- and
placebo-treated groups. In fact, fewer serious adverse events
were reported in the drug-treated than in placebo-treated
patients (4).
The HYVET results provide clear evidence that BP
lowering by drugs is associated with definite CV benefits in npatients80 years of age. They not only refute concern that
this may lead to an increase, rather than a decrease in
mortality, but also show that in this stratum of the popu-
lation, there is a prolongation of life. This finding is highly
relevant for public health because subjects 80 years of age
represent the fastest growing fraction of the population; the
prediction is that by 2050, they will account for more than
one fifth of all elderly individuals (535).
However, HYVET has some limitations that should be
taken into account when considering antihypertensive treat-
ment in very elderly patients. Patients with stage 1 hyper-
tension were not included. Patients on whom HYVET
results are based are not representative of the general very
elderly population. First, to limit dropouts, recruitment
focused on patients in relatively good physical and mental
condition and with a low rate of previous CVD. This is at
variance from the high rate of frail and medically compro-
mised patients typical in this very old age range. Second,
because identifying appropriate subjects was difficult, re-
cruitment required about 6 years and was only possible
through participation of Eastern European countries and
China, which together accounted for 98% of the patients.
Furthermore, premature interruption of the trial (because of
mortality benefit) made average follow-up relatively short
(median 1.8 years). It remains unknown whether benefits of
antihypertensive treatment persist or diminish after 2 or 3
years. Also, the mean age was 83 years, and only a small
fraction was 85 years of age, which leaves open the
uestion whether the benefit extends to ages much older
han those investigated in previous trials. Compared with
lacebo, drug treatment was not accompanied by significant
mprovement in the incidence of dementia or cognitive
ysfunction (260). Finally, the optimal BP goal for reducing
V events and mortality was not investigated.
.2.2. Initiation of Drug Therapy
he initial antihypertensive drug should be started at the
owest dose and gradually increased depending on the BP
esponse to the maximum tolerated dose. If the antihyper-
ensive response to the initial drug is inadequate after
eaching full dose (not necessarily maximum recommended
ose), a second drug from another class should be added,
rovided the initial drug is tolerated. If the person is having
o therapeutic response or significant adverse effects, a drug
rom another class should be substituted. If a diuretic is not
he initial drug, it is usually indicated as the second drug. If
he antihypertensive response is inadequate after reaching
he full dose of 2 classes of drugs, a third drug from another
lass should be added. When the BP is 20/10 mm Hg
bove goal, drug therapy should generally be initiated with
antihypertensive drugs, 1 of which should be a thiazide
iuretic; however, in the elderly, treatment must be indi-
idualized (22).
Before adding new antihypertensive drugs, possible reasons
or inadequate BP response should be examined. These include
oncompliance, volume overload, drug interactions (e.g., use of
BA
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taining sympathomimetics), and associated conditions such as
obesity, smoking, excessive intake of alcohol, insulin resistance,
and pseudoresistance (22). Pseudoresistance (536) is an inad-
equate response to antihypertensive therapy because the BPs
measured in the physician’s office are falsely high compared
with those measured at home or by 24-hour ambulatory BP
monitoring. Causes of secondary hypertension should be iden-
tified and treated (22,537).
Table 6. Drug Interactions
Drug Class/Drug Interacting Drug
eta blockers
ll beta blockers
(hemodynamic interactions)
Calcium antagonists, especially
nifedipine
Add
Verapamil or diltiazem; flecainide;
most anesthetics
Add
e
electrophysiologic interactions) Verapamil; diltiazem Add
n
in
Amiodarone Add
ll lipid-soluble beta blockers
(hepatic interactions):
carvedilol, labetalol,
metoprolol, propranolol,
probably timolol
Inhibitors of hepatic CYP2D6;
cimetidine, ritonavir, quinidine
Dec
b
so
alcium antagonists
erapamil (V) Beta blockers SA
m
Digitalis poisoning Add
in
Digoxin (D) Dec
in
P
Disopyramide Pha
Flecainide (F) Add
Prazosin and other alpha blockers Hep
Quinidine (Q) Add
in
Q
Beta blockers Add
n
iltiazem Digoxin (D) Som
Flecainide (F) Add
e
icardipine (see also nifedipine) Digoxin (D) Dec
Beta blockers; propranolol (P) Add
N
e
fl
Digoxin (D) Min
ifedipine (N) Prazosin (PZ), other alpha
blockers
PZ b
Quinidine (Q) N im
fu
faPolypharmacy and potential drug interactions are a greater
concern in the elderly than in younger patients. The average
elderly patient is taking 6 prescription drugs. Medications
likely to be used in the elderly that increase BP include
NSAIDS, corticosteroids, erythropoietin, amphetamines, er-
gotamine, and anabolic steroids. Agents that increase the
antihypertensive effect of beta blockers and CAs include
cimetidine, antifungal azolides, and grapefruit juice (538,539).
A detailed list of drug interactions is included (Table 6).
echanism Consequence Prophylaxis
otension Risk of myocardial
ischemia
BP control, adjust doses
gative inotropic Risk of myocardial
failure; hypotension
Check for CHF; adjust
doses; flecainide levels
ibition of SA, AV
added negative
ic effect
Bradycardia, systole,
complete HB,
hypotension
Exclude “sick-sinus”
syndrome; AV nodal
disease, LV failure
dal inhibition Bradycardia, HB Exclude nodal disease
hepatic
wn of the lipid-
beta blocker
Excess beta-blocking
effects
Avoid interaction or
reduce beta-blocker
dose
nodal inhibition;
dial failure
Added nodal and
negative inotropic
effects
Care during cotherapy;
check ECG, BP,
heart size
and AV nodal
n
Asystole; complete HB
after IV V
Avoid IV V
D clearance;
n of
protein
Risk of D toxicity Halve D dose;
blood D level
dynamic Hypotension, constipation Check BP, LV, and gut
gative inotropic Hypotension Check LV; F levels
teraction Excess hypotension Check BP during
cotherapy
ha receptor
n; V decreased
ance
Hypotension; increased
Q levels
Check Q levels and BP
nodal inhibition;
e inotropism
Bradycardia Check ECG and
LV function
in D clearance Only in renal failure Check D levels
gative inotropic Hypotension Check LV; F levels
D clearance Blood D doubles Decrease; check D levels
gative inotropism
have opposite
on blood liver
Excess hypotension N
decreased P levels; P
increases N levels
Check BP, use low initial
dose; readjust P and
N doses if needed
dest changes in D Increased D levels Check D levels
alpha-reflex to N Postural hypotension Low initial dose of N or
PZ or other alpha
blockers
s poor LV
; Q clearance
Decreased Q effect Check Q levelsM
ed hyp
ed ne
ffect
ed inh
odes;
otrop
ed no
reased
reakdo
luble
and AV
yocar
ed SA
hibitio
reased
hibitio
-glyco
rmaco
ed ne
atic in
ed alp
hibitio
clear
ed SA
egativ
e fall
ed ne
ffects
reased
ed ne
and P
ffects
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Drug Class/Drug Interacting Drug Mechanism Consequence Prophylaxis
iuretics
oop and thiazide NSAIDs Pharmacodynamic Decreased anti-
hypertensive effect
Adjust diuretic dose or
add another agent
Probenecid Decreased intratubular
secretion of diuretic
Decreased diuretic effect Increased diuretic dose
ACEI, ARBs Excess diuretics, high renins Excess hypotension;
prerenal uremia
Lower diuretic dose;
initial low-dose ACEI or
ARB
Captopril Possible interference with
tubular secretion
Loss of diuretic efficacy
of furosemide
Change to another ACEI
Loop Aspirin Inhibition of acute
vasodilator response
Presumed less efficacy
in HF
Delay aspirin when
initiating acute therapy
for HF
Potassium sparing ACEI, ARBs Both retain potassium Hyperkalemia Monitor potassium,
reduce ACEI dose
Aldosterone receptor antagonist
Eplerenone ACEI Retains potassium Hyperkalemia Monitor potassium,
reduce ACEI dose
Direct renin inhibitors
Aliskiren ACEI, ARB, potassium-sparing
diuretics
Retain potassium Hyperkalemia Monitor potassium,
reduce or eliminate
ACEI, ARB, or
potassium-sparing
diuretic
Angiotensin-converting enzyme
inhibitor
ACEI class effect Excess diuretics; rare in
hypertension
High renin levels in
overdiuresed patients;
volume depletion
First-dose hypotension;
risk of renal failure
Reduce diuretic dose;
correct volume
depletion
Potassium-sparing diuretics;
spironolactone
Added potassium retention Hyperkalemia Avoid combination or use
with care
NSAIDs Less vasodilation Less BP and2 less
antifailure effect
Avoid if possible
Aspirin Less vasodilation Less HF effects Low-dose aspirin
Loop diuretics Possible interference with
tubular secretion
Lessened diuretic effect
of furosemide
Consider alternate ACEI
Captopril (C) Immunosuppressive drugs,
procainamide–hydralazine
Added immune effects Increased risk of
neutropenia
Avoid combination;
check neutrophils
Probenecid (P) P inhibits tubular secretion
of C
Small rise in C levels Decrease C dose
Angiotensin receptor blockers
ARB class effect Excess diuretics; rare in
hypertension
High renin levels in
overdiuresed patients;
volume depletion
First-dose hypotension;
risk of renal failure
Reduce diuretic dose;
correct volume
depletion
Vasodilators Beta blockers (hepatically
metabolized)
Hepatic shunting Beta-blocker metabolism
2; blood levels1
Propranolol; metoprolol
dose2
Hydralizine Nitrates (N) Renal blood flow1; added
vasodilation; free radicals
scavenged
Less N tolerance
(benefit); risk of excess
hypotension
Start with low dose of an
alpha blocker or
dihydropyridine;
calcium blocker
Verapamil Hepatic metabolism Synergistic
antihypertensive effect
Adjust doses
Cilostazol (C) Inhibition of P450 3A4; diltiazem,
verapamil, erythromycin,
ketoconazole, cyclosporine
2 hepatic interaction 1 C levels, risk of
increased mortality
in HF
Lessen C dose or avoid
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV, atrioventricular; BP, blood pressure; CHF, congestive heart failure; CYP2D6, cytochrome P450 2 D6; ECG,
electrocardiogram; HB, heart block; HF, heart failure; IV, intravenous; LV, left ventricle; NSAIDs, nonsteroidal anti-inflammatory drugs; SA, sinoatrial; 1, increase; and 2, decrease.
Modified from Opie and Frishman (540).
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This section reviews the rationale for pharmacological
treatments in elderly subjects, some general considerations,
and experiences with specific drug classes. There is strong
clinical trial–based evidence that elderly patients with hy-
pertension benefit greatly from pharmacological BP reduc-
tion (541–546). This evidence shows that treatment reduces
both CV and cerebrovascular morbidity and mortality. A
meta-analysis (31 trials with 190,606 participants) showed
that BP reduction produces benefits in older adults with no
strong evidence that protection against major CV events
afforded by different drug classes varies substantially with
age (251). Individual drug classes are reviewed in the
following text, and their suggested use in treating hyperten-
sion is summarized in Figure 10.
Age-related physiologic changes that may affect absorp-
tion include reduced gastric acid secretion and emptying
rate, reduced splanchnic blood flow, and decreased mucosal
absorptive surface area (Table 7). Yet, oral absorption of CV
drugs is not significantly affected by aging, probably because
most drugs are absorbed passively (547). Drug distribution
may be altered in the elderly secondary to decreased lean
body mass and relative increased body fat. Age-related
declines in renal or hepatic function alter drug disposition in
elderly patients, mostly as a result of declines in first-pass
metabolism. This decline decreases total body clearance and
Figure 10. Algorithm for Treatment of Hypertension in the Elde
ACEI indicates angiotensin-converting enzyme inhibitor; ALDO ANT, aldosterone anta
CAD, coronary artery disease; CVD, cardiovascular disease; DBP, diastolic blood pre
diuretic. Modified from Chobanian et al. (22).increases elimination half-life. Individualized dose adjust-ments or dosing schedules help to decrease adverse effects
(548). Pharmacokinetic changes, route of elimination, and
dosage adjustment for antihypertensive drugs used among
the elderly, are summarized in Table 8.
4.2.2.1.1. DIURETICS
4.2.2.1.1.1. Thiazides. Thiazide diuretics, such as HCTZ,
chlorthalidone, and bendrofluazide (bendroflumethiazide),
a mainstay of antihypertensive treatment in the elderly, are
recommended for initiating therapy (22). Chlorthalidone
differs from HCTZ by its longer duration of action and
greater potency, and for this reason, may be associated with
a higher risk of metabolic adverse effects. Diuretics cause an
initial reduction in intravascular volume, peripheral vascular
resistance (551–553), BP in 50% of patients, and are
generally well tolerated and inexpensive. Several trials dem-
onstrate their ability to also reduce CV, cerebrovascular, and
renal adverse outcomes in the elderly.
Aging-related, physiological changes can be exacerbated
with diuretics. The elderly have contracted intravascular
volumes with impaired baroreflexes, and diuretics cause
sodium and water depletion (hypovolemia) and orthostatic
hypotension. Older people have a high prevalence of LVH,
which predisposes to ventricular ectopy and sudden death.
Diuretics can cause hypokalemia, hypomagnesemia, and
hyponatremia, which can increase arrhythmias. Hypokale-
mia and hypomagnesemia can develop within the first few
ARB, aldosterone receptor blocker; BB, beta blocker; CA, calcium antagonist;
RAS, renin-angiotensin system; SBP, systolic blood pressure; and THIAZ, thiaziderly
gonist;
ssure;days of treatment. However, after that, the body can achieve
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lessened. Nevertheless, these agents are not advised in
patients with baseline electrolyte abnormalities, and when
they are used, serum potassium levels should be monitored
and supplementation given if needed (554). With aging,
renal blood flow and GFR decrease; diuretics can further
decrease renal blood flow, creatinine clearance, and GFR.
The elderly have a tendency toward hyperuricemia and
glucose intolerance. The latter is a particular concern for
hypertension patients because many have insulin resistance
and related coronary vascular dysfunction (555,556). Di-
uretics can increase uric acid levels and need for antigout
therapy in patients 65 years of age with hypertension
(364,417), as well as glucose intolerance, and dyslipidemia
(557). However, their long-term use has been associated
with an overall decrease in serum cholesterol levels. Because
of side effects, about 3.6% of patients withdrew from the
MRC (Medical Research Council) trial (less than the
beta-blocker group) (15) and 15% (comparable to other
drug groups) withdrew from ALLHAT (9). In SHEP, the
most frequent adverse event was abnormal serum electrolyte
levels (16). Despite these side effects, diuretics have reduced
CV events in the elderly to a similar extent as other drug
classes, except for findings in ACCOMPLISH (8), when
combined with an ACEI discussed elsewhere.
4.2.2.1.1.2. Other Diuretics. Indapamide, a non-thiazide sul-
fonamide diuretic, was used in several hypertension trials
that included elderly patients (HYVET, PROGRESS,
etc.). This drug also increases blood glucose but not uric
acid and may cause hyponatremia. Because indapamide
reduces the renal clearance of lithium, caution is advised in
using this combination. Furosemide and its analogs (bumet-
anide or torsemide) are loop diuretics used for hypertension
(AASK [African American Study of Kidney Disease]) (558)
when complicated by HF or CKD. They also increase blood
sugar levels, and may cause headaches, fever, anemia, and/or
Table 7. Physiologic Changes With Aging Potentially Affecting
Process Physiological Change
bsorption Reduced gastric acid production Redu
dec
Reduced gastric emptying rate Decre
Reduced GI motility, GI blood flow, and
absorptive surface
Less
istribution Decreased total body mass; increased
proportion of body fat
Increa
dru
Decreased proportion of body water Decre
Decreased plasma albumin, disease-related
increased 1-acid glycoprotein, and
altered relative tissue perfusion
Chan
me
etabolism Reduced liver mass, liver blood flow, and
hepatic metabolic capacity
Accum
xcretion Reduced glomerular filtration, renal tubular
function, and renal blood flow
Accum
Ellipses indicate no drugs affected. ACE indicates angiotensin-converting enzyme; GI, gastrointeelectrolyte disturbances. hPotassium-sparing diuretics, mineralocorticoid antago-
nists (spironolactone and eplerenone), and epithelial sodium
transport channel antagonists (amiloride and triamterene)
are useful in hypertension when combined with other
agents. Because vascular stiffness and endothelial nitric
oxide production are influenced by sodium ion under
control of the mineralocorticoid receptor, these agents
reduce vascular stiffness and SBP (559). Alternately, an
increase in potassium softens vascular endothelium and
increases nitric oxide release. These drugs are also useful for
patients with hypertension with HF or primary aldosteron-
ism. Gynecomastia and sexual dysfunction are limiting
adverse reactions for men treated with spironolactone, but
these are less frequent with eplerenone (189). The epithelial
sodium transport channel inhibitors have minimal effects on
BP as monotherapy and are most useful for their potassium-
sparing effects when combined with another diuretic. The
combination of a HCTZ and amiloride was equivalent to
nifedipine gastrointestinal therapeutic system in preventing
CV adverse outcomes in INSIGHT (Intervention as a Goal
in Hypertension Treatment) (560) among patients 55 to 80
years of age with hypertension.
4.2.2.1.2. BETA-ADRENERGIC BLOCKERS. Although beta
lockers have been used for hypertension in the elderly for
ears, evidence for benefit has not been convincing (14–
6,18,327). A meta-analysis of 10 studies comparing beta
lockers and diuretics in patients 60 years of age showed
wo thirds of the patients assigned diuretics were well
ontrolled on monotherapy (561). Diuretics were superior
o beta blockade with regard to all clinical outcomes, and
ere more effective in preventing CV adverse outcomes.
Therefore, clinical benefits of beta blockers as mono-
herapy in the uncomplicated elderly patient are poorly
ocumented, although they may have a role in combination
herapy, especially with diuretics. Beta blockers have an
stablished role in the treatment of elderly patients with
Pharmacokinetics of Antihypertensive Drugs
Result Drugs Affected
blet dissolution and
d solubility of basic drugs
. . .
absorption for acidic drugs . . .
unity for drug absorption . . .
d of highly lipid-soluble Beta blockers, central alpha agonists
Vd of hydrophilic drugs ACE inhibitors
rcent of free drug, Vd, and
d levels of bound drugs
Propranolol
on of metabolized drugs Propranolol, diltiazem, labetalol, verapamil
on of renally cleared drugs ACE inhibitors, atenolol, sotalol, nadolol
and Vd, volume of distribution. Modified from Hui (549).the
ced ta
rease
ased
opport
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ulatiypertension complicated by certain arrhythmias, migraine
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should be given to adding beta blockers in patients with
Table 8. Pharmacokinetic Changes, Route of Elimination, and
in the Elderly
Drug Class/Drug Half–Life
Volume of
Distribution Clearanc
Alpha-adrenergic agonists, centrally acting
Guanfacine 1 . . . 2
Alpha1 selective adrenergic antagonists, peripherally acting
Doxazosin 1 1 *
Prazosin 1 . . . . . .
Terazosin 1 . . . . . .
ngiotensin-converting enzyme inhibitors
Benazepril 1 . . . 2
Captopril NS . . . 2
Fosinopril . . . . . . . . .
Lisinopril 1 . . . 2
Perindopril . . . . . . 2
Ramipril . . . . . . . . .
ngiotensin II receptor blockers
Candesartan . . . . . . . . .
Eprosartan . . . . . . 2
Irbesartan NS . . . . . .
Losartan . . . . . . . . .
Valsartan 1 . . . . . .
eta-adrenergic blockers
Nonselective without ISA
Nadolol NS . . . . . .
Propranolol 1 NS 2
Beta1 selective without ISA
Atenolol 1 NS 2
Metoprolol NS NS NS
Beta1 selective with ISA
Acebutolol 1 2 . . .
Dual acting
Carvedilol . . . . . . . . .
Labetalol . . . . . . NS
Nebivolol . . . . . . . . .
alcium antagonists
Amlodipine 1 . . . 2
Diltiazem 1 NS 2
Felodipine . . . NS 2
Nicardipine NS . . . . . .
Nifedipine 1 NS 2
Verapamil 1 NS 2
Diuretics
Loop
Bumetanide . . . NS . . .
Furosemide 1 NS 2
Torsemide . . . . . . . . .
Potassium sparing
Eplerenone . . . . . . . . .
Triamterene 1 . . . . . .
Spironolactone . . . . . . . . .
Ellipses indicate no information is available. NS indicates nonsignificant; 1, increase; and 2,hypertension and these comorbid conditions (562–566). Inolder patients with ISH, a clinic heart rate 79 bpm was a
significant predictor for an increase in all-cause, CV, and
ge Adjustment of Selected Antihypertensive Drugs
Primary Route(s) of
Elimination Dosage Adjustment
Hepatic/renal Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Renal No adjustment needed
Renal Initiate at lowest dose; titrate to response
Hepatic/renal No adjustment needed
Renal Initiate at lowest dose; titrate to response
Renal Initiate at lowest dose; titrate to response
Renal Initiate at lowest dose; titrate to response
Hepatic/renal No adjustment needed
Hepatic/biliary/renal No adjustment needed
Hepatic No adjustment needed
Hepatic No adjustment needed
Hepatic No adjustment needed
Renal Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Renal Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic/biliary Initiate at lowest dose; titrate to response
Hepatic/biliary Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic/renal No adjustment needed
Hepatic Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Hepatic No initial adjustment needed
Hepatic Initiate at lowest dose; titrate to response
Hepatic Initiate at lowest dose; titrate to response
Renal/hepatic No initial adjustment needed
Renal No initial adjustment needed
Hepatic No initial adjustment needed
Hepatic No initial adjustment needed
Hepatic/renal Initiate at lowest dose; titrate to response
Hepatic/biliary/renal No initial adjustment needed
se. Reprinted from Frishman (550).Dosa
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INVEST, with more than 11,000 CAD patients 66 years
f age with hypertension, those randomized to a beta-
locker strategy had lower on-treatment heart rates, but
here was no difference in death, MI, or stroke compared
ith a verapamil strategy (568). Although earlier generation
eta blockers have been associated with depression, sexual
ysfunction, dyslipidemia, and dysglycemia, no such asso-
iations were found with nebivolol (569). Nebivolol also
roduced favorable outcomes in SENIORS (Study of Ef-
ects of Nebivolol Intervention on Outcomes and Rehospi-
alization in Seniors With Heart Failure) 70 years of age
ith HF, the majority of whom also had hypertension
570).
4.2.2.1.3. ALPHA-ADRENERGIC BLOCKING AGENTS. In com-
arative trials, the efficacy and safety of alpha blockers have
een documented (562), but their usefulness is limited.
oxazosin 2 mg to 8 mg daily in the ALLHAT showed
5% excess CV events compared with chlorthalidone,
argely driven by a 204% increase in HF (571) and a 19%
ncrease in stroke. Based on this study, alpha blockers
hould not be considered as first-line therapy for hyperten-
ion in older adults. These drugs are used for urinary
ymptoms related to prostate hypertrophy, and caution
hould always be exercised for orthostatic hypotension. In
ddition, alpha-beta blockers are important in hypertensive
rgencies (labetalol) and congestive HF (carvedilol). How-
ver, due to concern for orthostatic hypotension in the
lderly, their use is discouraged.
4.2.2.1.4. CALCIUM ANTAGONISTS. CAs are a heterogeneous
group of drugs with widely variable effects on heart muscle,
sinus node function, atrioventricular conduction, peripheral
arteries, and coronary circulation (572–575). Chemically,
they can be divided into phenylalkylamines (verapamil);
benzothiazepines (diltiazem); and dihydropyridines (nifed-
ipine, nicardipine, nimodipine, amlodipine, felodipine, is-
radipine, nitrendipine). Despite their heterogeneity, they all
block influx of calcium ions into the cells of vascular smooth
muscle and myocardial tissue (576), and are significantly
more effective inhibiting contraction in coronary and pe-
ripheral arterial smooth muscle than in cardiac and skeletal
muscle. Vascular smooth muscle is more dependent on
external calcium (577) entry for contraction, whereas cardiac
and skeletal muscle rely on a recirculating internal pool of
calcium. Because CAs are membrane active, they reduce
calcium entry into cells and therefore exert a much greater
effect on vascular tissue. This preferential effect allows CAs
to dilate coronary and peripheral arteries in doses that do
not severely affect myocardial contractility or skeletal muscle
(573).
CAs appear well suited for elderly patients whose hyper-
tensive profile is based on increasing arterial stiffness and
diastolic dysfunction secondary to decreased atrial and
ventricular compliance (578–580). Because they have mul-
tiple clinical applications, including treatment of angina and
supraventricular arrhythmias, CAs hold promise for treat- mment of elderly patients with hypertension and comorbid
CV conditions.
In general, CAs appear well tolerated by the elderly. Most
adverse effects of the dihydropyridines relate to vasodilation
(e.g., ankle edema, headache, and postural hypotension).
Postural hypotension is associated with an increased risk of
dizziness and falls; thus, a serious concern for elderly
patients. Peripheral edema also may be confused with HF
(581). Verapamil, which may be useful for LV diastolic
dysfunction, may increase constipation (582). Verapamil
and diltiazem can precipitate heart block in elderly patients
with underlying conduction defects. Results of controlled
trials have demonstrated the safety and efficacy of CAs in
elderly patients with hypertension (9,17,19,20,583,584).
First-generation CAs (nifedipine, verapamil, and diltiazem)
should be avoided in patients with LV systolic dysfunction.
4.2.2.1.5. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.
ACEIs block conversion of angiotensin-I to angiotensin-II
both systemically and locally in multiple tissues as well as
plasma. The latter lowers total peripheral vascular resis-
tance, and BP is reduced without reflex stimulation of heart
rate and cardiac output. As aging occurs, angiotensin levels
are lower, and theoretically, ACEI should not be as effective
as other therapies, but multiple studies have shown other-
wise. Additional benefits of ACEI are reduction in morbid-
ity and mortality in patients with MI, reduced systolic
function HF (585–588), progression of diabetic renal dis-
ease (589), and progression of hypertensive nephrosclerosis
(558).
In the HOPE (Heart Outcomes Prevention and Evalu-
ation) study, ramipril significantly reduced CV death 26%,
all-cause mortality 16%, stroke 32%, and HF 23% in
high-risk older patients with pre-existing CVD or diabetes
mellitus (524). In PROGRESS, perindopril plus indap-
amide reduced stroke-related dementia 34% and cognitive
decline 45% in patients with prior stroke or transient
ischemic attack (mean age 64 years, 64% with prior hyper-
tension) (246). Available data indicate ACEIs should be
considered drugs of choice in elderly patients with hyper-
tension with HF and/or diabetes mellitus or CKD (22). The
main adverse effects of ACEIs include hypotension, chronic
dry cough, and, rarely, angioedema or rash. Renal failure can
develop in those with RAS. Hyperkalemia can occur in
patients with renal insufficiency or those taking potassium
supplements or potassium-sparing diuretics. Therefore,
these agents must be used carefully in patients with renal
impairment. Rarely, neutropenia or agranulocytosis can
occur; therefore, close monitoring is suggested during the
first months of therapy.
4.2.2.1.6. ANGIOTENSIN RECEPTOR BLOCKERS. ARBs selec-
ively block the AT1-receptor subtype that mediates all
nown physiological effects of angiotensin-II believed rele-
ant to CV and cardiorenal homeostasis (590,591). Overall,
RBs are similar to other agents in reducing BP and are
ell tolerated. ARBs protect the kidney in type 2 diabetes
ellitus (592), both in established diabetic nephropathy
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(593). ARBs also reduce mortality and morbidity in patients
with HF (593,594). In elderly patients with hypertension
with diabetes mellitus, ARBs are considered first-line treat-
ment and as an alternative to ACEI in patients with
hypertension and HF who cannot tolerate ACEI (594). In
patients with HF with an ejection fraction 40%, cande-
sartan reduced HF hospitalizations but did not significantly
impact mortality (595).
The LIFE study compared losartan with atenolol in
patients (age 55 to 80 years) with hypertension and LVH
(592), showing reduced stroke rate in the losartan-treated
group despite comparable BP reduction in both treatment
groups. The first occurrence of death, stroke, or CV
mortality was reduced in favor of losartan and there was also
a greater effect on LVH regression versus atenolol. In
SCOPE, candesartan reduced nonfatal stroke by 28% and
showed a trend for reduction of fatal stroke among patients
70 to 89 years of age. In the MOSES (Morbidity and
Mortality After Stroke–Eprosartan Compared With Ni-
trindipine in Secondary Prevention) study, eprosartan re-
duced stroke by 25% in patients with mean age 68 years
(596). The ACCESS (Acute Candesartan Cilexetil Therapy
in Stroke Survivors) study was stopped early because of
reduction in death, CV event, or cerebrovascular event (OR:
0.475; 95% CI: 0.252 to 0.895; p0.026) (597). ONTAR-
GET showed similar efficacy between telmisartan and
ramipril in a large (n25,620) elderly (mean age 66 years)
population (598), the majority of whom had hypertension.
4.2.2.1.7. DIRECT RENIN INHIBITORS. Aliskiren is an orally
active direct renin inhibitor approved for hypertension; 150
mg to 300 mg once daily appears as effective as ARBs and
ACEIs for BP management (599–601) for 24-hour BP
lowering with no evidence of dose-related increases in
adverse events in elderly patients (602). In another group of
elderly patients with systolic hypertension, aliskiren, with
optional add-on HCTZ (12.5 mg/d to 25 mg/d) and
amlodipine (5 mg/d to 10 mg/d), appeared more effective
and better tolerated overall versus ramipril (603). Combin-
ing aliskiren with HCTZ, ramipril, or amlodipine causes
greater BP lowering than with either agent alone (601,604).
Evidence is lacking with combination aliskiren and beta
blockers, or with maximal dose ACEIs, and only limited
data are available in black patients with hypertension (605).
In patients 75 years of age, including those with renal
disease with a GFR 30 mL/min/1.73 m2, aliskiren ap-
pears well tolerated with no dose adjustment necessary
(602). The major side effect is a low incidence of mild
diarrhea, which usually does not lead to discontinuation
(606). There are no data on treating patients with a
creatinine level 30 mL/min/1.73 m2. There are no out-
come data available at this time, but the AGELESS
(Aliskiren for Geriatric Lowering of Systolic Hypertension),
and APPOLO (Aliskiren in Prevention of Later Life
Outcomes) studies, as well as the ALOFT-Age substudy
(Aliskiren Observation of Heart Failure Treatment) (HFtrial and the majority have history of hypertension) (603)
have a large number of elderly patients and are in progress.
4.2.2.1.8. NONSPECIFIC VASODILATORS. Hydralazine and mi-
oxidil are potent vasodilators, but due to unfavorable side
ffects, they are fourth-line drugs as part of a combination
rug regimen. Hydralazine as a monotherapy causes tachy-
ardia, and minoxidil causes fluid accumulation and atrial
rrhythmias. Nitrates, which are a mainstay of antianginal
reatment in the elderly, have no role in chronic hyperten-
ion management because of tolerance.
4.2.2.1.9. CENTRALLY ACTING AGENTS. Centrally acting
gents (e.g., clonidine) are not first-line treatments in the
lderly because many patients experience troublesome seda-
ion or bradycardia, and abrupt discontinuation leads to
ncreased BP and heart rate, which aggravates ischemia
nd/or HF. These agents should not be considered in
atients who may be noncompliant. They can be used as
art of a combination regimen to maximize BP control after
ther agents have been deployed.
.2.3. Combination Therapy
ombination therapy provides more opportunity for cre-
tive solutions to a number of problems. Five issues in
ombined therapy—some practical, some speculative—are
isted in Table 9 (607). The most obvious benefit of drug
combinations is enhanced efficacy. Theoretically, some drug
combinations might produce synergistic effects that are
greater than predicted by summing efficacies of component
drugs. More commonly, combination therapy achieves a
little less than the sum of its component drug efficacies. In
contrast, some combinations of drugs produce offsetting
interactions that may weaken rather than strengthen anti-
hypertensive effects. A second benefit concerns avoidance of
adverse effects because each drug can be administered in a
lower dose. A third issue concerns convenience although a
combination regimen could be confusing and distracting to
elderly patients, and could lead to poor treatment compli-
ance. Conversely, a well-designed, combination pill that
incorporates logical doses of 2 agents enhances convenience
and compliance. Further potential value may result from the
reciprocal pharmacokinetic effects that 2 drugs have on each
other. Although this has not been well studied, there may be
situations where the duration of action of the drugs becomes
longer when used in combination. Finally, it is interesting to
Table 9. Rationale for Combination Drug Therapy
for Hypertension
● Increased antihypertensive efficacy
X Additive effects
X Synergistic effects
● Reduced adverse events
X Low-dose strategy
X Drugs with offsetting actions
● Enhanced convenience and compliance
● Prolonged duration of action
● Potential for additive target organ protectionReprinted from Weber et al. (607).
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exhibit antimitotic or antiatherosclerotic actions in addition
to BP lowering. Some combinations of these newer agents
may provide even more protective effects on the CV system
(Figure 10). The ACCOMPLISH trial of high-risk hyper-
tension patients (mean age 67 years) compared combination
therapy with benazepril plus either HCTZ (12 mg to 25 mg
daily) or amlodipine and found clear superiority for the
ACEI-CA combination in terms of reduction in morbidity
and mortality (8). Both combinations had the same effect on
24-hour mean daytime and nighttime BPs, and surges in
BP. Thus, the greater reduction in clinical events with the
benazepril-amlodipine combination could not be explained
by a greater reduction in BP. Although multiple combina-
tions of diuretics with other antihypertensive drugs have
been used to reduce BP, outcome data from RCTs in elderly
patients are lacking. The beneficial effect on outcomes was
only present for patients with an eGFR 60 mL/min; for
those with reduced renal function there was no difference in
CV outcomes between the 2 combinations (607a). Multiple
RCTs, including HYVET, EWPHE, MRC, and STOP-
HTN (Swedish Trial in Old Patients with Hypertension),
have shown combination therapy with a diuretic to be
efficacious in the elderly (4,12,15,18).
4.2.4. Uncomplicated Hypertension
The 2009 updated ESH guidelines recommend initiating
therapy in the elderly with either thiazide diuretics, CAs,
ACEIs, ARBs, or beta blockers based on a meta-analysis of
major hypertension trials (608,609). When BP is 20/10
mm Hg above goal, consideration should be given to
starting with 2 drugs (22). Most elderly persons with
hypertension will need 2 drugs to control their hyperten-
sion (22,610).
4.2.5. Complicated Hypertension
When additional comorbidities complicate hypertension, at
least 2 drugs should generally be used. In elderly patients
with hypertension at high risk for CV events, a benazepril–
amlodipine combination was more effective in reducing CV
events than a benazepril–HCTZ combination with a 2.2%
absolute risk reduction in CV events by the former combi-
nation (8). Recommended antihypertensive agents for spe-
cific comorbidities are detailed in the following text.
4.2.5.1. CORONARY ARTERY DISEASE
In elderly patients with hypertension and stable angina
and/or prior MI, the initial choice is a beta blocker (22,26,
611). A long-acting dihydropyridine CA should be admin-
istered in addition to the beta blocker when the BP remains
elevated or if angina persists. An ACEI should also be given,
particularly if LV ejection fraction is reduced (22,524,588,612–
614) and/or if HF is present where an aldosterone antagonist
should be added in the absence of hyperkalemia or significant
renal dysfunction (22,615). The INVEST demonstrated that a
verapamil SR–trandolapril-based strategy was as clinically ef-fective in terms of BP control and adverse outcomes as an
atenolol–HCTZ-based strategy in elderly patients with hyper-
tension with CAD, including those with prior MI (584).
Angina was better controlled with the verapamil SR–
trandolapril strategy. Elderly patients with hypertension at
high risk for coronary events should be treated with beta
blockers plus ACEI (22,26,524,612–614).
In elderly patients with acute coronary syndromes, hyper-
tension should be treated with beta blockers and ACEI,
with additional drugs added as needed for BP control
(22,26,616). Verapamil and diltiazem should not be used if
there is significant LV systolic dysfunction (26,616).
Some (26) recommend reducing BP to 130/80 mm Hg
in CAD patients, yet there is limited evidence to support
this lower target in elderly patients with CAD (584). In
INVEST, the nadir BP for risk was 135/75 mm Hg among
6,126 patients 70 to 80 years of age, and 140/70 mm Hg for
2,180 patients 80 years of age (13). Beta blockers with
intrinsic sympathomimetic activity must not be used after
MI. The hydrophilic beta blocker atenolol may not be as
efficacious as propranolol, timolol, metoprolol, or carvedilol
in treating hypertension (617,618), but in most of the
patients in these studies (e.g., LIFE), it was used only once
daily.
4.2.5.2. LEFT VENTRICULAR HYPERTROPHY
LVH associated with hypertension is an independent risk
factor for coronary events, stroke, PAD, and HF. LVH can
regress with antihypertensive therapy except for the direct
vasodilators hydralazine and minoxidil (22). A meta-
analysis of 109 treatment studies found that ACEI was
more effective than other antihypertensive drugs in decreas-
ing LV mass (619). Losartan was superior to atenolol in
reducing first occurrence of CV death, stroke, or MI in
elderly patients with ISH and electrocardiographic LVH
(620). Thus, antihypertensive therapy with ACEI or ARBs
should generally be used in elderly persons with hyperten-
sion and LVH. However, all antihypertensive agents except
for direct-acting vasodilators will reduce LV mass if BP is
controlled.
4.2.5.3. HEART FAILURE
Elderly patients with hypertension and systolic HF should
be treated with diuretics, beta blockers, ACEI, and an
aldosterone antagonist if necessary (22,585,615,621–627).
If a patient cannot tolerate an ACEI because of cough, rash,
or angioedema, an ARB should be used (594,621). Elderly
black patients with hypertension and HF may benefit from
isosorbide dinitrate plus hydralazine (628). Based on expert
opinion, the BP should be reduced to 130/80 mm Hg in
HF patients with CAD (26). Elderly patients with hyper-
tension and asymptomatic LV systolic dysfunction should
be treated with ACEI and beta blockers (22,26,588,629).
Because HF may improve in elderly patients with hyper-
tension and RAS after renal revascularization, a search for
RAS should be considered when HF is refractory or recurs
with conventional management (630). Diastolic HF is very
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treated with diuretics, hypertension should be adequately
controlled, and when possible, comorbidities should be
treated.
4.2.5.4. CEREBROVASCULAR DISEASE
Elderly patients with hypertension with prior stroke or
transient ischemic attack should be treated with a diuretic
plus an ACEI (22,246). Despite this, recommendation by
“The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure,” the overall data suggest that reduction of
stroke risk among elderly persons with hypertension is
related more to reduction in BP than to type of antihyper-
tensive drugs (632). Ischemic stroke was reduced 37% (18%
to 52%), and hemorrhagic stroke reduced 54% (2% to
79%) (95% CI: 0.21 to 1.02).
4.2.5.5. DISEASES OF THE AORTA AND PERIPHERAL ARTERIES
The presence of aortic aneurysm requires very intense BP
control to the lowest tolerated level, and therapy should
include an ACEI or ARB plus a beta blocker, because in
addition to lowering BP, beta blockers decrease peak LV
ejection rate (633,634).
In acute aortic dissection (acute aortic syndrome), control
of BP, with multiple drugs including beta blockade, is
needed for both type A and B (not involving the ascending
aorta) dissection. Surgery is indicated for type A dissections
(those involving the ascending aorta), and endovascular
techniques may be used in elderly patients with high
operative risk (301).
For PAD patients, lifestyle interventions including smok-
ing cessation, weight loss, a structured walking program,
and management of hypertension, as well as coexistent
CAD and HF, are essential, as is control of blood glucose
and lipids. ACEIs or ARBs, as well as antiplatelet therapy,
are required (635). Patients with critical limb ischemia,
(defined as PAD resulting in ischemic pain at rest), ulcer-
ation, or gangrene should be evaluated for revascularization.
In the HOPE study, compared with placebo, the ACEI
ramipril 10 mg daily significantly reduced CV events in
persons with symptomatic and asymptomatic PAD, most of
whom had increased BP and were elderly (636,637). The
absolute reduction in CV events was 50 events per 1,000
patients with an ankle-brachial index 0.9 compared with
24 events per 1,000 patients with an ankle-brachial index of
0.9. Multiple professional societies suggest the BP target
should be below 130/80 mm Hg in patients with PAD. But
in the INVEST, elderly patients with CAD and hyperten-
sion with PAD (n2,699, mean age 69 years, 44% 70
years old), followed for a mean of 2.7 years (6,970 patient-
years), showed a J-shaped relationship with BP treatment.
Adverse outcomes (22,26,28,29,608) (death, MI, or stroke)
occurred least frequently on treatment with SPB 135 to 145
mm Hg and DBP 60 to 90 mm Hg (638), suggesting that
PAD patients may require a different BP (638). Specific cdata in very elderly patients with PAD regarding benefits of
treatment and optimal BP target are sparse.
4.2.5.6. DIABETES MELLITUS
In the absence of RCT data, guidelines recommend that
patients with diabetes mellitus should have BPs 130/80
mm Hg, if tolerated (22,28,29,613,639), and often multiple
drugs are required to meet this goal. However, recent RCT
data from the ACCORD BP (see Section 1.4) found no
benefit of a SBP goal of 120 mm Hg compared with 140
mm Hg on CV endpoints in 4,733 patients (mean age 62
years) with type 2 diabetes mellitus (32). Observational data
from extended follow-up of the 6,400 INVEST diabetes
mellitus cohort of mostly elderly patients (mean age 66
years) showed an increase in mortality when on treatment;
SBP was 115 mm Hg or DBP 65 mm Hg (640). Based
on available data, reduction of macrovascular and microvas-
cular complications in elderly diabetics with hypertension
depends more on reducing the BP than on the type of drugs
used: drug choice depends on associated comorbidities
(22,28). However, thiazide diuretics will increase hypergly-
cemia and risk for incident diabetes mellitus. Incident
diabetes mellitus has been associated with increased HF
hospitalizations and other CV events in elderly patients
with hypertension (556,641). In ALLHAT, patients with
pre-existing diabetes mellitus appeared to receive the same
benefit on future coronary events from diuretics as patients
without diabetes mellitus (9) over an intermediate follow-up
period. Elderly persons with diabetes, hypertension, and
nephropathy should be treated initially with ACEIs or
ARBs (22,642–645). In ACCOMPLISH, over the back-
ground of ACEI, patients with diabetes mellitus who were
treated with amlodipine had a 21% relative risk reduction
and 2.2% absolute risk reduction in CV events (8) compared
with HCTZ plus the ACEI.
4.2.5.7. METABOLIC SYNDROME
Initially attempts should be made to reduce BP in elderly
persons with metabolic syndrome and prehypertension us-
ing lifestyle modification (646). In those who are hyperten-
sive, drug therapy should be used if needed to achieve BP
140/90 mm Hg (646).
4.2.5.8. CHRONIC KIDNEY DISEASE AND RENAL ARTERY STENOSIS
4.2.5.8.1. CHRONIC KIDNEY DISEASE. Based solely on expert
pinion and observational data, elderly patients with hyper-
ension and CKD should have BP 130/80 mm Hg, if
olerated (22,29,409). Drug regimens that include ACEIs
r ARBs are more effective than regimens without them in
lowing progression of advanced proteinuric nondiabetic
KD (647). ACEI therapy is also indicated in patients with
ondiabetic nephropathy. It should be noted, however, that
here are no data on outcomes with any class of antihyper-
ensive agents among elderly patients with hypertension
ith CKD. In the absence of proteinuria (i.e., 300 mg/d),
here are no data that ACEIs or ARBs are better than BP
ontrol alone with any agent that is well tolerated (648,649).
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tension persons with CKD if proteinuria is present
(22,29,409,642–645,647,650).
Hypertension and HF are associated with a more pro-
nounced decline in renal function in older age (324). With
the recognition of early renal dysfunction, more patients
should benefit from aggressive therapy. A retrospective
cohort of elderly individuals with CKD and acute MI found
benefit from combination cardioprotective therapy with
aspirin, beta blockers, and ACEI (651). In an observational
study of elderly (mean age 79 years) hospitalized patients
with acute systolic HF and advanced CKD (mean serum
creatinine 2.9 mg/dL), ACEI use was associated with a 31%
absolute mortality reduction (652).
4.2.5.8.2. RENAL ARTERY STENOSIS
4.2.5.8.2.1. Surgical Revascularization. Revascularization has
been used to treat hypertension, preserve renal function, and
treat HF and unstable angina in patients with RAS and
ischemic nephropathy. Techniques range from aortorenal
bypass with graft of autogenous hypogastric artery or saphe-
nous vein, to aortorenal endoarterectomy (298). Nephrec-
tomy is used only in select patients after revascularization
failure or when benefit in BP control or decrease in CV
morbidity is expected after kidney removal (298,653).
Surgical results in patients with atherosclerotic RAS (age
699 years, mean serum creatinine 2.6 mg/dL) showed that
at discharge, renal function remained unchanged in 41%,
declined in 16%, and improved in 43%, including 7 patients
removed from dialysis (654). At 1 year, renal function was
improved or unchanged in 72%. Aortorenal bypass was used
in 38%, endoarterectomy in 24%, combined aortic and renal
artery revascularization in 24%, and bilateral renal artery
revascularization in 27%, with perioperative death in 4.1%.
Predictors of worsened excretory function included decline
of renal function at hospital discharge, unilateral RAS, and
elevated baseline creatinine level. In another study, mean
age 668 years with RAS who underwent repair, 83/232
underwent unilateral and 149 bilateral renal artery repair,
including 17 with repair to a solitary kidney (655). A total
of 332 renal arteries were reconstructed and 32 nephrecto-
mies performed; 58% of patients had improved renal func-
tion after surgery, including 27 removed from dialysis. Renal
function was unchanged in 35% and worsened in 7%. Death
within 30 days of surgery occurred in 7.3% of the patients,
and advanced age and HF were independent predictors of
mortality.
In patients 669 years of age, the Nationwide Inpatient
Sample of all hospital discharges in the United States
reported a 73% decrease in combined aortic and renal
surgical revascularization; and in patients aged 6312 years,
a 56% decline in surgical renal revascularization between
1988 and 2001 (656). However, catheter-based renal revas-
cularization procedures increased 173% in patients aged
6712 years during the same period.4.2.5.8.2.2. Catheter-Based Interventions
4.2.5.8.2.2.1. PERCUTANEOUS TRANSLUMINAL RENAL ARTERY
BALLOON ANGIOPLASTY. Risks of surgical renal revascular-
ization and relatively good results with catheter-based in-
terventions have shifted therapy toward more percutaneous
catheter-based interventions. In 1 study, patients with
hypertension and RAS (stenosis 50% and serum creati-
nine 2.3 mg/dL) were assigned to percutaneous balloon
angioplasty (BA) or medical treatment and followed for a
total of 12 months (657). Average ages were 5910 years
and 6110 years for the angioplasty and drug therapy
groups, respectively. At 12 months, there were no signifi-
cant differences between groups in BP, daily antihyperten-
sive drug doses, or renal function. However, 40% of
patients assigned medical treatment crossed over to BA after
3 months. Other studies (658–660) confirmed that BA is
associated with low procedural success and high restenosis
rates in RAS, the most common pathology in the elderly.
BA stent placement has consistently proven superior when
compared to BA alone. Based on these results, stenting with
BA has replaced BA alone.
4.2.5.8.2.2.2. PERCUTANEOUS RENAL ARTERY STENTING. Be-
cause atherosclerotic RAS usually involves narrowing of the
ostium by aortic plaques extending into proximal vessels,
BA results in recoil, and stent use better maintains patency
(661). A study of patients (average age 65 years) found that
angioplasty with stent placement was more effective than
BA for ostial atherosclerotic stenosis (662). Primary patency
rate at 6 months was 79% in the stent versus 28% in the BA
group and in patients with restenosis, secondary patency was
also higher in the stent than in the BA group: 82% versus
46%, respectively. No differences occurred between groups
in the distribution of patients with improved BP or im-
proved, unchanged, or worse renal function; the number of
antihypertensive medications did not change in either group
after revascularization. Complications, including bleeding,
femoral artery aneurysm, renal artery injury, and cholesterol
embolism, were similar in both groups. This prospective
study concluded that stenting provides improved vessel
patency in the elderly population with ostial atherosclerotic
RAS; however, it does not prove that the clinical evolution
of the disease will change following revascularization.
One study summarized experience with angioplasty and
stenting in 39 patients (mean age 69.9 years) with recurrent
episodes of HF and flash pulmonary edema (630). Follow-
ing the procedure, 77% of patients had no hospitalization
for HF over 21 months, and 9 patients died. In another
study, the presence of HF was examined in a cohort (mean
age 73 years) of patients with significant hypertension and
RAS. Approximately one third (31%) of the patients re-
ferred for BA with stenting presented with HF. Outcomes
in HF and BP control were improved by revascularization
compared with outcomes of patients who underwent med-
ical management, but mortality was not affected (663).
Investigators from the ASPIRE II (renal Artery Stenting
After Unsuccessful Balloon Angioplasty) study analyzed
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failed renal artery BA in patients, average age 699.9 years.
tenting was immediately successful in 80.2% lesions
reated, and at 9 months, the restenosis rate was 17.4%. The
BP/DBP decrease was significant, but creatinine was
nchanged after 24 months, as adverse events occurred in
9.7% (664). Others (665) found patients 75 years of age
ave similar findings in follow-up after BA; however,
atients who are 75 years of age have a higher mortality at
years.
Uncertainty regarding the effect of stenting on BP control
nd progression of kidney failure continues. Some suggest
hat stenting for atherosclerotic RAS can stabilize declining
idney function; however, for patients with stable renal
unction, the benefit is less clear (666). Others advise
aution in performing percutaneous revascularization in
atients with CKD (667).
Early acute functional renal injury related to renal inter-
entions in patients with atherosclerotic RAS was analyzed
n a prospective study of patients who averaged70 years of
ge (668). Indications for the procedure were poorly con-
rolled hypertension, associated CKD (creatinine 1.5 mg/
L), diabetes mellitus, and hyperlipidemia. Acute functional
arenchymal renal injury occurred in 20%. In the injury
roup, there were more current smokers with non–insulin-
ependent diabetes mellitus and presence of AAA. The
KD was more advanced (GFR 20 mL/min), and con-
ralateral renal artery disease was more frequent in patients
ho suffered acute kidney injury after the procedure. Acute
idney injury was associated with more kidney morbidity 3
onths after the procedure and decreased survival at 5 years;
n addition, 3 times more patients progressed to hemodial-
sis as compared with those without acute kidney injury. It
eems that patients with unrepaired AAA, diabetes mellitus,
nd persistent renal disease are more predisposed to acute
unctional injury following RAS. Medical therapy or use of
distal renal protective device may be beneficial until results
f prospective trials (e.g., CORAL) help to address appro-
riate use of renal interventions.
The ASTRAL trial (669) recruited 806 patients with
AS (mean age 70 years, range 42 to 88 years) including
atients who quit smoking and those with a history of
iabetes, PAD, CVD, and stroke. Eighty percent were
reated with statins, 90% with antiplatelet drugs, and 90%
ith antihypertensive agents. Participants were randomized
etween renal artery revascularization (BA-S) plus medical
herapy versus medical therapy alone, and the primary
utcome was rate of decline of renal function; the secondary
utcomes were BP control, renal events (acute renal failure,
ialysis), serious vascular events, or mortality. At 12
onths, there were no differences between groups in renal
unction, SBP or DBP, combined renal events, and CV
vents, inducing death. During 4-year follow-up, there was
light benefit in favor of revascularization for creatinine (10
mol/L difference), SBP, combined renal (17% versus3%), and CV events (34% versus 41%), but the study wasnderpowered. Serious complications associated with revas-
ularization occurred in 23 patients (6%), including 2 deaths
nd 3 amputations of toes or limbs. Based on this definitive
rial, there is no evidence for benefit of BA-S for RAS. The
uthors concluded that in patients with a range of radiolog-
cally significant RAS lesions, there was no benefit in any
utcome measure but significant risk from additional revas-
ularization when both groups were treated with optimal
edical therapy (669). The ongoing CORAL study (670)
ill analyze response to medical treatment versus revascu-
arization and might also provide evidence about diagnostic
ests that may predict the best treatment.
Technical improvements in percutaneous renal artery
nterventions have evolved. These include polyurethane
lter and basket (Angioguard XP emboli capture guide wire
ystem) (671) to decrease the number of microembolic
articles introduced into the renal artery. Analysis of a
etrospective cohort of consecutive patients undergoing with
nd without distal embolic protection, ages 697 years and
56 years, respectively, did not show a difference between
roups in renal function or SBP changes. The authors
oncluded that renal artery stenting improves GFR and
BP, however distal embolic protection did not enhance
his effect (672).
4.2.5.9. OTHER CONDITIONS/SITUATIONS/SPECIAL POPULATIONS
Resistant hypertension: Resistant hypertension is defined as
BP that remains above goal when a patient adheres to
lifestyle measures (23) and maximum tolerated doses of 3
complementary antihypertensive agents including a diuretic
(673), has an unknown prevalence in the elderly. Data from
NHANES (2003 to 2004), show hypertension prevalence
progressively increases with age, reaching 77% in people
77 years of age (674), so increasing age, particularly 65
years of age, is associated with a higher prevalence of
resistant hypertension (675,676).
There are no studies specifically powered to address
prognosis of older patients with resistant hypertension. In
adults 40 to 69 years of age with no previous vascular
disease, each difference of 20 mm Hg in SBP or 10 mm Hg
in DBP was associated with more than a 2-fold difference in
the stroke death rate (Figure 8), and with 2-fold differences
in the death rates from vascular causes (Figure 11). This
association was consistent for the entire range of BP
studied, about 115/75 to 180/110 mm Hg. Differences in
vascular mortality were about half as extreme at 80 to 89
years of age versus 40 to 49 years of age, but the annual
absolute differences in risk were greater in old age. Age-
specific associations were similar for men and women, and
for cerebral hemorrhage and cerebral ischemia (42).
Increasing age was the characteristic that was most
significantly associated with lack of SBP control among
treated subjects. The FHS showed that subjects 75 years
of age are 4 times less likely to achieve SBP control
compared with those 60 years of age (677). This was
confirmed in another study where BP control gradually
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May 17, 2011:2037–114 Hypertension in the Elderlydeclined with age, from 74% among those 40 years of age
to 33% for those 70 years of age (674). Reasons for
resistant hypertension in the elderly include excess dietary
salt intake, weight, alcohol, and nicotine; decrease in efficacy
of antihypertensive medication with higher baseline BP;
higher incidence of organ damage comorbidities (e.g.,
dyslipidemia, metabolic syndrome, diabetes mellitus, CKD,
stroke, HF, PAD, CAD [674]); poor adherence to drug
treatment; volume overload; pseudohypertension; and use of
pain medications such as NSAIDs. NSAIDs inhibit pros-
taglandin production, followed by sodium and fluid reten-
tion (215) and volume overload, especially in elderly patients
with organ damage (675).
Elderly subjects with higher baseline SBP typically have a
more severe or longer duration of hypertension that makes it
more difficult to treat. Higher baseline SBP is also often
associated with dysfunction or damage of organs that play a key
role in BP regulation. In elderly patients, volume overload is a
common finding because of excessive salt intake, inadequate
kidney function, or insufficient diuretic therapy. Physicians are
less aggressive in treating elderly patients, as 25% of physicians
believe that hypertension treatment in an 85 year old has more
risks than benefits (678).
Pseudohypertension represents another reason for re-
sistant hypertension in the elderly population. Increased
arterial stiffness and the presence of heavily calcified
arteries that cannot fully compress makes BP readings
falsely higher than the intra-arterial BP (679). Managing
resistant hypertension in the elderly requires a careful
medical history, followed by BP measurements in seated
and in erect posture because of the increase risk of
postural hypotension. Complete investigation of comor-
Figure 11. Absolute Risk of Ischemic Heart Disease Mortality
(A) Systolic blood pressure. (B) Diastolic blood pressure. The Y axis is logarithmic.
CI indicates confidence interval; IHD, ischemic heart disease. Reprinted from Lewingbidities and concomitant medications, as well as subop- stimal compliance and dietary indiscretions may help
explain the difficulties in BP control.
Recommendations for modification and intensification of
antihypertensive regiments for elderly patients taking3 drugs
re based on pharmacological principles, underlying pathology,
linical experience, and comorbidities. We wish to reinforce
he importance of dietary sodium restriction, reduction in
lcohol intake, and the DASH diet in resistant hypertension.
ost patients should receive a RAAS blocker along with a CA
nd an appropriately dosed diuretic. It is extremely important
hat the agents be given in adequate dosages and at appropriate
ime intervals. An appropriate diuretic to decrease volume
xpansion remains the cornerstone of therapy in elderly pa-
ients. Thiazides can be selected if the eGFR is30 mL/min/
.73 m2; if hypoalbuminemia or hypokalemia is not present. If
GFR is 30 mL/min/1.73 m2, a loop diuretic is recom-
ended (675). Next, add either a CA or vasodilating beta
locker if pulse rate is not 50 bpm. Blockade of aldosterone
hould be considered especially in certain settings, (i.e., those
ith HF, obesity, or sleep apnea) (680). Peripheral alpha
lockers may be considered, especially in older men with
oexistent symptoms from benign prostatic hypertrophy,
ut these will increase orthostatic hypotension and are
ssociated with excess HF and stroke (Section 4.2.2.1.3,
lpha-Adrenergic Blocking Agents).
As discussed previously, RAS and other secondary causes
f hypertension should be considered in elderly patients
ith resistant hypertension. A key point in the management
f BP in this cohort of patients is that volume depletion
ith diuretics, especially during summer months, is to be
voided. Hence, CAs become useful agents as they are
fficacious for pressure reduction and avoid increases in
lation to Blood Pressure
al. (42).in Reerum creatinine and volume depletion.
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Hypertension in the Elderly May 17, 2011:2037–114Osteoporosis: Thiazide diuretics preserve hip and spine
bone mineral density in older patients (681–683), so those
with hypertension and osteoporosis should generally receive
a thiazide (22), which can increase blood calcium levels.
Loop diuretics (such as furosemide and bumetanide) can
decrease calcium levels. Amiloride (a potassium-sparing
diuretic) may decrease the amount of calcium excreted in
the urine (thus increasing blood calcium levels), and may
also be considered for people with calcium oxalate kidney
stones.
Arrhythmias: Beta blockers, verapamil, or diltiazem
should be used for ventricular rate control with supraven-
tricular tachyarrhythmias such as AF in elderly persons with
hypertension (22,286). Beta blockers should also be consid-
ered in treatment of elderly persons with complex ventric-
ular arrhythmias with abnormal (684) or normal (685)
ejection fraction. Beta blockers are also useful to treat elderly
persons with hypertension who have hyperthyroidism, pre-
operative hypertension, migraine, or essential tremor (22).
CAs are useful in patients with Raynaud’s disease, asthma,
or chronic obstructive lung disease, in whom beta blockers
are relatively contraindicated.
Blacks: In general, treatment of hypertension is similar
for all racial/ethnic groups (22) including blacks (686).
Blacks have reduced BP responses to monotherapy with
beta blockers, ACEIs, ARBs, and some CAs compared
with diuretics, but this is eliminated by including a diuretic
in combination (22). RAAS (686) inhibitors appear less
effective than other classes in decreasing BP in elderly
blacks, unless combined with diuretics or CAs. ACEIs
prevent adverse outcomes such as decline of renal function
in those with hypertensive nephropathy (558). The SHEP
demonstrated benefit in an older black cohort with
chlorthalidone-based treatment versus placebo (16). Pa-
tients were 60 years of age with SBP 160 to 219 mm Hg,
and DBP 90 mm Hg. Over 4.5 years, stroke was reduced
in black women (RR: 0.36; 95% CI: 0.16 to 0.83), but not
in black men. In LIFE, black patients aged 55 to 80 years
with stage 2 hypertension and LVH showed greater benefit
with atenolol plus diuretics versus losartan plus diuretics in
protection against stroke and CAD (687).
The initial agent in blacks with uncomplicated hyperten-
sion should be a thiazide diuretic. In ALLHAT, chlortha-
lidone was unsurpassed in blacks decreasing BP and major
CV events versus regimens based on lisinopril, amlodipine,
and doxazosin (9,688). CAs effectively lowered BP in blacks
and decreased CV event, especially stroke (688). Amlodip-
ine in ALLHAT was effective with similar protection
against CAD and stroke, although less effective for new
onset HF when compared with chlorthalidone (688). Be-
cause ALLHAT compared those agents with diuretics and
CAs, patients randomized to chlorthalidone or amlodipine-
based therapies could not additionally take lisinopril, despite
the fact that a diuretic or CA combination with an ACEI
would be a reasonable combination in blacks. In ALLHAT,
a 40% higher incidence of stroke in blacks with lisinopril-based therapy was noted versus the diuretic (68). This
occurred, to a large extent, related to 4 to 5 mm Hg less SBP
reduction in the lisinopril-based versus chlorthalidone-
based cohort, although BP reductions did not fully explain
outcome differences.
In the AASK, ramipril-based therapy versus metoprolol
succinate and amlodipine was renoprotective in those with
hypertensive nephropathy, especially with proteinuria. The
AASK results confirm benefit of ACEI when needed in
blacks, such as protection against progression of renal
disease in concert with diuretics (558); however, the diuretic
used was furosemide.
Although ACEIs and ARBs may be less efficacious for
BP reduction in blacks, at higher doses or combined with a
diuretic or long-acting CA, blacks benefit from these
agents. ACEIs are associated with a higher rate of cough
and angioedema among blacks versus whites (688). Never-
theless, in blacks, socioeconomic status, dietary, and other
lifestyle considerations must be examined and addressed,
because, to a large extent, these non-drug aspects of elevated
BP are of primary significance. Blacks, many of whom have
more severe and complicated hypertension, usually will not
reach control with monotherapy. Aldosterone antagonists,
spironolactone, and eplerenone are beneficial in patients
with resistant hypertension, including blacks (689).
Hispanics: Recommendations for pharmacological man-
agement of elderly Hispanic patients are the same as for
elderly patients in general. In INVEST, elderly Hispanic
patients with CAD had better BP responses to combination
therapy with either a CA plus ACEI or beta blocker plus
HCTZ versus white patients (76,77).
Women: There is no evidence that elderly women re-
spond differently than elderly men to antihypertensive drugs
(690,691). Recent studies have shown that multidrug ther-
apy is needed for elderly high-risk men and women with
hypertension (691). A recent meta-analysis of randomized
trials showed that different antihypertensive drug classes
protected similarly against major CV events in persons 65
ears of age and persons 65 years of age (251).
Octogenarians: Successful treatment of hypertension in
ctogenarians may be expected to substantially reduce CV
isk and mortality based on available data. Benefits on
ognitive function and appearance of dementia are less
ertain. Although a BP 140/90 mm Hg was recom-
mended for all patients by “The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure” (22), except for a
lower level in special populations, randomized trial evidence
to support this BP level in the very elderly is not robust.
Nevertheless, data available from RCTs, which included
patients over the age of 80 years, come largely from
subpopulations, which in some trials and collectively are
larger than HYVET. These trials (e.g., ACCOMPLISH,
INVEST) noted no difference in the effects on outcomes
among those 80 years of age versus 80 years of age
(8,584). Based on these results and limitations, the follow-
2089JACC Vol. 57, No. 20, 2011 Aronow et al.
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of age. Those with SBP 150 mm Hg are candidates for
antihypertensive drugs with target SBP 140 to 145 mm Hg
if tolerated (i.e., somewhat more conservative target than in
individuals 80 years of age).
Initiate treatment with a single drug followed by addition
of a second drug if needed. Low-dose thiazides, CAs, and
RAAS blockers are preferred. Concomitant conditions will
often dictate which drugs are appropriate, as detailed in the
preceding text. Indeed, because of the evidence that the
benefits of antihypertensive treatment largely depend on BP
lowering per se (22), all drugs (alone or in rational combi-
nations) may be used provided that they have a suitable
safety profile and no excessive effect on orthostatic BP.
In starting or continuing treatment, use precautions even
more stringent than those employed in younger patients.
Octogenarians should be seen frequently and the medical
history accurately updated at each visit. Standing BP should
always be checked for excessive orthostatic decline. Al-
though BP values below which vital organ perfusion is
impaired are not known, SBPs lower than 130 mm Hg and
DBP 60 mm Hg should generally be avoided, if possible.
Drug treatments for concomitant diseases should be care-
fully monitored to prevent adverse interactions with antihy-
pertensive drugs.
Drug treatment should not indiscriminately involve all
patients with hypertension who are 80 years of age. In
deciding whether to initiate treatment, physicians should
consider the general health condition of their patients.
Treatment may be withheld in more frail or medically
compromised patients, and there is less evidence of benefit
in patients approaching 90 years of age or who are 90
years of age.
4.2.5.10. COMPLIANCE WITH PHARMACOLOGICAL THERAPY
Compliance may be defined as the extent to which a patient
takes medication as prescribed. The term compliance is often
used interchangeably with adherence, but compliance is pre-
ferred because it implies a responsibility shared by both
patient and physician (692,693). Compliance rates are often
reported as percentage of prescribed dose of medication
actually taken over a period of time. Measurements of blood
or urine drug metabolites or serum drug concentrations can
also be used (694), but these have limited applications in a
primary care setting as they are invasive and potentially
costly. Clinicians are more inclined to evaluate compliance
by questioning the patient, taking pill count assessments at
checkup, and using electronic medication caps that record
when a bottle is opened (694,695). Unfortunately, patients
do not always report nonadherent behavior, and such
indirect measures can mislead providers to overestimate
compliance (694).
Definition and Predictors: Unfortunately, a large propor-
tion of elderly patients will discontinue or take the drugs
inappropriately (692,696,697). This noncompliance often
results in failing to reach guideline-recommended BP tar-gets and impacts outcomes; patients are much more likely to
be hospitalized and have greater healthcare costs than those
who follow their prescriptions (22). About 1 in 3 patients
remain highly adherent to antihypertensive medication after
12 months, and after that, adherent patients are much less
likely to discontinue medication. Older age, in addition to
previous noncompliance, low risk for CV events, competing
health problems, nonwhite race, low socioeconomic status,
complexity (e.g., multiple dosing, pill burden), side effects,
and cost of medication regimen predict noncompliance
(698,699).
Compliance Barriers: The asymptomatic state associated
with hypertension appears to be a common barrier
(692,697,700). A prospective study found that only 37% of
patients surveyed reported consistent compliance to antihy-
pertensive regimen (701). In a cross-sectional study, 21% of
patients with hypertension stopped treatment without being
advised to do so. A factor most commonly found to
distinguish nonadherent patients from those adherent to
medication regimens was perception of health status (700).
The poorer the patients perceived their health, the more
likely they were to adhere to prescribed treatment; the
reason given most often for discontinuation was that they
felt well without the medication. Although the mean age of
this cohort was only 58, elderly patients with hypertension
are likely to be asymptomatic with a variety of serious
comorbidities (e.g., AF, CAD, diabetes mellitus, HF)
(700). Prevalent comorbidities, polypharmacy, and high cost
of medications also contribute to lower BP control rates in
the elderly (610).
Some patients with hypertension are more likely to
adhere to their medication regimen. Patients who viewed
hypertension as a symptomatic disease and believed treat-
ment had beneficial effects on symptoms were more adher-
ent and had better BP control (702).
Side Effects: Side effects are another common reason for
therapy discontinuation in the elderly (703–705) and may be
more apparent in patients with hypertension. This because
the illness is often asymptomatic, which may increase
awareness of side effects associated with therapy. A drug’s
side-effect profile has been demonstrated to contribute to
poor compliance by affecting a patient’s QoL (701,706). In
patients with hypertension, approximately 10% of poor
compliance was due to adverse effects of prescribed medi-
cation (707). In addition to side effects, new symptoms that
may be unrelated to the medication regimen can also impact
compliance. It is therefore important to advise patients of
side effects that may be related to medications, as patients
tend to blame their drugs for any new symptoms they
experience (Table 10) (708).
Pill Burden and Dosing Complexity: Complexity of a
drug regimen influences compliance (709) and is especially
problematic for hypertension and HF, as dosing complexity
and number of medications increases with disease severity.
This problem has been growing as the number of medica-
tions and evidence-based guidelines have increased (710).
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Hypertension in the Elderly May 17, 2011:2037–114An average of 2 to 4 antihypertensive medications are
required for BP control in most high-risk patients with
hypertension and comorbid conditions such as renal disease
or diabetes mellitus (711). As seen in Figure 12, 2
antihypertensive agents were needed to achieve target BP
Figure 12. Percentage of People in Outcomes Trials of the Eld
ACCOMPLISH (8) indicates Avoiding Cardiovascular Events in Combination Therapy in
ing Treatment to Prevent Heart Attack Trial; Australian HTN (718), Australian Hyperte
lar End Points Trial; EWPHE (12), European Working Party on High Blood Pressure in
Verapamil-Trandolapril Study; LIFE (14), Losartan Intervention For Endpoint Trial; MR
Table 10. Adverse Effects of Antihypertensive Therapy
in the Elderly
Drug Class Adverse Effect
hiazide and loop diuretics Hypokalemia, hyponatremia, hypomagnesemia,
volume-depletion hypotension, renal
impairment, hyperuricemia, gout,
hyperglycemia
otassium-sparing diuretics Hyperkalemia, hypotension
eta-adrenergic blockers Sinus bradycardia, fatigue, AV nodal heart
block, bronchospasm, intermittent
claudication, confusion, aggravation of acute
heart failure, hyperglycemia
lpha-beta adrenergic
blockers (vasodilator-beta
adrenergic blockers)
Hypotension, heart block, sinus bradycardia,
bronchospasm
lpha1-adrenergic
antagonists
Orthostatic hypotension
Angiotensin-converting
enzyme inhibitors
Cough, hyperkalemia (only with eGFR
50 mL/min), angioneurotic edema, rash,
altered taste sensation, renal impairment
Angiotensin receptor blockers Hyperkalemia, renal impairment
Central-acting drugs Sedation, constipation, dry mouth
Calcium antagonists
(non-dihydropyridines)
Rash, exacerbation of GERD symptoms, sinus
bradycardia, heart block, heart failure,
constipation (verapamil), gingival hyperplasia
(dihydropyridines) Peripheral edema, heart failure, tachycardia,
aggravation of angina pectoris (short-acting
agents)
irect vasodilators Tachycardia, fluid retention, angina pectoris
AV indicates atrioventricular; eGFR, estimated glomerular filtration rate; and GERD, gastroesoph-
ageal reflux disease.dults; SBP, systolic blood pressure; SHEP (16), Systolic Hypertension in the Elderly Progr
wedish Trial in Old Patients with Hypertension; Syst-China (19), Systolic Hypertension in Cgoals in the majority of patients (712). As new treatment
strategies are added, the increased pill burden may contrib-
ute to problems with compliance.
There is an inverse relationship between the number of
daily drug doses and the adherence rate (692,699). A
meta-analysis for chronic conditions including CVD
showed that mean dose-taking compliance was 79% for 1
dose, 69% for 2 doses, 65% for 3 doses, and 51% for 4 doses
(p0.001 among dose schedules) (699). Thus, it is impor-
tant to prescribe therapies that will help to alleviate pill
burden. Reduction in dose frequency through selection of
once-daily agents improves medication compliance (713),
articularly in hypertension treatment (698). Once-daily
osing was shown to have the highest compliance rate
mong dosing schedules for a range of CV disorders: as the
umber of doses per day increased, compliance rates de-
lined (699,714). Although these data are from cohorts that
ncluded few elderly patients, reducing daily dose frequency
as found to produce a significant improvement in compli-
nce. The average compliance rate was significantly higher
or once-daily dosing compared with multiple-daily dosing
91.4% versus 83.2%, p0.001). Average compliance was
igher for once-daily (92.7%) versus twice-daily dosing
87.1%, p0.026).
One concern regarding once-daily formulations is that
hen patients are not adherent, they miss an entire day of
edication as opposed to missing half a day or less with
ultiple dosing. Although this is an important consider-
tion, the properties of long-acting oral formulations may
elp to provide protection from adverse events even when
ompliance is not perfect. Although BP control was signif-
cantly reduced in patients who were only partially adherent
80% of prescribed pills taken) to short-acting, twice-daily
iltiazem, this was not the case in patients who were only
aking 2 or More Antihypertensive Medications
nts Living with Systolic Hypertension; ALLHAT (9), Antihypertensive and Lipid-Lower-
Study; CONVINCE (719), Controlled Onset Verapamil Investigation of Cardiovascu-
lderly; HYVET (4), Hypertension in the Very Elderly Trial; INVEST (584), International
rly (15), Medical Research Council Trial of treatment of hypertension in oldererly T
Patie
nsion
the E
C-Elde
am; STONE (17), Shanghai Trial of Hypertension in the Elderly; STOP-2 (720),
hina Trial; and Syst-Eur (20), Systolic Hypertension in Europe Trial.
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May 17, 2011:2037–114 Hypertension in the Elderlypartially adherent to the once-daily amlodipine formulation
(715). This suggests that the negative consequences of
partial compliance for BP control may be offset by selecting
agents with a longer duration of action beyond the dosing
intervals. Overall, use of once-daily drug formulations
provide a significant improvement in compliance to a
prescribed regimen and may improve outcomes.
Cost Considerations: Although higher out-of-pocket
medication costs are associated with reduced compliance in
the overall population, this is a particular concern in the
elderly because of their generally lower incomes. Clinicians
should use generic and formulary drugs when possible.
Conversely, an impact on overall healthcare costs is also
observed with poor compliance. An analysis of the associa-
tion between interruption or termination of therapy and
total healthcare costs (716) using paid claims data (Califor-
nia Medicaid) found each patient with interrupted antihy-
pertensive drug therapy accumulated an additional $873 in
healthcare costs during the first year. These costs were
primarily the result of increased hospital expenditures (716).
These findings were confirmed in a patient primary database
in the United Kingdom (717).
5. Future Considerations
5.1. Prevention of Hypertension
Most consideration of preventing hypertension has been
targeted at young people, and little information is available
about preventive strategies in the elderly. Increases in SBP
occur with aging in most societies around the world.
Unfortunately, there are no clear explanations for these
exceptions and thus no clinical guidance (721). It is likely
that patterns of decreasing physical activity and weight gain
with age in industrialized societies partially explain this
trend for increasing SBP with age.
Usual recommendations for hypertension prevention are
based on the following lifestyle changes: reduced sodium
intake; weight loss; moderation of alcohol use; diets cen-
tered on fresh produce; and physical activity (722). Excess
weight is common in older people, so weight loss represents
an opportunity for slowing progression to hypertension.
Likewise, use of the DASH diet, based on increased intake
of fresh produce and discussed elsewhere in this report, has
a BP-lowering effect. Although dietary strategies are not
easy to achieve or sustain in younger people, it is possible
that elderly people might be more acutely sensitive to the
CV consequences of rising BPs and thus more motivated to
make lifestyle changes, including the assumption of in-
creased physical activity such as walking.
Perhaps the best documented of these approaches in
elderly people is reduced dietary sodium. A study in China
demonstrated that switching to sodium intake at the lower
end of the usual dietary range produced meaningful BP
reductions in older persons (723). A possible explanation for
this is that the reactive increase in activity of the RAAS thatblunts antihypertensive efficacy of salt restriction is less
active in the elderly (724,725). From a mechanistic point of
view, sodium and the RAAS have synergistic effects accel-
erating arterial disease, including arterial stiffening that
leads to systolic hypertension of the elderly (726). Indeed, it
has been suggested that aging may increase sensitivity of
arteries to sodium (727). Integrity of endothelium, vascular
smooth muscle cells, and connective tissue are all compro-
mised by sodium so as to reduce vascular compliance,
particularly in concert with effects of AII and aldosterone.
Evidence implicates the role of the high vascular tissue
concentrations of AII found in the elderly in amplifying
adverse changes in extracellular tissues, so increasing rigidity
of the wall structure (727).
These considerations would support the dual strategies of
dietary salt restriction and RAAS blockade for preventing or
modifying the appearance of hypertension in older people.
One trial, albeit in a young-to-middle-aged cohort, showed
2-year intervention with an ARB in patients with prehy-
pertension modestly but significantly reduced progression to
overt hypertension (728). It is not known whether this
strategy would be effective in an older group. On theoretical
grounds, addition of a CA to a RAAS blocker might
provide additional inhibition of adverse vascular prolifera-
tive changes (729).
At present, prevention of hypertension in the elderly
should be based primarily on a strategy of dietary salt
restriction, weight control, and physical activity. This could
be augmented by relatively early introduction of RAAS
blockade in stage 1 hypertension with the intent of limiting
further progression of hypertensive disease.
5.2. Unanswered Questions
There remain many important but unresolved issues regard-
ing hypertension treatment in the elderly. One is to agree on
a working definition of the term elderly. Another is to
establish BP values for making the diagnosis of hyperten-
sion as well as setting targets for treatment. A third is to
identify, for those patients in whom pharmacological ther-
apy is indicated, which drugs will be most effective for
reducing CV events. A final question is whether there is a
subgroup of elderly patients with hypertension in whom
treatment is not beneficial.
Defining elderly is a difficult task, as discussed earlier in
this document. Because of the great heterogeneity among
individuals in the aging process, it is not possible to readily
assign an overall chronological value that establishes the
state of being elderly. Some octogenarians can be fully active
in the work environment or elsewhere on a daily basis, but
others are not so fortunate. Given this marked heterogeneity
of health and physiological function in older adults, it is
more important to focus on defining the extent of these
age-associated conditions than on using chronologic age to
define and treat the elderly patient with hypertension.
Ongoing and future research will further explore the
causes and mechanisms of age-related development and
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Hypertension in the Elderly May 17, 2011:2037–114progression of vascular disease. It is clear that age, appar-
ently independent of other CV risk factors, is a powerful
predictor of events. In the future, it should be possible to
apply objective measurements of vascular or other clinical
properties to better define hypertension and to tailor therapy.
The most practical definition of hypertension in the elderly
should describe a BP level above which medical intervention—
lifestyle changes or drugs—could be expected to provide
clinical benefits. Although several clinical trials have reported
beneficial results of treating hypertension in the elderly, these
studies have not provided clear guidance for selecting a specific
BP value that could be used to diagnose hypertension or to use
as a target for treatment. A report from INVEST found that
patients who had BP 140/90 mm/Hg at 75% of their
ollow-up visits had the lowest risk for adverse outcomes (730).
s a simple generalization, it could be stated that pretreatment
BP 160 mm Hg would fit the profile of most of these
tudies, including HYVET (4), as would a target SBP 150
m Hg. These studies have shown clinical benefits with
chieved SBP values averaging in the 140s, 150s, and 160s.
hus, unlike previous guidelines that addressed the full spec-
rum of adults (22,23), there is limited evidence in the elderly
o support a value of 140 mm Hg as a diagnostic and
herapeutic threshold. There are also limited data as to whether
atients with initial SBP between 150 and 159 mm Hg would
enefit from treatment (731). Nevertheless, achieved values
140 mm Hg for those 79 years of age are appropriate; but
or those80 years of age, 140 to 145 mm Hg, if tolerated, can
e acceptable.
Until recently, no randomized trials had compared effects
n clinical outcomes of achieving different BP values in
lder adults. However, in 2009, the Cardio-Sis (Studio
taliano Sugli Cardiovascolari del Controllo della Pressione
rteriosa Sistolica) trial, in 1,111 nondiabetic patients
mean age 67 years) with baseline SBP 150 mm Hg
eported a reduction in the primary outcome, the rate of
CG LVH at 2 years median follow-up in patients ran-
omized to a SBP goal 130 mm Hg versus a goal of 140
m Hg using open-label drugs (11.4% versus 17%, OR:
.63; 95% CI: 0.43 to 0.91; p0.013). In addition, a
omposite CV endpoint occurred in 9.4% in the usual
ontrol group versus 4.8% in the tight-control group (HR:
.50; 95% CI: 0.31 to 0.79; p0.003) (732). Although the
ge–treatment group interaction was nonsignificant, the
reatest reduction in the primary outcome was seen in the
ubgroup 70 years of age (732). Other than Cardio-Sis,
omparisons of different BP treatment targets in the elderly
re limited to post hoc interpretations of previously con-
ucted studies comparing different achieved BP levels
4,11,15,16,18,20,526,529). However, as discussed earlier in
his report, these studies varied, not only in their target BPs,
ut also in patient selection, drug choices, and duration of
herapy. Furthermore, they were all based primarily on
BPs and generally did not attempt to reach the aggressive
P goals used in more contemporary hypertension trials in
ounger cohorts (8,9,21).Until additional data from RCTs comparing various BP
argets in the elderly become available, existing epidemiologic
nd clinical trial data suggest a diagnostic and therapeutic
hreshold for hypertension of 140/90 mm Hg remains reason-
ble in adults 65 to 79 years of age. As mentioned previously
see Section 1.4), the ACCORD BP, although limited to
igh-risk persons with type 2 diabetes mellitus, found no
dditional benefit from an intense BP-lowering strategy tar-
eting SBP of 120 mm Hg, with an increase in adverse
xperiences related to antihypertensive drugs in the cohort65
ears of age. The soon-to-be-launched SPRINT (Systolic
lood PRessure INtervention Trial) should provide additional
nformation about the optimal BP treatment goal in older
dults. Among individuals 80 years of age, HYVET data
uggest a SBP of 150 mm Hg as the diagnostic criterion for
ypertension and the treatment target in octogenarians and
eyond. Should SBP fall readily to lower levels, it would be
easonable to maintain this level of control, provided treatment
s well tolerated. Yet it is the low DBP that concerns many
linicians from the J-curves reported (268). Clinicians, how-
ver, should consider 2 exceptions to this recommendation.
irst, in those elderly patients in whom a SBP 150 mm Hg
s readily and safely obtained with just 1 or 2 drugs, a further
odest intensification of treatment to achieve a value 140
m Hg could be considered, even though there is no firm
vidence to support this target. The second exception to the
ecommendation applies to patients whose SBP remain 150
m Hg under the following 3 circumstances that: 1) despite
aking a regimen of 4 well-selected and appropriately dosed
rugs, this goal has not been achieved; 2) prescribed therapy is
ausing unacceptable side effects, particularly postural changes
hat could result in the potentially disastrous consequences of
hysical injury; and 3) in attempting to reach the SBP target,
he DBP is being reduced to a potentially dangerous level65
m Hg. Under any of these circumstances, the lowest safely
chieved SBP 150 mm Hg is acceptable.
Finally, there is no evidence in older people to support the
se of lower BP targets in patients at high risk because of
onditions such as diabetes mellitus, CKD, or CAD.
Drug choice to treat the elderly is often dictated by
oncomitant conditions (e.g., CAD, HF, diabetes mellitus,
nd kidney insufficiency). Diuretics, CAs, and RAAS
lockers have all been effective in reducing events in the
lderly. There are no authoritative comparison trials that
ould indicate superiority of monotherapy with 1 class over
he other. As discussed elsewhere, most patients will require
ombination drug therapy (Table 9). Diuretic-based regi-
ens were effective in earlier studies, although a large
ypertension trial that included mostly elderly patients
ndicated that amlodipine is preferable to a thiazide in
ombination treatment for reducing fatal and nonfatal CV
utcomes (579).
5.3. Future Research
Future research should include both fundamental and clin-
ical investigation directed toward defining the pathogenesis
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May 17, 2011:2037–114 Hypertension in the Elderlyof increased vascular and LV stiffness, characteristic of
elderly patients with hypertension. The goal of this research
should be to develop strategies to both prevent and reverse
this form of vascular pathology, which is the cornerstone of
systolic hypertension in the elderly. Another direction
should be well-designed randomized controlled outcome
trials to define appropriate thresholds and goals for antihy-
pertensive treatment in the elderly. These might include
randomizing persons with SBP 160 mm Hg to SBP goals
of either 150 mm Hg or 140 mm Hg. Safety considerations
would be important in these trials. Finally, comparative
effectiveness trials are needed to test various treatment
strategies (i.e., different drug regimens and different inten-
sities of lifestyle modification) and to assess the relative
safety and efficacy of these approaches in the prevention of
CV mortality and morbidity and total mortality. Strategies
using non-physician providers (nurses, pharmacists, and
trained laypersons) should be tested, given the increasing
demands of an expanding elderly population and the grow-
ing shortage of physicians.
Potential New Therapeutic Strategies: Because several
efficacious and well-tolerated antihypertensive drug classes
are now available, there are relatively few new classes in
development. It is likely that advances for the foreseeable future
will focus primarily on innovative strategies for selecting and
combining available drugs. Thiazide diuretics and dihydropyr-
idine CAs have been the best-studied drugs in older cohorts.
However, there is growing evidence both of the fundamental
role of RAAS mechanisms in the genesis of vascular pathology
and hypertension in the elderly and of the benefits of pharma-
cologically blocking this system.
As emphasized elsewhere in this document, a limiting
factor for therapy in older people is uncertainty about
appropriate BP targets. Whereas the general BP goal in
adults has been 140/90 mm Hg, HYVET results in
octogenarians showed meaningful event reduction with SBP
in the mid-150s (4). However, the Cardio-Sis trial showed
lower event rates in “younger” elderly hypertensive patients
with a goal of SBP 130 mm Hg versus 140 mm Hg
732). Yet the results of ACCORD BP (Section 1.4), found
o benefit targeting 120 mm Hg versus 140 mm Hg in
igh-risk patients with an increase in drug-related adverse
xperiences. A trial now underway in Japan is comparing
vent rates in elderly patients whose SBPs are reduced to
140 mm Hg versus 140 to 160 mm Hg (733). The
PRINT trial, sponsored by NHLBI, is comparing SBP
argets of 120 mm Hg versus 140 mm Hg in higher-risk
dults, and oversampling elderly patients. These trials and
thers will hopefully cast more light on 1 key treatment
bjective in older patients: avoidance of cognitive dysfunc-
ion, perhaps most readily accomplished by effective BP
ontrol (260).
Future treatment strategies should evaluate sodium re-
triction together with therapeutic blockade of the RAAS.
n fact, RAAS blockers are all effective in elderly patients
ith hypertension (602,734). Further research with brady-inin and related targets, including newly developed angio-
ensin immunotherapy (735), may also be warranted. Inno-
ative combinations of CAs with RAAS blockers have
emonstrated benefit in high-risk patients and could be
specially useful for the elderly (8).
Endothelin antagonists could also be valuable in older
atients. Endothelin antagonists provide efficacy in resistant
ypertension, and their main drawback, teratogenicity, is not
n issue in elderly patients (736). Likewise, increased use of
ldosterone antagonists could be anticipated, for in low doses,
hey can also be effective for adjunctive therapy (737). More-
ver, a new progestogen, drospirenone, has exhibited antialdo-
terone activity and BP-lowering effects in post-menopausal
omen and may represent a novel strategy (738).
There is limited information on non-drug substances for
ypertension treatment in the elderly. Soy nuts, for instance,
educe BP in elderly women, though it is not clear whether
oy proteins or other components produce this effect
739,740). Studies with calcium and vitamin D supplements
r vitamin C have not demonstrated useful BP effects (241).
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category of review. ACCF indicates American College of Cardiology Foundation; NIH, National Institutes of Health; and NHLBI, National Heart, Lung, and Blood Institute.
*Significant relationship.
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ACEI  angiotensin-converting enzyme inhibitors
AF  atrial fibrillation
AMD  age-related macular degeneration
ARB  angiotensin receptor blocker
BA  balloon angioplasty
BP  blood pressure
CA  calcium antagonist
CHD  coronary heart disease
CKD  chronic kidney disease
CV  cardiovascular
CVD  cardiovascular disease
DBP  diastolic blood pressure
eGFR  estimated glomerular filtration rate
GFR  glomerular filtration rate
HCTZ  hydrocholorothiazide
ISH  isolated systolic hypertension
LV  left ventricular
LVH  left ventricular hypertrophy
NSAIDs  nonsteroidal anti-inflammatory drugs
QoL  quality of life
RAAS  renin-angiotensin-aldosterone system
RAS  renal artery stenosis
RCT  randomized control trial
SBP  systolic blood pressure
TSH  thyroid stimulating hormone
